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Abstract 
A genome threading algorithm was employed by Inpharmatica to identify a 
number of proteins with a predicted structure similar to that of the ligand binding 
domain (LBD) of nuclear receptors (NRs), an approach that has been successfully 
used to annotate the yeast transcription factor Oaf1 (Phelps et al, 2006).  This work 
focuses on one such protein termed NR3, which is identical to TRPC4AP or TRUSS, 
a protein proposed to function as a scaffold protein in cell signalling processes and as 
a cell cycle regulator. It is conceivable that NR3 does not function as a transcription 
factor in contrast to bona fide NRs and that the putative LBD may function as an 
allosteric switch to control functional activity. 
To investigate the idea that NR3 may possess a fold similar to the LBD of NRs 
preliminary structural work has been undertaken, which has suggested the putative 
LBD folds into an autonomous domain as it is region resistant to proteolysis. In 
addition, the potential role of the putative LBD fold as a molecular switch was 
examined by using constitutively active fusion proteins in reporter gene assays. It was 
determined that the putative NR3 LBD acts in a repressive manner, potentially due to 
the alteration in subcellular localisation exerted by the putative NR3 LBD on the 
fusion protein. To further assess the role of the putative LBD a ligand screen was 
undertaken to identify compounds that may reduce its repressive activity, however no 
ligand was identified and it is conceivable NR3 may act in a ligand independent 
manner similar to some orphan receptors. 
Initial analysis of NR3 function indicates that its expression may have a positive 
effect on cell proliferation. To further assess the role of NR3 protein interaction 
assays were established to screen for binding partners. This identified the E3 ubiquitin 
ligase component DNA damage-binding protein 1 (DDB1) as an interacting protein 
involved in the regulation of cell cycle progression and DNA repair. Mapping studies 
suggest NR3 binds to the substrate docking site of DDB1 and further analysis showed 
NR3 to be ubiquitinated, affecting the stability of the protein. It is reported that the 
arylhydrocarbon receptor binds to a DDB1 complex, which then acts as a ligand 
regulated E3 ubiquitin ligase complex (Ohtake et al, 2007). This raises the possibility 
that NR3 may act in functionally analogous manner. To address NR3 function within 
the whole organism a targeting vector designed to inactivate the NR3 gene has been 
generated and currently a conditional knockout mouse line are being bred. 
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1.1 Overview 
Nuclear receptors (NRs) can be defined as ligand activated transcription factors 
that regulate the expression of genes involved in diverse processes (Rosenfeld et al., 
2003). The nuclear receptor superfamily currently consists of 48 members within the 
human genome, a number that has been confirmed by bioinformatic DNA sequence 
homology searches (Robinson-Rechavi et al., 2001). Although the protein sequence 
of NRs may be divergent throughout the superfamily, members possess a conserved 
canonical modular domain structure. The ligand binding domain (LBD) region is 
moderately homologous at the primary sequence level, yet 3-dimensional structures 
gained from X-ray crystallography show that the overall fold for the LBD is 
conserved between NRs (Renaud et al., 1995; Wagner et al., 1995). This domain is 
proposed to act as a multifunctional switch controlled by the binding of ligands. 
A bioinformatic program named Genome Threader has been employed to 
produce protein alignments based on the 3-dimensional structure of NR LBDs rather 
than primary sequence homology. This method has identified several novel nuclear 
receptor-like proteins, predicted to contain a fold similar to that of NR LBDs. A 
number of the identified proteins were initially characterised in the literature, and 
although none are reported to act as direct regulators of transcription, the presence of 
a ligand binding domain within such proteins may indicate the ability of a small 
molecule to modulate a number of biological pathways within which the putative 
receptor protein functions. This project will focus on novel receptor 3 (NR3), which is 
strongly predicted to possess a NR LBD-like fold. 
 
1.2 Identification and Classification of Nuclear Receptors 
Initially the concept of nuclear receptors developed from observations that 
steroid hormones bound to specific tissues, providing evidence that hormone binding 
factors were present (Jensen, 1962). The oestrogen receptor (ER) was the first NR to 
be isolated over forty years ago from rat uterus homogenate (Toft and Gorski, 1966), 
and initial functional characterisation showed that upon activation the receptor 
produced an increase in mRNA and protein synthesis, and thus was thought to be 
involved in the regulation of gene transcription (O'Malley and McGuire, 1968). The 
purification and characterisation of the glucocorticoid receptor (GR) showed that the 
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receptor could bind to mammary tumour virus DNA upstream of the transcriptional 
start site in a sequence specific manner, suggesting that the mechanism by which NRs 
regulate transcription involved receptors recognising and binding to distinct DNA 
sequences at target genes (Payvar et al., 1981). Additional work from the same 
laboratory later showed that the sequences to which GR binds acted as enhancer 
elements, termed response elements (REs), that were separate from elements within 
the core promoter region already known to be essential for transcription (Chandler et 
al., 1983).  
Further identification and characterisation of REs showed they were inverted 
repeat motifs (Evans, 1988), lending support to the postulation that nuclear receptors 
bound to REs in dimeric complexes, which arose from the observations that receptors 
could be purified as dimers (Schrader et al., 1975). From these initial descriptive 
experiments a simple model emerged for the steroid hormone activation of their 
respective nuclear receptors in which ligand binding can induce receptor dimerisation, 
binding to specific response elements and the modulation of target gene transcription 
(figure 1.1). 
During the 1980s and 1990s much emphasis was placed on the cloning of 
nuclear receptors. Comparison of the complementary DNA (cDNA) and deduced 
amino acid sequences showed the receptors shared a high level of homology, and thus 
are thought to form a superfamily (Evans, 1988). Low stringency hybridisation 
techniques using probes corresponding to the highly homologous DNA binding 
domain (DBD) region of NRs were initially used to identify members of the 
superfamily. Completion of the human genome project aided the identification of 
additional NR superfamily members by allowing homology searches based on DNA 
sequence. At present, such searches show that there are 21 nuclear receptors in the 
Drosophila genome, 48 in the human, 49 in the mouse, and over 270 receptors 
currently identified in the Caenorhabditis elegans genome (Robinson-Rechavi et al., 
2001; Robinson-Rechavi et al., 2003). The superfamily may be subdivided and 
classified in different ways. Historically, nuclear receptors have been divided into 4 
different classes based upon the dimerisation and DNA binding properties of 
individual receptors (Mangelsdorf et al., 1995). The type I receptors, also known as 
steroid receptors, form homodimers and bind to inverted repeat REs, whereas type II 
receptors form heterodimers with retinoid X receptor (RXR) and bind direct repeat
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Figure 1.1 Simplified Model of NR Action 
Cartoon showing a basic model of nuclear receptor function. Upon ligand binding 
receptors dimerise and bind to hormone specific response elements within the 
promoters of target genes, producing an upregulation of gene transcription. 
 
A) Classical receptors homodimerise and bind to inverted repeats. ER binds to half 
sites. 
 
B) Non-classical receptors heterodimerise with RXR and bind to direct repeats. 
RE Transcribed Gene 
Inverted Repeats 
Half Sites 
Steroid 
Classical 
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A) 
RE Transcribed Gene 
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REs. Type III receptors, which include RXR, bind to direct repeat REs as homodimers, 
although RXR may also heterodimerise with type II receptors. Type IV receptors bind 
to extended half site REs as monomers. 
Alternatively, the nuclear receptor superfamily may be divided based on the 
type of ligand they bind (figure 1.2A) (Sonoda et al., 2008). Such a classification 
possesses three groups of receptors, endocrine receptors that bind a defined hormone, 
adopted orphan receptors for which a ligand has been identified, and orphan receptors 
for which a ligand has yet to be identified or may not bind a ligand. However, 
receptor classification may be problematic due to the complexity and redundancy in 
the nomenclature. As such a unified nomenclature was devised to offer simplicity and 
scope for the addition of newly discovered receptors to the superfamily. This system 
is based on the phylogenetic tree derived from the receptors from vertebrates, 
arthropods and nemotodes (Laudet, 1997). This classification produces 6 subfamilies 
of nuclear receptor, named subfamilies 1-6, and a separate subfamily, named 
subfamily 0, was used to group receptors not conforming to the standard structural 
architecture of the superfamily (figure 1.2B) (Nuclear Receptors Nomenclature 
Committee, 1999). Each subfamily is grouped by receptor family and each member of 
the receptor family is numbered. This method of classification also provides a form of 
nomenclature that names receptors based on subfamily and grouping. 
Recent work investigating the receptors present within the Schistosoma mansoni 
genome has led to the postulation of creating a new subfamily, named subfamily 7, 
which consists of 3 NRs from the S. mansoni genome, termed 2DBDα,β,γ (Wu et al., 
2006; Wu et al., 2007). The receptors possess two DBDs in tandem repeat, a feature 
that appears to be restricted to the flatworms. The first DBD is most homologous with 
the DBD of Drosophila proteins Knirps, KNRL and Eagle, and the second DBD 
shares similarities with the DBD of the receptors grouped in subfamily 1, indicating 
the ancestral origins of the DBDs in the receptors are not monophyletic (Wu et al., 
2006). However, it remains unclear as to the timings of the DBD duplication, and thus 
whether the event occurred before the divergence of the flatworm phylum and one 
DBD was subsequently lost in receptors belonging to other phyla, or whether the 
duplication event occurred after phylum divergence suggesting the appearance of two 
DBDs within a receptor is unique to flatworms. 
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B) 
Figure 1.2 Classification of Human Nuclear Receptors 
Human NRs classified by A) the type of ligand they bind and B) subfamily based on 
phylogenetic analysis. 
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Such phylogenetic studies have made it clear that the members of the NR 
superfamily are evolutionarily related. In addition, structural studies have shown that 
NRs also share a similar architecture consisting of distinct regions, some of which are 
modular autonomous domains responsible for different aspects of NR function. 
 
1.3 Structure of Nuclear Receptors 
1.3.1 Structural Paradigm for the Nuclear Receptor Superfamily 
Receptor homology across the superfamily is variable, for example aligning 
ERα (accession NP_000116) with peroxisome proliferator activated receptor (PPAR) 
α (accession AAB32649) shows there is 16.5% identity between the proteins. Despite 
the variability between protein sequences, NRs share a canonical protein architecture 
within which there are several identifiable domains (figure 1.3). The idea of a 
domain-like structure emerged from the observations that limited proteolysis of the 
dexamethasone bound GR could separate the ligand binding and DNA binding 
regions of the receptor (Wrange and Gustafsson, 1978). Currently up to six regions 
have been identified within NRs on the basis of sequence homology, denoted regions 
A-F (Krust et al., 1986).  Of these six regions, regions A-E are relatively well 
characterised, however the biological function of region F remains unclear. 
The A/B region, also known as the modulator domain, is the most variable 
region between nuclear receptors. This variation may be generated through alternative 
splicing, gene transcription occurring from different promoters, and translation 
beginning from different start sites (reviewed in Giguere, 1999). The region is thought 
to be a largely disordered domain and contains activation function (AF) -1, which 
provides constitutive activity and may provide a mechanism for receptor activation in 
the absence of ligand. It is likely that the transcriptional activation conferred by the 
A/B region is due to an interaction between the A/B domain and coactivators 
(Giguere, 1999). The level of A/B domain activity may be dependent on 
phosphorylation status of the receptor as exemplified by ERα, which is activated by 
direct phosphorylation at serine-118 by mitogen-activated protein kinase pathways 
(Bunone et al., 1996; Kato et al., 1995). In addition to providing constitutive and 
ligand-independent activity, the A/B region can also confer receptor dependent 
ligand-responsiveness and cell type specific activity (Ali et al., 1993). 
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Modulator DBD LBD 
Hinge 
A/B C D E F 
Figure 1.3 Schematic of the Canonical Structure of the Nuclear Receptor Superfamily 
The schematic show the 6 identifiable regions of nuclear receptors, termed A-F. The A/B region (modulator) contains the constitutively active 
activation function-1 (AF-1) and region E (LBD) contains the ligand dependent activation function-2 (AF-2). 
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The DBD (region C) is the most highly conserved domain and is responsible for 
recognising the appropriate response element within the promoters of target genes. 
There are several identifiable regions within the DBD. The DBD possesses two 
Cys2/Cys2 zinc finger motifs, which are the core of the DBD and are responsible for 
binding DNA, and a region of approximately 25 amino acids termed the 
carboxyterminal-extension (CTE). Within the zinc finger motifs are the P-box and D-
box, named according to their relative position within the DBD, which have been 
shown to be involved in the recognition of different nuclear receptor REs (Umesono 
and Evans, 1989). Crystallographic studies have provided insightful structural models 
of the way NRs bind and recognise the appropriate response elements. The domain 
includes two main α-helices, of which the N-terminal helix possesses the P-box and 
the C-terminal helix resides between the D-box and the CTE. Such studies on the 
DBD have indicated that the N-terminal helix binds to DNA in the major groove 
making direct contacts to the nucleotides of the RE, and the C-terminal helix 
overlaying the structure (Luisi et al., 1991; Rastinejad et al., 1995; Zhao et al., 1998). 
In addition, the D-box has also been shown to be important in the determination of 
partner when receptors dimerise (Zechel et al., 1994). The CTE is also reported to be 
involved in dimerisation and may make additional contacts with DNA (Rastinejad et 
al., 1995; Zhao et al., 1998). 
The hinge region (region D) lacks sequence conservation across the superfamily 
and acts as a linker between the DBD and LBD. It confers flexibility between the two 
domains and plays a role in receptor dimerisation and RE recognition. Although 
relatively little is known about the role of this region, it appears it may be involved in 
transcriptional repression both by a corepressor independent mechanism (Liao et al., 
2003), and also by potentially stabilising corepressor binding (Wang et al., 2001). The 
LBD (region E) is moderately conserved throughout the superfamily, and is a 
multifunctional domain. Ligand binding can induce nuclear localisation, receptor 
dimerisation (Fawell et al., 1990), and the binding of ligand dependent cofactors 
(Cavailles et al., 1994; Onate et al., 1995). The LBD forms a second independent 
activation domain, termed AF-2 that contrasts the function of AF-1 due to its ligand 
dependence (Danielian et al., 1992). Although these actions are receptor specific and 
thus do not apply to all NRs, the LBD can be thought of as a molecular switch that, 
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upon ligand binding, is responsible for a conformational change resulting in activation 
of the receptor. 
The structural paradigm of the nuclear receptor superfamily clearly indicates 
NRs possess distinct modular regions that underpin the biological function of the 
proteins. The LBD is of particular interest to both academia and the pharmaceutical 
industry as it is responsible for activating NRs in response to ligand, and as such is an 
attractive region to target pharmacologically. Structural studies and molecular 
dissection of the LBD have proved fruitful in aiding the understanding of the 
mechanisms by which the domain functions.  
 
1.3.2 Structure of the Ligand Binding Domain 
Solution of the 3-dimensional structures of several nuclear receptor LBDs in the 
apo and holo configurations through X-ray crystallography has shown a strong 
conservation in overall structure. The first ligated LBDs structures to be solved were 
the thyroid hormone receptor (TR) α and retinoic acid receptor (RAR) γ (Renaud et 
al., 1995; Wagner et al., 1995), and such structural studies have shown that the 
secondary structure of LBDs generally consists of 12 α-helices separated by 3 
antiparallel β-sheets producing a box-like structure. The structural conservation of the 
LBD is observed across the superfamily, even in receptors that possess a relatively 
low homology. Comparison of the PPARα and TRα LBD crystal structures show 
conservation in 3-dimensional structure, yet they only share ~22% homology (figure 
1.4) (Cronet et al., 2001; Ye et al., 2003). 
Within the 3-dimensional structure of the LBD a region has been identified 
termed the ligand binding pocket, which contains residues responsible for physical 
interaction with the ligands. However, the crystal structures of several NR LBDs has 
shown the exact positioning of the ligand binding pocket within the LBD is variable 
(Love et al., 2002; Nolte et al., 1998; Renaud et al., 1995; Wagner et al., 1995; 
Watkins et al., 2001). Furthermore, the size of the ligand binding pocket varies 
greatly across the superfamily ranging from 30Å3 within the Drosophila DHR38 
receptor to 1400Å3 in the PPAR receptors (reviewed in Li et al., 2003). It appears that 
those receptors with larger binding pockets, such as the PPARs and the pregnane X 
receptor (PXR), function to sense metabolites and may be regarded as promiscuous as 
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Figure 1.4 The NR LBD Architecture is Conserved Across the Superfamily 
Schematic of the LBD crystal structures of A) PPARα bound to AZ242 (protein 
data bank ID: 1I7G; Cronet et al, 2001) and B) TRα bound to IH5 (protein data 
bank ID: 1NAV; Ye et al, 2003). The 3-dimensional architecture of the LBDs is 
well conserved despite the divergence of the amino acid sequence. In both 
structures helix 12 (H12) is positioned over the ligand binding pocket and provides 
a surface upon which cofactors may bind through LXXLL domains to modulate 
transcription. Image was generated using 3D Molecule Viewer which forms part of 
the Vector NTI software suite. 
A) 
B) 
H12 
H12 
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they bind a wide range of ligands, which contrasts with the steroid receptors that bind 
a narrower range of ligands and possess smaller cavities (Li et al., 2003). It is 
conceivable that a larger ligand binding pocket enables a receptor to bind a number of 
different ligands with potentially different amino acids within the cavity forming 
molecular interactions to mediate such binding. This has been found to be the case for 
PXR, which is not only promiscuous in its ligand binding, but also may bind a single 
ligand in a number of orientations (Watkins et al., 2001). Interestingly, a recent study 
has shown that the large cavity within PPARγ can accommodate two copies of 
oxidised fatty acids at the same time, which is the first example of such ligand binding 
(Itoh et al., 2008). Furthermore, a number of ligand binding determinants were 
observed for the different ligands bound within the PPARγ binding pocket. 
Structural studies have also provided mechanistic insights to the effects of 
ligand binding. Potentially the most important mechanistic observation made from 
structural studies is that upon the binding of ligand, receptor LBDs undergo a 
conformational change that allows helix 12 to be repositioned above the ligand 
binding pocket and held tight towards the body of the LBD (figure1.4) (Bourguet et 
al., 1995; Cronet et al., 2001; Love et al., 2002; Renaud et al., 1995; Wagner et al., 
1995; Ye et al., 2003). Such repositioning is thought to promote the release of 
corepressor molecules that bind to unligated receptors, and also provides a surface to 
which coactivators can bind and positively modulate the transcription of target genes.  
Although there is a strong conservation of 3-dimensional structure across the 
superfamily, the amino acid sequences of NR LBDs can be rather divergent when 
aligned. However, such alignments show that certain key residues are conserved 
within most NR LBDs. Receptor alignments show the (F/Y/W)(A/S/I) 
(K/R/E/G)XXXX(F/L)XX(L/V/I)XXX(D/S)(Q/K)XX(L/V)(L/I/F) motif is present in 
all receptors, however a much simpler form of the motif is present in most receptors 
consisting of the consensus (F/W)AKXXXXFXXLXXXDQXXLL (figure 1.5A) 
(Wurtz et al., 1996). These residues form parts of helix 3 to helix 5 and are thought to 
be in close proximity to the core of the ligand binding pocket, and thus are potentially 
involved in the downstream effects following ligand binding. In addition, the AF-2 
region of helix 12 is well conserved across the super family. The consensus sequence 
of AF-2 is represented by a glutamic acid residue flanked either side by 2
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FAK       L        L 
YSKxxxxFxxVxxxDQxxLI H3 and H5 Consensus 
WIE    L  I   SK  VF 
  G 
 
FAKxxxxFxxVxxxDQxxLI Simplified Consensus 
W 
LL  ML 
MIxEII  AF-2 Consensus 
FF  VF 
A) 
B) 
1.5 Consensus Sequences of the Nuclear Receptor Ligand Binding Domain 
A) The conserved motif present within helices 3 and 5 of all nuclear receptor 
LBDs, and the simplified consensus sequence present in most nuclear receptors 
(Wurtz et al., 1996). 
 
B) The conserved AF-2 motif present in helix 12 of nuclear receptor LBDs 
(Danielian et al., 1992; Wurtz et al., 1996). The glutamic acid required for full AF-
2 activity is shown in red. 
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hydrophobic residues (figure 1.5B). The glutamic acid present at the centre of the 
amphipathic helix is required for AF-2 mediated receptor activity (Danielian et al., 
1992). 
In the structural paradigm described, the ligand binding domain of nuclear 
receptors clearly plays an important role in the function of the receptor by acting as a 
molecular switch to activate the receptor to mediate the recruitment and interaction 
with other signalling proteins. However the orphan NR, Nur77-related factor 1 (Nurr1) 
is considered to be a constitutively active receptor important in developmental 
processes. Initially studies focussed on the identification of the endogenous ligand for 
Nurr1, however the solution of the Nurr1 LBD crystal structure showed that it was 
unlikely to bind ligand (Wang et al., 2003). The LBD exists in a conformation similar 
to that of an activated NR, however no ligand binding pocket appears to be present 
due to the tight packing of bulky side chains from amino acid residues within the 
surrounding helices. Similarly, the adopted orphan receptor hepatocyte nuclear factor 
(HNF) 4α binds to fatty acids constitutively, which retains the LBD in an active 
conformation (Wisely et al., 2002). This allows the receptor to possess constitutive 
activity, which is thought may be regulated by post translational modifications to the 
receptor (Viollet et al., 1997; Wisely et al., 2002). 
 
1.4 Function of Nuclear Receptors 
1.4.1 Regulation of NR Mediated Transcription 
The actions of nuclear receptors with regards the transcriptional control of genes 
is well characterised. However, observations in the 1990s showed that NR function 
was regulated by a class of proteins termed coregulators, as had been predicted by 
initial squelching experiments (Tasset et al., 1990). Later reports showed they could 
be recruited in a ligand dependent fashion, and provided another layer of control to 
the transcriptional activation of NR target genes (Cavailles et al., 1994; Halachmi et 
al., 1994). 
The NR coregulators consist of coactivator and corepressor molecules, which 
function as platforms to recruit other activating or repressive proteins capable of 
remodelling the chromatin to which they are bound. Coactivators include proteins 
such as p300, CREB binding protein, thyroid hormone receptor-associated protein, 
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and the p160 family of proteins, which consist of steroid receptor coactivator-1, 
glucocorticoid receptor interacting protein-1 and receptor-associated coactivator-3 
(Chakravarti et al., 1996; Fondell et al., 1996; Hong et al., 1996; Li et al., 1997; 
Onate et al., 1995). Their recruitment occurs through the NR box, an amphipathic α-
helical LXXLL that is critical for NR interaction (Heery et al., 1997). Some 
coactivators possess intrinsic histone acetyltransferase activity, which produces an 
open chromatin structure associated with transcriptionally active genes acetylating 
histones H3 and H4 within the chromatin (Spencer et al., 1997). The open 
configuration of transcriptionally active chromatin then allows the recruitment of 
general transcription factors and the basal transcription machinery to the promoter. 
Conversely corepressors, such as SMRT and N-CoR, bind to NRs in the absence 
of ligand (Chen and Evans, 1995; Horlein et al., 1995). This interaction occurs 
through a motif that is analogous to the NR box, termed the CoRNR box. The 
consensus sequence for the this motif is (L/I)XX(I/V)I, of which the corepressors 
SMRT and N-CoR possess two each (Hu and Lazar, 1999). This consensus 
duplication is thought to have a functional role in the mechanism by which 
corepressors interact with NRs, and may provide a receptor-dimer specificity allowing 
the differentiation between receptor complexes. In contrast to other corepressors 
RIP140 is binds to NRs in the presence of agonist, which initially led to the 
assumption that the protein acted as a coactivator (Cavailles et al., 1995). In addition, 
RIP140 bound to NRs via the coactivator NR box motifs, 10 of which are present 
within the structure of RIP140 (Heery et al., 1997). However, further functional 
analysis identified RIP140 as a corepressor of nuclear receptors (Joyeux et al., 1997; 
Lee et al., 1998; Lee and Wei, 1999; Subramaniam et al., 1999; Treuter et al., 1998). 
The binding of corepressors results in the recruitment of histone deactylases that 
possess enzymatic activity capable of removing the activating acetyl groups from the 
histones within the chromatin (Nagy et al., 1997). This epigenetic regulation of target 
gene promoters allows chromatin to condense preventing the recruitment of 
transcription factors. 
 
1.4.2 Elucidation of NR Function Using Null Animals 
The use of knockout mice in which the target gene of interest has been disrupted 
has led to many insights into nuclear receptor physiology. One of the most well 
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studied models is that of the ER knockout (ERKO) mice. ERα (αERKO), ERβ 
(βERKO) or both receptors (αβERKO) have been deleted in mice (Couse et al., 1999; 
Dupont et al., 2000; Krege et al., 1998; Lubahn et al., 1993), producing different 
phenotypes dependent on the physiological signalling of the respective receptor. 
Deletion of ERα in mice resulted in infertility in both sexes (Lubahn et al., 1993), 
which was later shown to be independent of oestrogen synthesis for male mice, 
suggesting the ERα signalling required for fertility in males may be ligand 
independent (Fisher et al., 1998). In βERKO mice, females displayed a compromised 
reproductive phenotype although they were fertile, indicating that both ERα and ERβ 
are required for normal female fertility and only ERα is required for normal male 
fertility (Krege et al., 1998). Unsurprisingly, αβERKO mice are infertile, similar to 
the phenotype of αERKO (Couse et al., 1999; Dupont et al., 2000). Examination of 
the respective phenotypes of ERKO mice has demonstrated a role for both ERα and 
ERβ in regulating bone density. αERKO mice possess bones with decreased density 
in both sexes, whereas βERKO females possess denser bones but males appear 
normal (Vidal et al., 2000). This suggests ERα plays a positive role in the 
mineralisation of bone in both sexes but ERβ is a negative regulator of mineralisation 
in females. 
The use of knockout mouse technology has clearly proven to be useful in 
understanding the physiological role of proteins within the context of the whole 
organism. However, disruption of a gene that is required for development may lead to 
embryonic lethality or, as exemplified by GR null animals, can result in gross 
phenotypic abnormalities that can be lethal at birth (Cole et al., 1995; Schmid et al., 
1995). In the case of GR a conditional knockout mouse system was used that allows 
the disruption of a targeted gene in specific tissues. Conditionally disrupting GR by 
crossing floxed GR mice with mice expressing Cre recombinase from the nestin 
promoter showed that GR expression was not required in the nervous system for 
development (Tronche et al., 1999). Furthermore, such animals were shown to 
possess reduced stress levels, implicating GR signalling in such processes. The use of 
knockin mice has also proved fruitful when studying the physiological roles of GR. 
Mice carrying the point mutation A458T were generated by targeting exon 4 of the 
gene (Reichardt et al., 1998). The resultant mice, named GRdim/dim mice, possessed a 
mutant GR receptor that failed to dimerise, bind to glucocorticoid REs and 
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transactivate target genes, although the expressed mutant GRs were still capable of 
transrepression (Reichardt et al., 1998). The use of such mice has allowed the 
dissection of the pathways involved in physiological functions that GR regulates. The 
growth, development, and spatial learning of an animal is dependent on GR 
expression but not its ability to directly activate target genes (Bayo et al., 2008; Cole 
et al., 1995; Oitzl et al., 2001; Schmid et al., 1995; Tronche et al., 2004). This is in 
contrast with the ability of GR to regulate T-lymphocyte development, which is 
dependent on direct gene regulation by GR (Reichardt et al., 1998). However, the 
involvement of GR in the regulation of stress responses appears to require both the 
direct and indirect regulation of target genes (Reichardt et al., 1998). 
The use of animal studies to examine the effects of gene disruption has proved 
to be a powerful research tool and provided an insight into the physiological functions 
of nuclear receptors. However, studies using explanted tissue and cell based assay 
systems have also been useful in understanding the function of nuclear receptors. 
Such studies have shown that the effects mediated by nuclear receptor signalling may 
not necessarily result in transcription of target genes directly, but may result in 
stimulation of intracellular signalling pathways. These are regarded as non-genomic 
effects exerted by nuclear receptors. 
 
1.4.3 Non-genomic Actions of NRs 
Although much is clearly known about NR function within the context of direct 
target gene regulation, evidence is emerging to suggest NRs may be involved in non-
genomic functions. The most well characterised receptor in terms of actions outside 
those of transcriptional regulation is the ER. Preliminary observations almost three 
decades ago first showed that oestrogen could bind to the outer surfaces of 
endometrial and liver cells (Pietras and Szego, 1977). It was later shown that 
macromolecules capable of oestrogen binding could be isolated from purified 
membranes of hepatocytes derived from ovariectomised rat liver (Pietras and Szego, 
1980), giving rise to the idea of functional membrane steroid receptors. In the 
proceeding years there were many observations that steroid hormone administration 
could produce rapid effects on intracellular signalling pathways associated with 
membrane receptors (Castoria et al., 2001; Migliaccio et al., 2000; Migliaccio et al., 
1996; Migliaccio et al., 1998). However, confusion arose as to whether the receptors 
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responsible for mediating the effects of the steroid hormones acting at the plasma 
membrane were identical to those responsible for transcriptional regulation. To 
address this confocal laser microscopy was used to confirm the presence of the ER 
nuclear receptor at the cell membrane (Pappas et al., 1995). Furthermore, it was 
confirmed through transfection of Chinese hamster ovary cells, which do not express 
endogenous ER, that both exogenous ERα and ERβ isoforms are present at the cell 
membrane (Razandi et al., 1999). 
The mechanism by which the ER is localised to the membrane remains unclear 
as the receptor itself is lacking in any hydrophobic region thought to be typically 
necessary for integration into the plasma membrane. It is known that the cysteine 
residue at position 447 is palmitoylated, a post-translational modification that is 
important in localising ERα to the cell membrane and for interactions with other 
proteins (Acconcia et al., 2005). Such interactions may also be a potential mechanism 
by which the ER is localised to the membrane, as an interaction with a membrane 
integrating protein would tether the receptor to the plasma membrane. ERα interacts 
with caveolin-1 (Razandi et al., 2003), a typical marker for caveolae (Rothberg et al., 
1992), suggesting ERα may be recruited to lipid microdomains at the cell surface. 
Mutation of serine 522 in ERα prevented this interaction, although this effect did not 
ablate ERα recruitment to the plasma membrane (Razandi et al., 2003), thus other 
mechanisms must be involved in ERα membrane recruitment. There is evidence to 
suggest ER interacts with other cell surface molecules, supporting the idea that cross-
talk between ER and other receptors occurs to activate intracellular signalling 
pathways. It has been observed that ER can form ligand dependent ternary complexes 
with Shc and IGFR, and with c-Src and PELP1 to modulate mitogen activated protein 
kinase signalling pathways (Song et al., 2004; Wong et al., 2002). However, the 
relevance of such interactions in determining the localisation of the ER to the plasma 
membrane is unclear, as the interactions have been described to be ligand dependent, 
yet the ER can be observed at the cell membrane in the absence of ligand (Pappas et 
al., 1995). 
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1.4.4 Non-Nuclear Receptor Mediated Steroid Signalling 
In addition to the observations that oestrogen could signal through ER mediated 
non-genomic pathways, further complexity arose from reports that oestrogen could 
signal through receptors at the membrane that were not related to the ER. GPR30 is an 
orphan G-protein coupled receptor, for which evidence is building to suggest its 
involvement in non-genomic oestrogen signalling. SKBR3 cells that lack both ERα 
and ERβ are responsive to oestrogen, resulting in activation of extracellular signal-
regulated kinase (ERK) through cross-talk with the epidermal growth factor receptor 
in a heparin-bound epidermal growth factor dependent manner (Filardo et al., 2000). 
In addition the same study showed that overexpression of GPR30 in MDA-MB-231 
cells, which lack ERα and GPR30, but express ERβ, also resulted in ERK activation 
in response to oestrogen. Later work from the same group in a similar set of 
experiments showed that GPR30 also activates adenylyl cyclase in response to 
oestrogen (Filardo et al., 2002), suggesting the receptor couples with Gs proteins. 
Further evidence that the rapid activation of ERK and adenylyl cyclase in response to 
oestrogen is mediated through GPR30 is gained from the observation that 
antioestrogens act as agonists in the above adenylate cyclase and ERK activity assays 
(Filardo et al., 2000; Filardo et al., 2002). Therefore questions are raised as to exactly 
what effects antioestrogenic drugs have when taken therapeutically and also whether 
it is possible to produce selective drugs that can target either nuclear receptor or 
GPR30 activated pathways. 
It is evident that the LBD region of NRs plays a role in the different NR modes 
of action when transducing endocrine signalling in the nucleus, cytoplasm and at the 
cell surface within the context of both gene regulation and effects on non-genomic 
signalling pathways. Thus it is conceivable that a ligand binding domain-like region 
may be present within proteins not directly related to NRs, functioning as a regulatory 
domain or molecular switch within cell signalling pathways. 
 
1.5 Evolution of the Nuclear Receptor Superfamily 
It has been known for some time that the nuclear receptor superfamily existed 
prior to the evolutionary divergence of deuterostomes and protostomes (Laudet et al., 
1992), which raises questions regarding the evolutionary origin of the superfamily. It 
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has been postulated that the superfamily is likely to have arisen from a single 
ancestral gene and that gene duplication events played an important role in the 
expansion and divergence of the superfamily (Laudet, 1997). Two waves of such 
duplication are thought to have occurred, with the first wave happening prior to the 
divergence of arthropods and vertebrates resulting in the emergence of the six 
subfamilies receptors within the superfamily (Escriva et al., 1997; Laudet, 1997). The 
second wave of gene duplication is thought to be responsible for the diversification of 
the superfamily, giving rise to subfamilies of receptor type, such as the α and β forms 
of ER and the α, β and γ forms of the oestrogen related receptors (Laudet, 1997). 
Other analyses support the idea that gene duplication played a central role in the 
expansion and diversification of the superfamily, as it is thought that such duplication 
events account for the presence of over 270 receptors within the genome of C. elegans 
(Sluder et al., 1999), many of which are related to HNF4 (Robinson-Rechavi et al., 
2005). 
The members of the nuclear receptor superfamily possess divergent ligand 
binding properties as there are orphan receptors that are predicted not to bind ligand, 
adopted orphans that are promiscuous in their ligand binding characteristics, and some 
receptors, such as the steroid receptors, that are more specific in their ligand binding. 
Study of the evolution of the superfamily may provide some clues as to how such 
divergence in ligand binding properties arose from a putative single ancestral gene. 
Phylogenetic analysis has suggested that orphan receptors with no known ligand may 
be more ancient than receptors possessing ligand, leading to the suggestion that the 
putative ancestral gene was an orphan receptor and ligand binding was an evolutional 
gain of function (Escriva et al., 1997). Recent work has reported that heme binds 
within the ligand binding pocket of the Drosophila E75 receptor and appears to be 
required for stability of the LBD (Reinking et al., 2005). The oxidative state of the 
heme molecule may be altered when bound to the LBD of E75, suggesting the 
receptor acts as a redox sensor (Reinking et al., 2005). Further studies have shown 
that the mammalian orthologues of E75, Rev-erbα and Rev-erbβ, also bind heme as a 
ligand, although the receptors were capable of forming stable structures in the apo 
state (Raghuram et al., 2007). In addition, the ecdysone receptor, which is the 
Drosophila orthologue of the farnesoid X receptor in mammals, is known to bind 
ecdysteroids to regulate target genes (Koelle et al., 1991). It is therefore clear that 
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gain of function for receptors to bind ligands emerged prior to evolutionary 
divergence of deuterostomes and protostomes, or that the ability to bind ligand 
simultaneously emerged in both taxa. 
Analysis of the steroid receptor evolution suggests that the ability to bind ligand 
predates the evolutionary divergence of deuterostomes and protostomes. The cloning 
of a mollusc ER orthologue from Aplysia californica suggested that the steroid 
subfamily of NRs was present in invertebrates (Thornton et al., 2003). Protein 
sequence alignments of the mollusc ER to the human ERα showed the mollusc 
receptor was 88% similar to the human ERα DBD, and 35% similar to the LBD. 
Functional characterisation of the mollusc receptor in reporter gene assays showed 
that the DBD was capable of binding to an oestrogen RE, and that the LBD possessed 
an AF-2 dependent constitutive activity that was unaltered by ligand administration. 
Furthermore, the LBD did not bind oestradiol (Thornton et al., 2003). To determine 
whether oestrogen binding is a gain of function in mammalian ERs, or a loss of 
function in mollusc ERs an ancestral LBD was generated by Thornton et al (2003) 
using maximum likelihood reconstruction techniques to infer the amino acid sequence. 
The ancestral LBD was observed to activate transcription in reporter gene assays in 
response to oestradiol, and also bind oestradiol with a Kd of 198nM, which is a 
relatively low affinity compared to the dissociation constant of 0.8nM associated with 
the human ERα LBD (Thornton et al., 2003). The evidence presented by Thornton et 
al (2003) suggests that the steroid subfamily of nuclear receptors have emerged prior 
to the evolutionary divergence of deuterostomes and protostomes, and that such 
ancestral steroid receptors may have bound a ligand to regulate their activity. 
The view that mollusc receptors may bind ligand has also been strengthened by  
the cloning of the Biomphalaria glabrata orthologue of RXR (Bouton et al., 2005). 
Electrophoretic mobility shift assays with a number of direct repeat RE binding sites 
showed that the mollusc RXR could weakly bind to the REs as homodimers, and 
much more strongly as heterodimers with human FXR and PPARα. In addition, it was 
observed that the mollusc RXR binds 9-cis retinoic acid, which could result in 
transactivation in reporter gene assays (Bouton et al., 2005). These data indicate that 
the RXR orthologue potentially possesses a ligand similar to 9-cis retinoic acid in the 
mollusc, which may regulate its activity. As the ligand for the mollusc RXR is likely 
to be related to that from mammals, it is possible that the emergence of an ancestral 
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nuclear receptor that could bind ligand occurred prior to evolutionary divergence of 
deuterostomes and protostomes. 
The multiple domain architecture of nuclear receptors has also led to the idea 
that the ancestral NR gene may be the product of genomic rearrangements that 
brought together DNA coding for pre-existing protein modules (Barnett et al., 2000; 
Laudet et al., 1992). The zinc finger-possessing DBD of the NR superfamily shares 
homology to those of the LIM and GATA transcription factors, orthologues of which 
are found in yeast, suggesting a common evolutionary ancestor for the module 
(Clarke and Berg, 1998). Furthermore, primary sequence alignments have provided 
evidence that the LBD region of NRs is related to Pex11p (Barnett et al., 2000). 
Pex11p is present in eukaryotes, and is implicated in peroxisome proliferation (Li et 
al., 2002a; Li et al., 2002b). Reported alignments show that Pex11p is most similar to 
the LBDs of the PPAR family of NRs, and possesses moderately conserved key 
residues pertaining to NR LBDs (Barnett et al., 2000). Analysis of the predicted 
secondary structure of Pex11p in conjunction with the crystal structures of the PPARs 
allowed the authors to conclude that Pex11p is likely to possess a similar folded 
structure as the LBD of NRs (Barnett et al., 2000). The suggestion may therefore be 
raised that the ancestral nuclear receptor gene may have arisen from a fusion of the 
zinc finger DBD, similar to that found in LIM and GATA transcription factors, and an 
LBD-like module related to Pex11p. Both modules are present within eukaryotes 
outside the animal kingdom. However the putative single ancestral gene that the NR 
superfamily arose from is generally thought to be metazoan in origin, as NRs appear 
to be restricted to the animal kingdom (Escriva et al., 1997). However a recent study 
in yeast has indicated NR superfamily members may be present in unicellular 
eukaryotes (Phelps et al., 2006), adding support to the idea that the ancestral gene or 
genes related to the nuclear receptor superfamily may date further back in evolution 
than initially anticipated. 
 
1.6 NRs that do not Conform to the Structural Paradigm 
Although the nuclear receptor superfamily shares a common domain and 3-
dimensional architecture, there are examples of receptors that do not fit in the 
generalised model above. The orphan nuclear receptors dosage sensitive sex reversal - 
adrenal hypoplasia congenita gene on the X chromosome, gene 1 (DAX-1) and short 
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heterodimers partner (SHP) also do not possess the canonical zinc finger DBD 
associated with the nuclear receptor superfamily. DAX-1 was originally identified as 
the gene responsible for the developmental disorder X-linked adrenal hyperplasia 
congenital, and SHP was identified through a yeast two-hybrid screen for proteins that 
interact with nuclear receptors (Seol et al., 1996; Zanaria et al., 1994). Both receptors 
have been shown to interact with other nuclear receptors, and there is evidence to 
suggest they function as repressors. However, the mechanisms by which the receptors 
exert their respective repressive may differ. DAX-1 is thought to recruit corepressors, 
such as N-CoR, and function as a trans-repressive molecule (Crawford et al., 1998). 
SHP has also been reported to inhibit the transcriptional effects of several nuclear 
receptors, although the mechanism by which this occurs has yet to be elucidated 
(Ourlin et al., 2003). Furthermore, more recently SHP has also been shown to interact 
with non-nuclear receptor transcription factor HNF3, exerting a repressive effect on 
its transcriptional activity through an interaction with the forkhead domain of HNF3, 
resulting in inhibition of DNA binding (Kim et al., 2004). As neither receptor 
possesses a DBD, they differ from the rest of the superfamily members, however it is 
unclear as to whether their evolution has resulted from the loss of the DBD from an 
ancestral NR, or if their existence supports the idea that NRs originated from two 
distinct modules that were fused as a result of DNA rearrangements. 
It is clear that in general the members of the nuclear receptor superfamily are 
subject to the same structural paradigm. However nuclear receptors such as DAX-1 
and SHP represent a class of nuclear receptor superfamily members that do not 
conform precisely to the suggested structural model. It is therefore conceivable that 
there may be a number of other proteins that share some similarities in structure to 
NRs, yet are not homologous nor possess all the domains associated with the typical 
NR architecture. 
 
1.7 Bioinformatic Predictions for Novel Nuclear Receptors 
Clearly nuclear receptors are important regulators within the cell, and as such 
are implicated in many disease processes, including cancer, obesity and osteoarthritis. 
Furthermore, as NRs are known to be responsive to endogenous ligands they 
represent a prime target for the development of therapeutics. Together this has led to 
much interest from both academia and the pharmaceutical industry in characterising 
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NR biology. Currently, bioinformatic analysis using sequence homology searches 
with the databases available online suggests that there are a total of 48 nuclear 
receptors within the human genome (Robinson-Rechavi et al., 2001). Inpharmatica 
are a biotechnology company specialising in the prediction of protein folds using 
bioinformatic annotations. By employing sequence-structure compatibility or 
“threading” techniques using their protein fold prediction algorithm, Inpharmatica 
have identified several proteins thought to possess regions within their structure that 
fold in a similar way to the ligand binding domain of nuclear receptors. 
As discussed above, the NR LBD is moderately conserved at the primary 
sequence across the superfamily, however possesses an overall conserved 3-
dimensional structure. Detecting structural relationships between sequences of ~20% 
homology, as in the case for TRα and PPARα, may not be possible through primary 
sequences alignments. To overcome this issue, threading techniques were pioneered 
to enable protein fold recognition, and thus detect groups of proteins that may be 
analogous in function yet lack primary sequence homology. Such techniques involve 
the threading of the target sequence through a representation of a fold family, whilst 
estimations are made as to whether the target sequence and the fold representation are 
compatible (Shortle, 1997). This has been shown to provide an accurate method of 
fold recognition, and in the guise of GenTHREADER has been developed such that 
the technique may be automated, vastly improving sequence throughput (Jones, 1999; 
Shortle, 1997). 
Building on the GenTHREADER technology, Inpharmatica have developed a 
powerful algorithm termed Genome Threader, which compares all the sequences 
available in the proteome to all the crystal structures available in the protein data bank 
to determine compatibility. When compatible sequences are identified their predicted 
secondary structures are aligned to those of target proteins, and conserved residues are 
searched for. This technology has been used to successfully identify the yeast 
transcription factor Oaf1 as possessing a LBD fold (Phelps et al., 2006). Oaf1 is 
known to upregulate target genes in the absence of glucose and presence of oleate, 
and was shown to be critical for oleate signal transduction (Baumgartner et al., 1999). 
The structural predictions assigned the LBD of Oaf1 to the region of the protein 
between amino acids 254 and 563, with the highest compatibility observed with the 
structure of human ERβ, despite only sharing 12% sequence identity. Alignment of 
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the predicted secondary structure of Oaf1 to that of human nuclear receptors showed 
an overall conservation (Phelps et al., 2006). The motif present within helices 3 and 5 
of the LBD as described by Wurtz et al (1996) is not conserved in Oaf1, and the 
hydrophobic motif pertaining to AF-2 is semi-conserved, however lacks the glutamic 
acid residue reported to be important for AF-2 mediated receptor activation 
(Danielian et al., 1992). Functional analysis showed that oleate was able to activate 
Oaf1 as observed in reporter gene assays, which was abrogated following mutation of 
residues thought to line the putative ligand binding pocket (Phelps et al., 2006). 
Furthermore, binding studies also showed that the region predicted to fold as a ligand 
binding domain within Oaf1 is capable of binding oleate with a Kd of 17nM. The 
functional characterisation of Oaf1 as a protein with a region capable of binding 
oleate as a ligand, lends support to the structural predictions made by Inpharmatica, 
and begins to prove the principle that it is possible to detect similar structures between 
proteins that do not share sequence homology.  
Inpharmatica have used the threading approach offered by Genome Threader to 
identify novel proteins within the human proteome that possess putative folds within 
their structure, particularly those that possess kinase-like domains and nuclear 
receptor-like ligand binding domains. In the case of the NR LBDs, a number of novel 
proteins predicted to possess a similar fold were identified, which were named novel 
receptors. To further investigate the likelihood that the identified novel receptors 
possessed a similar structure to NR LDBs, the identified sequences were individually 
aligned to the LBD regions pertaining to bone fide NRs and conservation of key 
residues forming part of the conserved NR LBD motifs were examined. Of these 
annotated proteins, the candidate with the strongest prediction was NR3, which 
possessed a prediction that was at least comparable to the strength of prediction 
observed for Oaf1 (Phelps et al., 2006). NR3 is identical to the protein transient 
receptor potential cation channel, subfamily C, member 4 associated protein 
(TRPC4AP), which is also known as TNF receptor-associated ubiquitous scaffolding 
and signalling protein (TRUSS), which has been proposed to modulate TNFα 
signalling (Soond et al., 2003; Soond et al., 2006). 
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1.8 NR3 Bioinformatic Predictions 
Genome Threader identified NR3, which comprises 797 amino acids, as 
possessing a NR LBD structure between amino acids 477-722. An armadillo repeat 
structure was also predicted to be present between amino acids 53-525, a motif which 
is known to be important in protein-protein interactions in many processes such as 
intracellular signalling, cell-cell interactions and nuclear import (Herold et al., 1998; 
Kaufmann et al., 2000; Song et al., 2003). A summary of the bioinformatic 
predictions for NR3 is presented in figure 1.6. The putative LBD structure within 
human NR3 is predicted to be compatible with the structures of 18 bona fide nuclear 
receptors from the PDB, yet the strongest match is with RARγ, which shares only 
16% identity. Examining other species, the NR3 protein sequences from the mouse, 
rat, pufferfish, zebrafish and a simple chordate named Oikopleura dioica were also 
predicted by the Genome Threader algorithm to possess a NR LBD fold, supporting 
the bioinformatic predictions for the human protein. Alignment of these sequences 
shows the region is very well conserved, with absolute conservation between the 
human, mouse and rat (figure 1.7). Alignment of both the full length and putative 
LBD sequences of human NR3 to the other species on an individual basis allows the 
level of identity and similarity between species to be determined (table 1.1). This 
analysis shows the homology between mouse and rat sequences to the human 
sequence is almost 100% in terms of the full length protein. Homology between 
pufferfish and zebrafish sequences is also high when compared to the human 
sequence, ranging from 70-80% identity. Homology between Oikopleara and human 
sequences is less conserved in terms of amino acid identity and similarity, which is 
not unexpected due to the evolutionary distance between the species. This analysis 
therefore further highlights the level of conservation of the NR3 across different 
species, which may suggest NR3 plays an important biological role. 
The predicted secondary structure of NR3 is mainly alpha helical overall, and 
predicted secondary structure alignment of the NR3 putative LBD and the LBD of 
bona fide nuclear receptors shows the proteins have a reasonable degree of similarity 
(figure 1.8). Furthermore, the (F/W)AKXXXXFXXLXXXDQXXLL motif thought to 
form part of the ligand binding pocket core is semi-conserved in NR3 (figure 1.8) 
(Wurtz et al., 1996). There is also semi-conservation of the hydrophobic residues 
present within the putative helix 12 of NR3, although it does not possess the glutamic
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Figure 1.6 Summary of the Bioinformatic Predictions for NR3 
The Armadillo Repeat-like structure is predicted to reside between amino acids 53 and 525. The NR LBD-like structure is 
predicted to span amino acids 477-722. 
Nuclear Receptor LBD Armadillo Repeat 
1 53 477 722 797 525 
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Human       NNQELNELSAISLKANIPEVEAVLNTDRSLVCDGK--RGLLTRLLQVMKKEPAESSFRFWQARAVESFLRGTTSYADQMFLLKRGLLEHILYCIV 
Mouse       NNQELNELSAISLKANIPEVEAVLNTDRSLVCDGK--RGLLTRLLQVMKKEPAESSFRFWQARAVESFLRGTTSYADQMFLLKRGLLEHILYCIV 
Rat       NNQELNELSAISLKANIPEVEAVLNTDRSLVCDGK--RGLLTRLLQVMKKEPAESSFRFWQARAVESFLRGTTSYADQMFLLKRGLLEHILYCIV 
Pufferfish  NSQELNELSAISMKANIPEVEALVNTDRSLVCDGK--KGLLTRILTVMKREPPDSSFRFWQARAVESFLRGATSYADQMFLLKRGLLEHILFCII 
Zebrafish 1 NAQELNELSAISLKANIPEVEALVNTDRSLVCDGK--KGLLTRVLTVMKKEPPDSSFRFWQAKAVESFLRGATSYADQMFLLKRGLLEHILFCII 
Zebrafish 2 SGQELNELSDIYLNANIFEMEALNNTDRNLVCDGK--KGLLTRLISVMKKEPIDSSFRFWQARAVESFLRGTPSYADQVFLLRRGLLEHILYCII 
Oikopleura  SKPELQEIIRSCAELGTEPNPSVLHVLENKLYCGEGERGLLSNILVAMKEAKETSTLRFWIARAVESFLRGPTCLVDQTFYLNRGILDHLLHLLL 
 
Human       DSECKSRDVLQSYFDLLGELMKFNVDAFKRFNKYINTDAKFQVFLKQINSSLVDSNMLVRCVTLSLDRFENQ-VDMKVAEVLSECRLLAYISQVP 
Mouse       DSECKSRDVLQSYFDLLGELMKFNVDAFKRFNKYINTDAKFQVFLKQINSSLVDSNMLVRCVTLSLDRFENQ-VDMKVAEVLSECRLLAYISQVP 
Rat       DSECKSRDVLQSYFDLLGELMKFNVDAFKRFNKYINTDAKFQVFLKQINSSLVDSNMLVRCVTLSLDRFENQ-VDMKVAEVLSECRLLAYISQVP 
Pufferfish  DSGCTSRDVLQSYFDLLGELMKFNIDAFKRFNKYVNTPEKFQTFLTQINSSLVDSNMLVRCIVLSLDRFESQTEDVKVVEVLSECCLLSYMARVE 
Zebrafish 1 DSGCKSRDVLQSYFDLLGELMKFNIDSFKRFNKYVNTDEKFQVFLTQINSSLVDSNMLVRCIVLSLDRFESQTEDVKVVEVLSECCLLSYMARVE 
Zebrafish 2 DSGCKSHDVLQSYFDLLGELMKFNIDAFKRFNKYVTTEEKFQMFLTQINSSLVDSNMLVRCIVLSLDRFENETNDVKVVEVFSECRLLSYMAQVE 
Oikopleura  EIKTTS-EVSQGHFDLLAELMKFNEQAFEQFEKAIGSDARFKRFMALAENSLVDSNMFIRCATLTYHKFLRA------GYDFNKSKLLHYMSSKQ 
 
Human       TQMSFLFRLINIIHVQTLTQENVSCLNTSLVILMLARRKER-LPLYLRLLQRMEHSKKYP 
Mouse       TQMSFLFRLINIIHVQTLTQENVSCLNTSLVILMLARRKER-LPLYLRLLQRMEHSKKYP 
Rat       TQMSFLFRLINIIHVQTLTQENVSCLNTSLVILMLARRKER-LPLYLRLLQRMEHSKKYP 
Pufferfish  NRLSFLFRLINIINVQTLTQENVSCLNTSLVILMLARRKAK-LPFYLNALREKEYAEKYP 
Zebrafish 1 NRLSFLFRLVNIINVQTLTQENVSCLNTSLVILMLARRRGK-LPFYLNALREKEYAEKYP 
Zebrafish 2 NRLLFLLRLISIINVQTLTQENVSCLNTSLVILMLARGRGK-LPLYLSALREKEYSEKYP 
Oikopleura  VRARLVASLIQLITPETLNQENVSCLNTSLVFMITARQIPNGLGYYLSDLSKRINSSGTP 
Figure 1.7 Alignment of the Putative NR3 LBD Protein Sequence from Different Species 
Residues identical to those in human NR3 are shown in yellow and residues with similar properties are shown in green. Semi-
conservation of key residues within NR LBD motifs are highlighted in boxes (Danielian et al., 1992; Wurtz et al., 1996). Zebrafish 1 and 
2 refer to the 2 protein sequences available from the NCBI database. 
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  Full Length NR3 Putative NR3 LBD 
  % ID % Sim % ID % Sim 
Mouse 97.6 98.0 100.0 100.0 
Rat 97.7 98.2 100.0 100.0 
Pufferfish 70.8 80.3 80.2 88.3 
Zebrafish 1 71.4 81.6 80.6 89.5 
Zebrafish 2 64.3 73.6 76.5 85.0 
Oikapleura 29.7 40.6 40.2 53.4 
Table 1.1 Homology Between the Human NR3 Sequence and Different 
Species 
Comparison by sequence alignment of the percentage identity (ID) and similarity 
(Sim) of residues between the human full length and putative LBD sequences to 
those of different species.  
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Ultraspiracle  FSIERIIEAEQRAETQCGDRALTFLRV-----GPYSTVQPDYKGAVSALCQVVNKQLFQMVEYARMMPHFAQV--PLDDQVILLKAAWIELLIAN 
Human RARγ    LSPQLEELITKVSKAHQETFPSLCQLGKYTTNSSADHRVQLDLGLWDKFSELATKCIIKIVEFAKRLPGFTGL--SIADQITLLKAACLDILMLR 
Mouse ERα    LTADQMVSALLDAEPPMIYSEYDPSR------------PFSEASMMGLLTNLADRELVHMINWAKRVPGFGDL--NLHDQVHLLECAWLEILMIG 
Human NR3      NNQELNELSAISLKANIPEVEAVLNTDVCD----------GLLTRLLQVMKKEPAESSFRFWQARAVESFLRGTTSYADQMFLLKRGLLEHILYC 
 
 
Ultraspiracle  VAWCSIVSLDDGGAGGGGGGLGHDGSFERRSPGLQPQQLFLNQSFSYHRNSAIKAGVSAIFDRILSELSVKMKRLNLDRRELSCLKAIILYNPDI 
Human RARγ    ICTRYTP---------------------------EQDTMTFSDGLTLNRTQMHNAGFGPLTDLVFAFAGQLLPLE-MDDTETGLLSAICLIC--- 
Mouse ERα    LVWRSMEH---------------------------PGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGV 
Human NR3      IVDSE-------------------CKSRDVLQSYFDLLGELMKFNVDAFKRFNKYINTDAKFQVFLKQINSSLVDSNMLVRCVTLSLDRFENQVD 
 
 
Ultraspiracle  R--------GIKSRAEIEMCREKVYACLDEHCRLEHP---GDDGRFAQLLLRLPALRSISLKCQDHLFLFRITSDRPLEELFLEQLEAPPPPG 
Human RARγ    -----GDRMDLEEPEKVDKLQEPLLEALRLYARRRRP---SQPYMFPRMLMKITDLRGISTKGAERAITLKMEIPGPMPPLIREMLE 
Mouse ERα    YTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHRRLAQLLLILSHIRHMSNKGMEHLYNMKCKNVVPLYDLLLEMLDAHRLHAP 
Human NR3      MKVAEVLSECRLLAYISQVPTQMSFLFRLINIIHV-----QTLTQENVSCLNTSLVILMLARRKERL---------PLYLRLLQRMEHSKKYPG 
 
Figure 1.8 Alignment of the Putative NR3 LBD with Bona Fide Nuclear Receptor LBDs 
Predicted secondary structure and sequence alignments of ultraspiracle from Drosophila, human RARγ, mouse ERα and human NR3. 
Red denotes predicted α-helical structure. Blue denotes predicted β-strands. Non-coloured regions are predicted coil regions. Boxes 
represent the semi-conservation of the (F/W)AKXXXXFXXLXXXDQXXLL motif (Wurtz et al., 1996), and AF-2  (Danielian et al., 
1992). 
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acid residues present in all NRs (figure 1.8) (Danielian et al., 1992). In addition, 
sequence homology searches performed by Inpharmatica using PSI-BLAST to search 
for proteins related to NR LBDs aligns the Danio Rerio orthologue of NR3 with 4 
different nematode NR LBDs at the third iteration, suggesting NR3 is related at the 
sequence level. 
Examination of the NR3 protein sequence reveals there are no obvious DNA 
binding motifs present. Furthermore, NR3 has been initially characterised within the 
literature, and functional studies to date suggest NR3 is involved in TNFα signalling 
through the TNFR1 pathway (Soond et al., 2003; Soond et al., 2006), and potentially 
involved in cell cycle regulation (Nicassio et al., 2005), thus it is unlikely that NR3 
acts in the same manner as bone fide nuclear receptors. The LBD of NRs may be 
considered to be a molecular switch that undergoes a conformational change upon 
ligand binding (Nagy and Schwabe, 2004), and as such it is conceivable that any 
ligand binding domain present in the NR3 structure may act as a molecular switch to 
modulate the signalling pathways with which it is involved. 
 
1.9 Functional Characterisation of NR3 
1.9.1 Role in TNF Signalling 
In parallel with the bioinformatic predictions made regarding the structure of 
NR3, the protein was initially described as TRUSS in the literature when it was 
identified as a binding partner for the membrane proximal region of TNFR1 in a 
transcription-based yeast two-hybrid screen (Soond et al., 2003). Further 
characterisation of the putative protein-protein interaction between TRUSS and 
TNFR1 by GST pulldown assays showed TRUSS could directly interact with TNFR1, 
an interaction that was mapped to amino acids 207-300 of TNFR1 by using TNFR1 
deletion mutants fused to GST (Soond et al., 2003). Co-immunoprecipitation of full 
length HA-tagged TRUSS and a series of deletion mutants co-overexpressed with 
FLAG-tagged TNFR1 mapped the region within TRUSS responsible for the 
interaction to amino acids 1-440 (Soond et al., 2003). The initial characterisation of 
NR3 examined the proteins within the TNFR1 signalling pathway that interact both 
directly and indirectly with TRUSS. Upon activation, TNFR1 recruits a signalling 
complex formed by TRADD, TRAF2, RIP, and the IKK complex consisting of IKKα, 
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IKKβ and IKKγ. It was shown that TRUSS coprecipitates with all members of this 
signalling complex in immunoprecipitation assays where TRUSS and the protein of 
interest were overexpressed (Soond et al., 2003; Soond et al., 2006). In addition, it 
was shown that TRUSS can interact directly with TRADD, TRAF2, IKKα, IKKβ and 
IKKγ, but not RIP, in GST and HIS in vitro pulldown assays (Soond et al., 2003).  To 
examine the function of the protein, Soond et al (2003) overexpressed TRUSS in 
NIH/3T3 cells in NF-κB reporter gene assays. TRUSS expression increased NF-κB 
activation in a biphasic dose dependent manner, which was potentiated by treatment 
with TNFα (Soond et al., 2003). Additionally, truncating TRUSS to amino acid 723 
abolished the response, suggesting the putative NF-κB activation domain resides 
between amino acids 723-797. In a later paper the same authors showed that TRUSS 
overexpression resulted in c-Jun NH2-terminal kinase and AP-1 activation, which was 
thought to be due to an interaction with TRAF2 (Soond et al., 2006). 
 
1.9.2 Role in Cell Cycle and Implication in Alzheimer’s Disease 
In addition to the reported role of NR3 in TNF signalling (Soond et al., 2003; 
Soond et al., 2006), NR3 has been proposed to be involved in regulation of the cell 
cycle (Nicassio et al., 2005). Deletion of the cell cycle inhibitor retinoblastoma 
protein or overexpression of the E2F family of transcription factors, which are 
positive regulators of the cell cycle, is insufficient to induce re-entry into the cell 
cycle in terminally differentiated cells (Camarda et al., 2004; Pajalunga et al., 1999). 
However, expression of E1A can induce terminally differentiated cells to re-enter the 
cell cycle, thus Nicassio et al (2005) performed a biased screen to identify genes in 
terminally differentiated cells that upon E1A transformation are upregulated, but are 
not so following E2F1 overexpression or retinoblastoma protein deletion. The authors 
identified 5 such genes (Nicassio et al., 2005). These were SF3B1, Ch-TOG, SKIN, 
SMU-1 and TRPC4AP (NR3). The expression of all five genes was unaltered during 
the cell cycle progression of proliferating cells, and as such it was concluded that their 
over expression following re-entry into the cell cycle was not a downstream effect of 
cell cycle progression (Nicassio et al., 2005). The expression of the identified genes 
were also semi-quantitatively analysed in cancerous samples as compared to normal 
surrounding tissue from the same donor using tissue microarray techniques (Nicassio 
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et al., 2005). Although the results are only semi-quantitative the authors report that 
NR3 was found to be significantly overexpressed in 41-60% of colon cancers, and 21-
40% of lung and stomach cancers tested in the microarray. Nicassio et al (2005) 
focused on the identified gene SKIN to determine that knockdown with siRNA 
resulted in a negative effect of cell proliferation, however similar studies were not 
reported for TRPC4AP (Nicassio et al., 2005). The work performed by Nicassio et al 
(2005) does implicate NR3 in the regulation of the cell cycle, and as such the 
expression of NR3 may have an effect on the proliferation of cells. 
NR3 has also been identified in a genome-wide analysis of the single nucleotide 
polymorphisms (SNPs) associated with late-onset Alzheimer’s disease by microarray 
analysis (Poduslo et al., 2008). The screen was performed on two families in which 
there are multiple members with the disease, representing rare large groups of related 
sufferers. Of the SNPs identified in the microarray analysis, four were found in the 
NR3 gene, however all were found in intronic regions (Poduslo et al., 2008). It is 
possible that the regulatory elements may be present within introns (Fedorova and 
Fedorov, 2003), and that their disruption may result in deleterious effects. However as 
the SNPs identified by Podulso et al (2008) do not code for amino acids mutations it 
is unclear as to the significance of the findings with regards a physiological role for 
NR3 in the development of late-onset Alzheimer’s disease. 
 
1.10 Aims and Hypothesis 
The aim of this project is to characterise the biological role of NR3, and 
examine the role of the LBD region within that function. It is hypothesised that the 
LBD region possesses a structure similar to that of a nuclear receptor LBD, and may 
bind a ligand, allowing the region to act as a molecular switch to modulate the activity 
of NR3 within its biological function. 
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 2.1 Materials 
All chemicals and solvents used were of analytical grade and obtained, as 
indicated, from Abcam, Cambridge, UK; Ambion, Abingdon, UK; Amersham 
Biosciences/GE Healthcare, Amersham, UK; Applied Biosystems, Cheshire, UK; BD, 
Oxford, UK; BDH/VWR Chemicals, Lutterworth, UK; Bioline, London, UK; Biomol, 
Exeter, UK; Bio-Rad, Hemel Hempstead, UK; Calbiochem/Novagen, Nottingham, 
UK; Cambrex, Iowa, USA; Chemicon, Harrow, UK; Corning, New York, USA; 
DAKO Cytomation, Glostrup, Denmark; Dharmacon, Louisiana, UK; Finnzymes, 
Espoo, Finland; Fisher Scientific, Loughborough, UK; Genome Research Ltd, 
Cambridge, UK; Invitrogen/Gibco BRL/Zymed, Paisley, UK; LUX Biotechnology, 
Edinburgh, UK; MRC Geneservice, Cambridge, UK; National Diagnostics, Georgia, 
USA; New England Biolabs, Hitchin, UK; Perkin Elmer, Massachusettes, USA; 
Pierce, Illinois, USA; Premier Foods, St. Albans, UK; Promega, Southampton, UK; 
Q-Biogene, Cambridge, UK; Qiagen, Crawley, UK; Roche, Lewes, UK; Santa Cruz 
Biotechnology, Heidelberg, Germany; Sigma-Aldrich Company Ltd, Poole, UK; 
Stratagene, Texas, USA; Thermo, Fife, UK; Web Scientific, Crewe, UK; Zymo 
Research, California, USA. 
 
2.1.1 Chemicals, Reagents and Solvents 
20% (w/v) Sodium Dodecyl Sulfate (SDS) Solution  National Diagnostics 
30% (w/v) Acrylamide/Bis 37.:1    Bio-Rad 
37% (w/w) HCl      BDH 
4-(2-Aminoethyl) Benzenesulfonyl Fluoride HCl (AEBSF) Sigma-Aldrich 
Acetic Acid       VWR 
Adenine Hemisulfate      Sigma-Aldrich 
Adenosine Triphosphate (ATP)    Sigma-Aldrich 
Agarose       Cambrex 
Ammonium Persulphate     Bio-Rad 
Ammonium Sulfate      Sigma-Aldrich 
Ampicillin       Sigma-Aldrich 
Amplify       Amersham Biosciences 
β-Mercaptoethanol      Sigma-Aldrich 
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Betaine       Sigma-Aldrich 
Big-Dye Terminator 3.0     Applied Biosystems 
Bio-Rad Protein Assay Reagent    Bio-Rad 
Bovine Serum Albumin (BSA)    Sigma-Aldrich 
100x BSA (10mg/mL)     New England Biolabs 
Bromophenol Blue      Sigma-Aldrich 
CaCl2        Sigma-Aldrich 
CellTiter 96 AQueous MTS Reagent    Promega 
Chloramphenicol      Sigma-Aldrich 
Chloroform       Sigma-Aldrich 
Coelenterazine      LUX Biotechnology 
Complete Protease Inhibitors     Roche 
Cyclohexamide      Sigma-Aldrich 
DEPC-Treated Water      Ambion 
Dextrose       Sigma-Aldrich 
Deoxynucleotide Triphosphate (dNTP)   Sigma-Aldrich 
DEPC-treated H2O      Ambion 
Dharmafect 1 Transfection Reagent    Dharmacon 
Dimethyl Sulfoxide (DMSO)     Sigma-Aldrich 
Dithiothreitol (DTT)      Bio-Rad 
ECL Plus Western Blotting Detection System  GE Healthcare 
ECL Western Blotting Detection System   Pierce 
Ethanol       Fisher Scientific 
Ethidium Bromide      Bio-Rad 
Ethylenediaminetetraacetic Acid (EDTA)   Sigma 
Ethyleneglycoltetraacetic Acid (EGTA)   Sigma 
EZ Gel Staining Regent (G1041)    Sigma-Aldrich 
Fugene 6 Transfection Reagent    Roche 
Full-Range Rainbow Molecular Weight Markers  GE Healthcare 
Galactose       Sigma-Aldrich 
Glucose       Sigma-Aldrich 
Glutathione Sepherose 4B     GE Healthcare 
Glycerol       BDH 
Glycine       Sigma-Aldrich 
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HEPES       Sigma-Aldrich 
HyperLadder I-VI DNA Marker    Bioline 
Isopropanol       Fisher Scientific 
Isopropyl β-D-1-Thiogalactopyranoside (IPTG)  Sigma-Aldrich 
Kanamycin       Sigma-Aldrich 
KCl        Sigma-Aldrech 
KH2PO4       Sigma-Aldrich 
LiOAc        Sigma-Aldrich 
Lipofactamine 2000 Transfection Reagent   Invitrogen 
Methanol       Fisher Scientific 
MG132       Calbiochem 
MgCl2        Sigma-Aldrich 
MgSO4       Sigma-Aldrich 
NaAc 3M pH5.5      Sigma-Aldrich 
NaCl        Sigma-Aldrich 
Na2HPO4       Sigma-Aldrich 
NaOH        Sigma-Aldrich 
Nonylphenyl Polyethylene Glycol (NP40) Alternative Calbiochem 
Novex Sharp Pre-Stained Protein Standards   Invitrogen 
NuPage 4-12% (w/v) Polyacrylamide Gels   Invitrogen 
Oligo (dT)12-18  Primer     Invitrogen 
Oligonucleotides      Invitrogen/Thermo 
Phenol-Chloroform      Sigma-Aldrich 
Phenylmethanesulphonylfluoride (PMSF)   Sigma-Aldrich 
Prolong Gold       Invitrogen 
Protamine Sulfate      Sigma-Aldrich 
Protease Inhibitor Cocktail     Sigma-Aldrich 
Protein A-Agarose      Roche 
Raffinose       Sigma-Aldrich 
Polyethylene Glycol 3350     Sigma-Aldrich 
SeaPrep Ultralow Temperature Agarose   Cambrex 
Skimmed Milk Powder (Marvel)    Premier Foods 
Sonicated Salmon Sperm DNA (sssDNA)   Stratagene 
Sorbitol       Sigma-Aldrich 
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TEMED       Sigma-Aldrich 
Trichloro Acetic Acid (TCA)     Sigma-Aldrich 
Tris Base       Sigma-Aldrich 
Tris Borate       Sigma-Aldrich 
Tris HCl       Sigma-Aldrich 
Triton X-100       Sigma-Aldrich 
TRIZOL Reagent      Invitrogen 
Tumour Necrosis Factor (TNF) α    Calbiochem 
Tween-20       Sigma 
West Pico Detection System     Pierce 
 
2.1.2 Radiochemicals 
L-[35S] Methionine    >1000Ci/mmol, Amersham Biosciences 
[α-32P] dATP     >1000Ci/mmol, Amersham Biosciences 
 
2.1.3 Enzymes 
Accuprime Taq Polymerase     Invitrogen 
Bacterial Alkaline Phosphotase    Invitrogen 
DNase I (RNase-free)      Invitrogen 
EcoICRI Restriction Endonuclease    Promega 
Endoproteinase Glu-C from Staphylococcus aureus V8 Sigma-Aldrich 
KOD DNA Polymerase     Novagen 
MMLV Reverse Transcriptase    Sigma 
Pfu Turbo DNA Polymerase     Stratagene 
Phusion DNA Polymerase     Finnzymes 
Restriction Endonucleases (except EcoICRI)   New England Biolabs 
RNasin Ribonuclease Inhibitor    Promega 
T4 DNA Ligase      Invitrogen 
T4 PNK       New England Biolabs 
Taq Polymerase      Invitrogen 
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2.1.4 Miscellaneous 
3mm non-acid washed glass beads    Sigma-Aldrich 
1mL Disposable Pipette     BD Biosciences 
Cell Lifter       Corning 
Dynabeads Oligo (dT)25     Dynal 
ECL Hyperfilm      Amersham Biosciences 
Electroporation Cuvette (1mm gap)    Web Scientific 
Glass Plates for Setting Polyacrylamide Gels  Web Scientific 
Hybond PVD-F Membrane     GE Healthcare 
Optical 96-well Plates for QRT-PCR    Abgene 
 
2.1.5 Kits 
Cytrotrap XR Library Construction Kit   Stratagene 
Geneclean Spin Kit      Q-Biogene 
HiSpeed Plasmid Maxi Kit     Qiagen 
Large Construct Kit      Qiagen 
LucLite Reporter Assay Kit     Perkin Elmer 
pcDNA3.1 Directional TOPO Expression Kit  Invitrogen 
QIAprep Spin Miniprep Kit     Qiagen 
QIAquick Gel Extraction Kit     Qiagen 
Power SYBR Green Master Mix    Applied Biosystems 
TNT Coupled Reticulocyte Lysate System   Promega 
TNT Quick Coupled Transcription/Translation System Promega 
Zymoprep II Yeast Plasmid Minipreparation Kit  Zymo Research 
 
2.1.6 Plasmids 
Working stocks of plasmid DNA were stored at 4°C at a concentration of 0.25-
1mg/mL. Plasmid DNA was stored long term at -20°C. 
 
G112     Genoway 
G139     Genoway 
pBACe3.6-NR3   Genome Research Limited, bMQ-418A20 
 Chapter 2  Materials and Methods 
54 
pCMV-SPORT6-14-3-3η  MRC Geneservice, IMAGE 4949445 
pCMV-SPORT6-DDB1  MRC Geneservice, IMAGE 3487617 
pCMV-SPORT6-NR3  MRC Geneservice, IMAGE 3673725 
pCR2.1    Invitrogen 
pCR4     Invitrogen 
pcDNA3.1-V5-6H   Invitrogen 
pcDNA3.1-DDB11-353-V5-6H 
pcDNA3.1-DDB11-704-V5-6H 
pcDNA3.1-DDB11-1043-V5-6H 
pcDNA3.1-DDB117-1043-V5-6H 
pcDNA3.1-DDB117-1140-V5-6H 
pcDNA3.1-DDB1361-1140-V5-6H 
pcDNA3.1-DDB1396-704-V5-6H 
pcDNA3.1-DDB1∆BPB-V5-6H 
pcDNA3.1-NR3-V5-6H 
pcDNA3.1-NR3477-797-V5-6H 
pcDNA3.1-NR31-722-V5-6H 
pGEX-6P2    Amersham 
pGEX-6P2-NR3 
pGEX-6P2-NR31-722 
pGEX-6P2-NR31-120 
pGEX-6P2-NR31-239 
pGEX-6P2-NR361-120 
pGEX-6P2-NR361-239 
pGEX-6P2-NR3120-722 
pGEX-6P2-NR3239-722 
pGEX-6P2-NR3358-722 
pGEX-6P2-NR3419-722 
pGEX-6P2-NR3477-722 
pGL3-NFκB 
pGL3-GAL4 
pMyr XR    Stratagene 
pSG5     Stratagene 
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pSG5-GAL4-ER 
pSG5-VP16 
pSG5-VP16-GAL4-CTRL 
pSG5-VP16-GAL4-ER 
pSG5-VP16-GAL4-NR3 
pSOS     Stratagene 
pSOS-NR3 
pSOS-NR3 LBD 
pRL-EF1α 
pRL-TK 
RWH1-GA1-linker 
RWH1-HR1 
RWH1-LA-LoxP 
RWH1-LAbac 
RWH1-LSA-Neo 
RWH1-Neo/SA 
RWH1-SA-C+ 
RWH1-SAmod 
 
2.1.7 siRNA 
siRNA was stored at -80°C at a concentration of 20µM or 50µM depending on 
the manufacturer’s guidelines. 
 
Custom synthesised control siRNA    Dharmacon 
Smartpool siRNA to TRPC4AP    Dharmacon 
Silencer Negative Control #2     Ambion 
siTOX        Dharmacon 
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2.1.8 Antibodies 
Primary Antibodies 
14-3-3 (SA-483)      Biomol 
CDT1 (ab22716)      Abcam 
DDB1 (ab13562)      Abcam 
GAL4 (sc-510) (used for western blotting)   Santa Cruz 
GAL4 (sc-577) (used for immunostaining)   Santa Cruz 
GAPDH (MAB374)      Chemicon International 
TNFR1 (ab19139)      Abcam 
Ubiquitin (P4D1)      Santa Cruz 
V5 (46-0705)       Invitrogen 
 
Secondary Antibodies 
Anti-Mouse FITC      DAKO Cytomation 
Anti-Mouse HRP      DAKO Cytomation 
Anti-Rabbit FITC      DAKO Cytomation 
Anti-Rabbit HRP      DAKO Cytomation 
 
2.1.9 Bacterial Strains 
BL21 [F, ompT, hsdSB (rB-rB), dcm, gal, (DE3), pLysS, Cmr] are chemically 
competent E. coli for use with T7 RNA polymerase-based protein expression systems. 
DH5α [F-mcrA ∆ (mrr-hsdRMS-mrcBC) φ80lacZ∆M15] are chemically 
competent or electrocompetent Escherchia coli (E. coli) used when cloning DNA 
fragments into vectors and for amplification of plasmids. They replicate DNA with 
high efficiency, making them suitable for preparing DNA in small and large quantities. 
TOP10 (Invitrogen) [F- mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacΧ74 
recA1 araD139 ∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG] are chemically 
competent E. coli used for transformation with the resulting plasmid from a TOPO 
reaction. 
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XL10 Gold (Stratagene) Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZ∆M15 Tn10 (Tetr) Tn5 
(Kanr) Amy] are chemically competent cells used for transformation of plasmids 
when constructing and amplifying a cDNA library to be used with the CytoTrap yeast 
two-hybrid system (Stratagene). 
 
2.1.10 Yeast Strains 
cdc25H (Stratagene) Matα ura3-52 his3-200 ade2-101 lys2-801 trp1-901 leu2-3 
112 cdc25-2 Gal+ are chemically competent yeast cells used in the CytoTrap 
(Stratagene) method for yeast two-hybrid screens. Cell division in this strain is 
temperature dependent, with 37ºC being non-permissive for growth in the absence of 
Ras activation. 
 
2.1.11 Cell Lines 
COS-1 African green monkey kidney cell line immortalised with SV40 
(Gluzman, 1981) 
HEK-293  Human embroyonic kidney cell line immortalised with adenovirus type 
5 DNA (Graham et al., 1977)  
NIH/3T3 Mouse fibrosblast cell line (Todaro and Green, 1963) 
 
2.1.12 Bacterial Media 
Bactotryptone, yeast extract and Bactoagar were supplied by BD. 
 
LB-Agar   1% (w/v) Bactotryptone 
0.5% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
0.1% (w/v) Glucose 
1.5% (w/v) Bactoagar 
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2x LB-Agarose  2% (w/v) Bactotryptone 
1% (w/v) Yeast Extract 
1% (w/v) NaCl 
0.2% (w/v) Glucose 
0.3% (w/v) SeaPrep Ultralow Temperature Agarose 
 
LB-Broth   1% (w/v) Bactotryptone 
0.5% (w/v) Yeast Extract 
0.5% (w/v) NaCl 
0.1% (w/v) Glucose 
 
SOC Media (Invitrogen) 2% (w/v) Bactotryptone 
0.5% (w/v) Yeast Extract 
10mM NaCl 
2.5mM KCl 
10mM MgCl2 
10mM MgSO4 
20mM Glucose 
 
2.1.13 Yeast Media 
Yeast extract, Bactopeptone and Bactoagar supplied by BD. All amino acids and 
yeast extract without amino acids were supplied by Sigma-Aldrich. 
 
YPAD Broth   1% (w/v) Yeast Extract 
2% (w/v) Bactopeptone 
2% (w/v) Dextrose 
40mg/L Adenine Hemisulfate 
 
YPAD Agar   1% (w/v) yeast extract 
2% (w/v) Bactopeptone 
2% (w/v) Dextrose 
40mg/L Adenine Hemisulfate 
2% (w/v) Bactoagar 
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10x Dropout Solution   300mg/L L-Isoleucine 
     1500mg/L L-Valine 
     200mg/L L-Adenine Hemisulfate Salt 
     500mg/L L-Arginine HCl 
     200mg/L L-Histidine HCl Monohydrate 
     500mg/L L-Lysine HCl 
     200mg/L L-Methionine 
     500mg/L L-Phenylalanine 
     2000mg/L L-Threonine 
     500mg/L L-Tryptophan 
     500mg/L L-Tyrosine 
     1000mg/L L-Glutamate 
     1000mg/L L-Aspartate 
     400mg/L L-Serine 
 
SD Glucose Medium (-UL)  0.17% (w/v) Yeast Nitrogen Base  
     without amino acids 
     0.5% (w/v) Ammonium Sulfate 
     2% (w/v) Dextrose 
     1x Dropout Solution 
 
SD Glucose Plates (-UL)  0.17% (w/v) Yeast Nitrogen Base  
     without amino acids 
     0.5% (w/v) Ammonium Sulfate 
     2% (w/v) Dextrose 
     1.9% (w/v) Bactoagar 
1x Dropout Solution 
 
SD Galactose Medium (-UL)  0.17% (w/v) Yeast Nitrogen Base  
     without amino acids 
     0.5% (w/v) Ammonium Sulfate 
     2% (w/v) Galactose 
     1% (w/v) Raffinose 
     1x Dropout Solution 
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SD Galactose Plates (-UL)  0.17% (w/v) Yeast Nitrogen Base  
     without amino acids 
     0.5% (w/v) Ammonium Sulfate 
     2% (w/v) Galactose 
     1% (w/v) Raffinose 
     1.9% (w/v) Bactoagar 
     1x Dropout Solution 
 
2.1.14 Cell Culture Materials 
Dextran charcoal stripped foetal bovine serum (FBS) was routinely prepared by 
colleagues in the laboratory. Where appropriate some cell culture plates were coated 
with 0.01% (w/v) gelatine for 20 minutes. 
 
Dulbecco’s Modified Eagle Medium (DMEM) Sigma-Aldrich 
DMEM without phenol red    Sigma-Aldrich 
FBS       Gibco 
G418       Gibco 
Gelatine      Sigma-Aldrich 
L-Glutamine      Sigma-Aldrich 
Optimem      Gibco 
Penicillin (100U/mL)     Sigma-Aldrich 
Streptomycin (50µg/mL)    Sigma-Aldrich 
Tissue Culture Grade Plasticware   Corning 
Trypsin      Sigma-Aldrich 
 
2.1.15 Buffers, Solutions and Gels 
DNA Techniques 
Annealing Buffer   400mM NaCl 
20mM Tris pH7.5 
2mM EDTA pH8.0 
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10x DNA Loading buffer  0.2% (w/v) Bromophenol Blue 
40% (v/v) Glycerol 
100mM EDTA pH8.0 
 
10x TBE    900mM Tris Borate 
     20mM EDTA pH8.0 
 
TE Buffer    10mM Tris HCl pH8.0 
     1mM EDTA pH8.0 
 
Protein Analysis 
Immunostaining Buffers 
Blocking Buffer   140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH7.2 
10mM Na2HPO4 pH7.2 
     1% (w/v) BSA 
 
Permeabilising Buffer   140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH7.2 
10mM Na2HPO4 pH7.2 
     0.1% (v/v) Triton X-100 
 
Lysis Buffers 
HEPES Lysis Buffer   150mM NaCl 
     50mM HEPES pH7.6 
     5mM EDTA pH8.0 
     1% (v/v) NP40 Alternative 
     Protease Inhibitor Cocktail (50µL/10mL) 
     2mM PMSF 
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NETN Buffer    100mM NaCl 
20mM Tris HCl pH8.0 
     1mM EDTA 
0.5% (v/v) NP40 Alternative 
Complete Protease Inhibitors (1 tablet/50mL) 
1mM DTT 
2mM PMSF 
 
Nuclear Extract Buffer A  10mM HEPES 
10mM KCl 
0.1mM EDTA 
0.1mM EGTA 
2mM DTT 
Protease Inhibitor Cocktail (50µL/10mL) 
 
Nuclear Extract Buffer B  10mM HEPES 
10mM KCl 
0.1mM EDTA 
0.1mM EGTA 
2mM DTT 
400mM NaCl 
1% (v/v) NP-40 
Protease Inhibitor Cocktail (50µL/10mL) 
 
SDS-PAGE 
2x Laemmli Sample Buffer  4% (w/v) SDS 
     20% (v/v) Glycerol 
     10% (v/v) β-mercaptoethanol 
     0.004% (w/v) Bromophenol Blue 
     125mM Tris HCl pH6.8 
 
 Chapter 2  Materials and Methods 
63 
Polyacrylamide Gels (resolving) 375mM Tris HCl pH8.8 
     10-12% (w/v) Acrylamide/Bis 
     0.1% (w/v) SDS 
     0.1% (w/v) Ammonium Persulfate 
     0.04% (v/v) TEMED 
 
Polyacrylamide Gels (stacking) 125mM Tris HCl pH6.8 
     5% (w/v) Acrylamide/Bis 
     1% (w/v) SDS 
     1% (w/v) Ammonium Persulfate 
     0.1% (v/v) TEMED 
 
SDS-PAGE Fixing Buffer  30% (v/v) Methanol 
     10% (v/v) Acetic Acid 
 
SDS Running buffer   25mM Tris base 
     190mM Glycine 
     0.1% (w/v) SDS 
 
Silver Fixing Buffer   50% (v/v) Ethanol 
     10% (v/v) Acetic Acid 
 
Western Blotting Buffers 
Milk Solution    5% (w/v) skimmed milk powder 
     130mM NaCl 
     20mM Tris pH7.6 
     0.1% (v/v) Tween-20 
 
TBS-T     130mM NaCl 
     20mM Tris pH7.6 
     0.1% (v/v) Tween-20 
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Transfer Buffer   25mM Tris Base 
     190mM Glycine 
     20% (v/v) Methanol 
 
Yeast Two-Hybrid Buffers 
LiSORB    100mM LiOAc 
     10mM Tris-HCl p8.0 
     1mM EDTA pH8.0 
     1M Sorbitol 
 
PEG/LiOAc    10mM Tris HCl pH8.0 
     1mM EDTA pH8.0 
     100mM LiOAc pH7.5 
     40% (w/v) Polyethylene Glycol 3350 
 
STE Buffer    100mM NaCl 
     20mM Tris HCl pH7.5 
     10mM EDTA 
 
Miscellaneous Buffers and Solutions 
PBS     140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH7.2 
10mM Na2HPO4 pH7.2 
 
Polyacrylamide Gel Fixing Solution 30% (v/v) Methanol 
     10% (v/v) Acetic Acid 
 
Renilla Buffer    500mM HEPES pH7.8 
40mM EDTA 
10µg/mL Coelenterazine 
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Defined Qiagen Supplied Buffers and Solutions 
Qiagen Buffer EB   10mM Tris HCl pH8.0 
 
Qiagen Buffer P1   50mM Tris HCl pH8.0 
     10mM EDTA 
     100µg/ml RNase A 
 
Qiagen Buffer P2   200mM NaOH 
1% (v/v) SDS 
 
Qiagen Buffer P3   3M KAc pH5.5  
 
Qiagen Buffer QBT   750mM NaCl 
     50mM MOPS pH7.0 
     15% (v/v) Isopropanol 
     0.15% (v/v) Triton X-100 
 
Qiagen Buffer QC   1M NaCl 
50mM MOPS pH7.0 
     15% (v/v) Isopropanol 
 
Qiagen Buffer QF   1.25M NaCl 
     50 mM Tris HCl pH8.5 
     15% (v/v) Isopropanol 
 
Qiagen TE Buffer   10mM Tris HCl pH8.0 
     1mM EDTA 
Dharmacon Supplied Buffers 
5x siRNA Buffer   300mM KCl 
     30mM HEPES 
     1mM MgCl2 
     40mM KOH 
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Dynal Supplied Buffers 
Binding Buffer   20mM Tris-HCl pH7.5 
     1M LiCl 
     2mM EDTA 
 
Wash Buffer B   10mM Tris-HCl pH7.5 
     150mM LiCl 
     1mM EDTA 
 
Invitrogen Supplied Buffers 
MOPS Running Buffer  50mM MOPS 
     50mM Tris Base 
     0.1% (w/v) SDS 
     1mM EDTA 
 
5x T4 Ligase Buffer   250mM Tris HCl pH7.6 
     50mM MgCl2 
     5mM ATP 
     5mM DTT 
     25% (w/v) Polyethylene Glycol-8000 
 
10x DNase I Reaction Buffer  200mM Tris-HCl pH8.4 
     20mM MgCl2 
     500mM KCl 
 
New England Biolabs Supplied Buffers 
NEBuffer 1    10mM Tris Propane HCl pH7.0 
     10mM MgCl2 
1mM DTT 
 
 Chapter 2  Materials and Methods 
67 
NEBuffer 2    10mM Tris HCl pH7.9 
     10mM MgCl2 
     50mM NaCl 
1mM DTT 
 
NEBuffer 3    50mM Tris HCl pH7.9 
     10mM MgCl2 
     100mM NaCl 
1mM DTT 
 
NEBuffer 4    20mM Tris Acetate pH7.9 
     10mM MgCl2 
     50mM KAc 
1mM DTT 
 
Perkin Elmer Supplied Buffers 
2x LucLite Reagent 10mL LucLite buffer added to 1 bottle of 
lyophilised LucLite solution 
1mM CaCl2 
     1mM MgCl2  
 
Sigma Supplied Buffers 
10x Reverse Transcriptase Buffer 500mM Tris-HCl pH8.3 
     500mM KCl 
     30mM MgCl2 
     50mM DTT 
 
2.1.16 In Silico Materials 
Software Packages 
Vector NTI Software Suite  Invitrogen 
Office Software Suite   Microsoft
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Websites and Databases 
http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/ 
http://genome.ucsc.edu/ 
http://www.ensembl.org/ 
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi 
http://www.ncbi.nlm.nih.gov/sites/entrez 
http://www.strubi.ox.ac.uk/RONN 
 
2.2 Methods 
2.2.1 Bacterial Techniques 
All bacterial techniques were performed aseptically. 
 
Storage of Bacteria 
Amplification of DNA plasmids was performed in Escherichia coli strain DH5α. 
All the plasmids described possessed resistance genes to ampicillin, kanamycin, or 
chloramphenicol. Transformed bacteria were grown in LB-broth or LB-agar 
containing either 100µg/mL ampicillin, 50µg/mL kanamycin or 30µg/mL 
chloramphenicol. Bacterial stocks were stored in LB-broth containing 40% (v/v) 
glycerol at -80°C. 
 
Preparation of Competent Bacteria for Transformation by Heatshock 
DH5α were streaked onto an LB-agar plate without antibiotic and incubated at 
37°C overnight. A single colony was used to inoculate 100mL LB-broth in a 1L flask 
and cultured at 37°C until the bacteria were in log-phase growth, as judged when the 
OD600 measured 0.5. The culture was then transferred to two pre-chilled centrifuge 
tubes and incubated on ice for 10 minutes. The cells were then recovered by 
centrifugation at 4500xg and 4°C for 10 minutes, and the media discarded. The pellets 
were resuspended in 10mL pre-chilled 0.1M CaCl2, the bacteria recovered by 
centrifugation at 4500xg and 4°C for 10 minutes, and the supernatants discarded. 
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Each pellet was then resuspended in 2mL pre-chilled 0.1M CaCl2 containing 10% 
(v/v) glycerol and aliquoted for storage at -80°C. 
 
Transformation of Bacteria by Heatshock 
Chemically competent DH5α cells were thawed on ice and 50µL transferred to 
a pre-chilled microfuge tube. Between 250-500ng plasmid DNA or 1µL of a TOPO 
cloning reaction was added to the competent cells and mixed. The bacteria/DNA 
mixture was incubated on ice for 30 minutes before heatshock at 42°C for 30 seconds. 
Cells were placed back on ice for 2 minutes and 150µL SOC media added to each 
transformation. Transformation reaction were then incubated at 37°C and 220rpm for 
1 hour, plated on selective plates and incubated at 37°C overnight. 
 
Preparation of Competent Bacteria for Transformation by Electroporation 
DH5α were streaked onto an LB-agar plate without antibiotic and incubated at 
37°C overnight. A single colony was used to inoculate 10mL LB-broth and cultured 
overnight. The overnight culture was used to inoculate 1L LB-broth, which was split 
into four 250mL cultures and incubated at 37°C until the bacteria were in log-phase 
growth, as judged when the OD600 measured 0.5-0.8. The 250mL cultures were then 
transferred to pre-chilled centrifuge tubes and centrifuged at 4500xg and 4°C for 10 
minutes. The media was discarded and the pellets washed by resuspending in 250mL 
of pre-chilled sterile H2O and the bacteria recovered by centrifugation at 4500xg and 
4°C for 10 minutes. Each pellet was then washed again with 125mL H2O, and then 
resuspended in 5mL H2O containing 10% (v/v) glycerol and pooled together. The 
bacteria were centrifuged at 4500xg and 4°C for 10 minutes, and the pellets 
resuspended in 2mL pre-chilled H2O containing 10% (v/v) glycerol and aliquoted for 
storage at -80°C.  
 
Transformation of Bacteria by Electroporation 
Electrocompetent DH5α cells were thawed on ice and 50µL transferred to a pre-
chilled electroporation cuvette. 0.5µL of a ligation reaction was added to the 
competent cells and mixed. The bacteria/DNA mixture was electoporated using a Bio-
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Rad gene pulser, at 1.67kV, 25µF and 200Ω, providing a time constant of between 4-
5 milliseconds. Cells were placed back on ice for 2 minutes and 150µL SOC media 
added to each transformation. Transformation reaction were then incubated at 37°C 
for 1 hour, plated on selective plates and incubated at 37°C overnight. 
 
2.2.2 Nucleic Acid Manipulation 
Restriction Digest 
Restriction digests were performed in accordance with New England Biolabs 
guidelines. 
 
Analytical Restriction Digests 
200-500ng of miniprep DNA was digested with 0.2µL of appropriate restriction 
endonucleases in a 10µL reaction containing the recommended supplied buffer and 
10ng/µL BSA if required, and incubated at the appropriate temperature, typically 
25°C, 37°C or 65°C, for 1 hour. Restriction digest products were analysed by agarose 
gel electrophesis. 
 
Restriction Digests for Cloning 
To generate vector backbone DNA, 1µg of plasmid DNA was digested with 1µL 
of the appropriate restriction endonucleases in a 50µL reaction containing the 
recommended buffer and 10ng/µL BSA if required, and incubated at the appropriate 
temperature for 3 hours. 1µL bacterial alkaline phosphotase was added to each digest 
and the reaction incubated at 65°C for 30 minutes. The restriction products were then 
analysed by agarose gel electrophoresis, the vector backbone DNA excised from the 
gel and purified by Geneclean Spin Kit or QIAquick Gel Extraction Kit. 
Insert DNA was derived from digesting 1µg of the appropriate plasmid DNA or 
the purified product from a PCR reaction. 1µL of the appropriate restriction enzymes 
were used in a 50µL reaction and incubated for 3 hours at the appropriate temperature. 
Restriction products were then analysed by agarose gel electrophoresis, the insert 
DNA excised and purified using Geneclean Spin Kit or QIAquick Gel Extraction Kit. 
 Chapter 2  Materials and Methods 
71 
Oligonucleotide Phosphorylation and Annealing 
Lists of oligonucleatides used for cloning applications can be found in appendix 
A. Oligonucleotides were phosphorylated by combining T4 PNK and buffer with 
1.4µL of the appropriate forward and reverse 100µM oligonucleotides separate 25µL 
reactions, and incubated for 30 minutes at 37°C. The phosphorylated oligonucleotides 
were then combined and 50µL annealing buffer added. The oligonucleotides were 
then incubated at 100°C for 15 minutes and allowed to cool slowly to room 
temperature before being placed on ice. 
 
Polymerase Chain Reaction 
Generating DNA Fragments for Cloning 
List of oligonucleotides used for PCR can be found in appendix A. Polymerase 
chain reactions (PCRs) were performed with Accumprime Taq polymerase, KOD 
polyermase, Pfu Turbo polymerase or Phusion polymerase. Reactions were typically 
50µL and were performed in accordance with polymerase manufacturer’s guidelines 
and with the supplied buffers. Briefly, the reactions contained 200-400µΜ dNTPs, 
0.2-1µM forward and reverse oligonucleotide primers, 1.5-2mM MgCl2, either 2% 
(v/v) DMSO or 1M betaine, and 50-100ng of DNA template for Pfu Turbo PCRs and 
Accuprime Taq PCRs, or 5-10ng of DNA template for KOD PCRs and Phusion PCRs. 
The amount of enzyme added to each reaction was as directed by the manufacturers. 
Cycling conditions were determined empirically for each reaction, and were within 
the polymerase manufacturer’s guidelines, however typical cycling conditions for 
each polymerase are shown in table 2.1. PCR products were analysed by agarose gel 
electrophoresis, excised from the gel and purified using Geneclean Spin Kit or 
QIAquick Gel Extraction Kit. Purified products could then be used for TOPO cloning 
or for restriction digest and ligation into a vector. 
 
Screening Bacterial Clones by PCR 
PCR reactions to screen bacterial clones were performed with Taq polymerase 
in accordance with manufacturer’s guidelines. Briefly, reactions were 50µL and
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Table 2.1 Summary of PCR Cycling Conditions for Different Polymerases 
The different polymerases used for PCR reactions required different cycling conditions. A summary is shown above, although some reactions 
required conditions to be determined empirically. Tm refers to the lowest melting temperature of the primers in the reactions. Product extension 
times are given per kilobase of amplicon. 
Cycle Step Temp (ºC) Time Temp (ºC) Time Temp (ºC) Time Temp (ºC) Time
Initial Template Denaturation 94 2 mins 95 2 mins 95 4 mins 98 30 secs
Template Denaturation 94 30 secs 95 20 secs 95 45 secs 98 10 secs
Primer Annealing Tm-5 30 secs Tm 10 secs Tm-5 45 secs Tm+3 30 secs 35 cycles
Product Extension 68 1 min/kb 70 10secs/kb 68 1 min/kb 72 15 secs/kb
Final Product Extension 68 10 mins 70 10 mins 68 10 mins 72 10 mins
Accuprime Taq KOD Pfu Turbo Phusion
 Chapter 2  Materials and Methods 
73 
contained 200µM dNTPs, 1.5mM MgCl2, 1µM forward and reverse primers, and 
0.2µL Taq polymerase. Bacterial colonies were harvested by transferring from a 
selective agar plate and adding directly to the PCR mix using a 200µL pipette tip, 
which were saved and used to inoculate selective LB-broth to grow positive colonies 
up for miniprep. Reactions were subjected to an initial denaturing step of 94ºC for 3 
minutes, followed by 35 cycles of 94°C for 45 seconds, primer Tm-5ºC for 30 
seconds, and 72ºC for 1 minute per kilobase of amplicon. A final product extension 
step of 72ºC for 10 minutes was included. Reactions were analysed by agarose gel 
electrophoresis to determine positive clones. 
 
Agarose Gel Electrophoresis 
0.8-1% (w/v) agarose gels were cast by dissolving agarose into TBE buffer by 
heating in a microwave, allowing the solution to cool, adding 1µL 0.2µg/mL ethidium 
bromide per 50mL gel, and pouring into an appropriate size mould. Gels were then 
submerged in TBE buffer and DNA samples loaded into wells following the addition 
of 10x DNA loading buffer to the samples. Electrophoresis was performed at 110V 
until the DNA fragments were resolved. Ethidium bromide stained DNA fragments 
were then visualised in a transilluminator (UVP). The size of fragments was estimated 
by comparing to HyperLadder DNA markers. DNA fragments required for cloning 
were then excised from the gel using a scalpel and purified using Geneclean Spin Kit 
or QIAquick Gel Extraction Kit. 
 
DNA Purification by Geneclean Spin Kit 
DNA fragments were purified in accordance with manufacturer’s instructions. 
400µL of suspended glassmilk was added to each gel slice in a microfuge tube. The 
gel slice was heated to 55ºC with occasional agitation to for 5 minutes or until the gel 
had melted, and the sample transferred to a spin filter. Samples were centrifuged 
17530xg for 1 minute to pass the solution though the spin filter into the catch tube to 
be discarded. The glassmilk retained on the spin filter was then resuspended with 
500µL wash buffer and centrifuged as before to pass the wash buffer into the catch 
tube to be discarded. The glassmilk was dried by centrifuging the filter and catch tube 
at 17530xg for 2 minutes to allow any traces of wash buffer to pass into the catch tube. 
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The filter was then transferred to a fresh microfuge tube and the purified DNA eluted 
by resuspending the glassmilk in 15mL elution solution and centrifuging at 17530xg 
for 2 minutes. 1µL of purified DNA was then analysed by agarose gel electrophoresis 
to determine the size and concentration of the DNA fragment. 
 
DNA Purification by QIAquick Gel Extraction Kit  
DNA fragments were purified in accordance with the manufacturer’s guidelines. 
Briefly, excised gel slices containing the required DNA fragments were placed in a 
fresh microfuge tube and weighed. 3 gel volumes of buffer QG was added to 1 
volume of gel slice and incubated at 50ºC with occasional agitation for 10 minutes or 
until the gel melted. 1 gel volume of isopropanol was then added to samples, the 
samples transferred to a spin column, and centrifuged at 17530xg for 1 minute. The 
flowthrough was discarded and the DNA washed by applying 500µL buffer QG to the 
spin column and centrifuged as before. The flowthrough was then discarded and the 
DNA washed with 750µL buffer PE. The flowthrough was discarded and the spin 
column dried by centrifugation at 17530xg for 2 minutes. 20µL EB was then applied 
to the spin column in a fresh microfuge tube and incubated for 1 minute at room 
temperature before centrifugation at 17530xg for 2 minutes to recover the DNA. 1µL 
of the eluted product was then subjected to agarose gel electrophoresis to determine 
the size and concentration of the recovered DNA. 
 
Purification of DNA by Phenol-Chloroform Extraction 
Phenol-chloroform methods were used to purify DNA from protein in samples. 
An equal volume of phenol-chloroform was added to the DNA samples and vortexed. 
Samples were centrifuged at 17530xg for 2 minutes, and the upper aqueous layer was 
transferred to a fresh microfuge tube. An equal volume of chloroform was added and 
the samples vortexed, before centrifugation at 17530xg for 2 minutes. The upper 
aqueous layer was transferred to a fresh microfuge tube and the DNA was ethanol 
precipitated from the sample. 
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DNA Precipitation 
DNA was precipitated by addition of salt and either ethanol or isopropanol and 
resuspended in an appropriate volume to increase the concentration of the DNA and 
purify DNA from samples. 0.1 sample volumes of 3M NaAc was added to the DNA 
and mixed, followed by either 2.5 volumes of ethanol or 0.7 volumes of isopropanol, 
and incubated on ice for 1 hour. Samples were centrifuged at 17530xg and 4°C for 30 
minutes to pellet the DNA. The pellets were washed with 1 volume of 70% (v/v) 
ethanol and centrifuged as before for 15 minutes. The supernatant was discarded and 
the pellets allowed to air-dry. The DNA was resuspended in an appropriate amount of 
TE buffer or H2O and quantified by measuring absorbance at 260nm. 
 
DNA Ligation 
Ligation reactions were performed in accordance with the enzyme manfacturer’s 
instructions. Backbone vectors and PCR product inserts were prepared by restriction 
digest, purified, and quantified by agarose gel electrophoresis. Oligonucleotide inserts 
with the appropriate 5’ and 3’ overhangs were prepared by annealing and 
phosphorylating. Ligation reactions were 10µL in total volume and consisted of 1x T4 
ligase buffer, 1µL T4 ligase and 30ng DNA. The DNA used in ligation reactions 
consisted of vector and insert combined in a 1:1 or 3:1 ratio, or of vector alone for 
control reactions. Ligation reactions were incubated at 16°C overnight and 1µL was 
used to transform electrocompetent bacteria. The presence of the insert in the vector 
backbone was determined by PCR or by preparing minprep DNA and performing an 
analytical restriction digest. 
 
TOPO Cloning 
TOPO reactions were performed in accordance with Invitrogen’s guidelines. 
Inserts possessed the 5’-CACC strand invasion sequence required to provide 
directional ligation into pcDNA3.1-V5-6H, and were either oligonucleotides or 
generated by PCR using KOD, Phusion or Pfu Turbo polymerases. 0.5µL Insert was 
added to 0.5µL TOPO vector and 2µL H2O in a fresh microfuge tube and incubated at 
room temperature for 5 minutes. The reaction was then transformed into 50µL TOP10 
bacteria and plated on ampicillin selective plates. The presence of the insert in the 
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vector backbone was determined by preparing minprep DNA and performing an 
analytical restriction digest. 
 
 
DNA Preparation 
All DNA preparation techniques were performed in accordance with Qiagen or 
Zymo Research guidelines. 
 
Small Scale DNA Preparation by Qiagen QIAprep Spin Miniprep Kit 
Qiagen QIAprep Spin Miniprep Kits were routinely used to prepare plasmid 
DNA on a small scale, typically generating 15-25µg of DNA. Briefly, individual 
transformed colonies were selected from agar plates to inoculate 5mL selective LB-
broth and incubated overnight at 37°C. The cultures were then centrifuged at 4500xg 
and 4°C for 10 minutes to pellet the bacteria and the media removed. Pellets were 
resuspended in 250µL buffer P1 and the cells lysed by addition of 250µL buffer P2. 
The lysis reaction was neutralised and bacterial genomic DNA and proteins 
precipitated by addition of 350µL buffer N3. Samples were then centrifuged at 
17530xg for 10 minutes and the supernatant applied to the provided spin column, 
which binds DNA to a silica resin under high salt concentrations. Plasmid DNA was 
bound to the resin by passing the supernatant through the column by centrifugation or 
by using a vacuum manifold. The DNA was then washed with 750µL buffer PE and 
dried by centrifugation. The purified plasmid DNA was eluted with 50µL buffer EB 
by incubating at room temperature for 1 minute and centrifugation at 17530xg for 2 
minutes. The concentration of the eluted DNA was determined by measuring 
absorbance at 260nm. Miniprep DNA was then used for analytical restriction digests, 
DNA sequencing, in vitro protein expression or downstream cloning procedures. 
  
Large Scale DNA Preparation by Qiagen HiSpeed Plasmid Maxi Kit 
For larger scale DNA preparations, Qiagen HiSpeed Plasmid Maxi Kits were 
routinely used to prepare 0.5-1mg of plasmid DNA. The Maxi Kits work by the same 
principle as the miniprep procedure. Briefly, an individual colony from a selective 
plate was used to inoculate 5mL selective LB-broth and incubated for 8 hours at 37ºC. 
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200µL of this starter culture was then used to inoculate 200mL of fresh selective LB-
broth and incubated overnight at 37°C. Cultures were centrifuged at 4500xg and 4°C 
for 10 minutes to pellet the bacteria and the media removed. Pellets were resuspended 
with 10mL buffer P1, lysed with 10mL buffer P2, and the reaction neutralised by 
10mL buffer P3. Bacterial lysates were then filtered with the provided QIAfilter 
Cartridge and applied to a HiSpeed Maxi Tip previously equilibrated with 10mL 
buffer QBT. The lysate was passed through the tip by gravity flow, allowing the 
plasmid DNA to bind to the silica resin. The DNA was washed with 60mL buffer QC 
and eluted with 10mL buffer. 10.5mL isopropanol was added to the eluate and 
incubated at room temperature for 5 minutes to precipitate the DNA. Precipitated 
DNA was then applied to the provided QIAprecipitator, washed with 2mL 70% (v/v) 
ethanol, and air-dried. The plasmid DNA was eluted in 1mL TE buffer, and the 
concentration measured by absorbance at 260nm. Maxiprep DNA was then used for 
transfection, in vitro protein synthesis or downstream cloning procedures. 
 
BAC Clone DNA Preparation by Qiagen Large Construct Kit 
To prepare BAC clone DNA free from bacterial genomic DNA contamination, 
Qiagen Large Construct Kits were used. Typical yields were up to 50µg. The kit is 
similar in principle to the Maxiprep procedure, but also incorporates an additional 
exonuclease digestion step to remove non-circular DNA such as contaminating 
genomic DNA or sheared BAC clone DNA. Briefly, a single colony transformed with 
pBACe3.6-NR3 was transferred to 5mL LB-broth with ampicillin and incubated at 
37°C for 8 hours. 500µL of this starter culture was then used to inoculate 500mL LB-
broth with ampicillin and incubated overnight at 37°C. The bacteria were recovered 
by centrifugation at 4500xg and 4°C for 10 minutes and the resultant pellets 
resuspended in 20mL buffer P1, lysed in 20mL buffer P2 and the reaction neutralised 
by 20mL buffer P3. The lysate was then incubated on ice for 10 minutes before 
clearing by centrifugation at 15000xg for 30 minutes and filtration through pre-wetted 
filter paper. BAC DNA was precipitated from the cleared lysate by addition of 36mL 
isopropanol and centrifugation at 15000xg for 30 minutes. The DNA pellet was 
washed with 5mL 70% (v/v) ethanol, allowed to air-dry, and resuspended in 9.5mL 
buffer EX. 200µL of the provided ATP-dependent exonuclease and 300µL 100mM 
ATP were added to the DNA and incubated for 1 hour at 37°C. 10mL buffer QS was 
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added and the sample applied to a Qiagen-Tip 500 pre-equilibrated with 10mL buffer 
QBT, and the DNA allowed to bind the silica resin by gravity flow. The DNA was 
washed with 60mL buffer QC and eluted with 15mL buffer QF heated to 65°C. The 
BAC DNA was then precipitated by adding 10.5mL ispropanol and centrifugation at 
15000xg. The DNA pellet was washed with 5mL 70% (v/v) ethanol, air-dried, and 
resuspended in 100µL TE buffer. The concentration of the eluted DNA was measured 
by absorbance at 260nm. The BAC clone DNA was then used for downstream cloning 
applications. 
 
Plasmid Preparation from Yeast using Zymoprep II Kit 
Plasmid preparation from yeast cells were performed on patches grown on 
selective plates. A ~10µL volume of yeast was transferred from the plate to 200µL 
Zymoprep solution 1 and cells dispersed. 3µL Zymolase added to each preparation 
and incubated at 37°C for 1 hour. 200µL Zymoprep solution 2 was added and mixed 
before addition of 400µL Zymoprep solution 3. Samples were centrifuged at 17530xg 
for 3 minutes and the supernatant solution applied to a Zymo-Spin-I column. Samples 
were centrifuged 17530xg for 30 seconds to bind plasmid DNA to the column. After 
discarding the flow-through solution, column-bound DNA was washed by applying 
550µL Zymoprep wash buffer to the columns and centrifugation at 17530xg for 2 
minutes. The column was then placed in a fresh 1.5mL microfuge tube and DNA 
eluted by applying 10µL TE buffer to the column and centrifuging at 17530xg for 2 
minutes. Zymoprep DNA was then used for PCR or to transform into DH5α cells to 
generate miniprep DNA. 
 
DNA Sequencing 
Lists of oligonucleotides used for sequencing can be found in appendix A. DNA 
sequencing was performed on an Applied Biosystems 3100 Genetic Analyser and 
typically 0.5-1µg miniprep DNA or maxiprep DNA that had been precipitated and 
resuspended in H2O was used. The DNA was combined with 8µL Big-Dye 
Terminator 3.0, 3.2pmol of the appropriate oligonucleotide sequencing primer, and 
5% (v/v) DMSO in a final reaction volume of 20µL. Although annealing temperatures 
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for primers were determined empirically, cycling conditions typically consisted of an 
initial denaturating step of 96°C for 3 minutes, followed by 25 cycles of 96°C for 10 
seconds, 50°C for 5 seconds, and 60°C for 4 minutes. Ramping rates were set to 1°C 
per second. Following the PCR reaction, 80µL 75% (v/v) isopropanol was added, and 
the samples centrifuged at 2600xg for 50 minutes. The supernatant was decanted and 
150µL 70% (v/v) isopropanol was added and the samples centrifuged as before for 20 
minutes. The supernatant was decanted and the pellets were dried by centrifuging 
inverted at 522xg for 1 minute. Samples were then processed by the sequencing 
services at the Institute of Reproductive and Developmental Biology or the MRC 
Genomics department, Hammersmith Hospital. DNA sequence files were analysed 
using Contig Express software package, which is part of the Vector NTI software 
suite. 
 
RNA Extraction 
RNA extraction was performed using Trizol reagent in accordance with the 
manufacturer’s guidelines. 1mL Trizol was added per 50mg of tissue, which was then 
homogenised in a power homogeniser (Polytron), for extraction of RNA from tissue. 
To extract RNA from cells cultured as a monolayer 1mL Trizol was added to 1 well 
of a 6-well plate to lyse the cells directly and the lysate was transferred to a 1.5mL 
microfuge tube free from ribonucleases. For extractions of RNA from cells cultured in 
smaller formats the volume of Trizol was adjusted accordingly. Samples were 
incubated at room temperature for 5 minutes to allow dissociation of protein 
complexes with nucleic acid. 0.2mL chloroform per 1mL Trizol was added to each 
sample, which were then shaken vigorously for 15 seconds, before incubating at room 
temperature for 3 minutes. Samples were then centrifuged at 12000xg and 4°C for 15 
minutes to separate the phases of the samples. The upper aqueous phase was then 
transferred to a fresh microfuge tube free from ribonucleases. 0.5mL isopropanol per 
1mL Trizol was added to each sample, incubated at room temperature for 10 minutes 
and centrifuged at 12000xg and 4°C for 15 minutes to precipitate RNA. The 
supernatant solution was discarded and precipitated RNA pellets were washed by 
adding 1mL 75% (v/v) ethanol and centrifuging at 7500xg and 4°C for 5 minutes. The 
supernatant solution was discarded and pellets allowed to air-dry, before resuspension 
in an appropriate amount of DEPC-treated H2O. RNA was then quantified by 
 Chapter 2  Materials and Methods 
80 
measuring absorbance at 260nm. Extracted RNA was then used for purifying mRNA 
or for cDNA synthesis. 
 
Purification of mRNA 
Messenger RNA was purified from total RNA using Dynabeads in accordance 
with the manufacturer’s guidelines. 150µg total RNA was placed in a 1.5mL 
microfuge tube free from ribonuclease and the volume adjusted to 200µL with DEPC-
treated H2O. Samples were then heated to 65°C for 2 minutes and placed on ice to 
disrupt secondary structure. 400µL Dynabeads were placed in a microfuge tube free 
from ribonucleases and washed by placing on a magnet (Dynal) for 2 minutes to 
collect the beads, the supernatant solution was removed and 200µL binding buffer 
added and mixied. The beads were then collected again using the magnet and the 
supernatant solution removed. The beads were resuspended in 200µL binding buffer 
and 200µL total RNA added. Samples were then rotated at room temperature for 5 
minutes to allow the oligo (dT) to anneal to the poly-A tail of mRNA molecules, and 
the beads collected using a magnet as before. The supernatant solution was discarded 
and the beads were washed twice with wash buffer B by placing tubes on a magnet 
and discarding the supernatant solution. The mRNA was eluted from the beads by 
addition of 10mM Tris-HCl pH7.5 and incubating at 80°C for 2 minutes to disrupt the 
interaction between mRNA molecules and oligo (dT), before placing the samples on 
the magnet to collect the beads. The mRNA present in the supernatant solution was 
transferred to a fresh microfuge tube free from ribonuclease. Purified mRNA was then 
used for cDNA library construction. 
 
cDNA Synthesis 
Synthesis of cDNA was performed using MMLV reverse transcriptase in 
accordance with manufacturer’s instructions. Briefly, 1µg total RNA, 0.5U DNase I 
and 0.5µL 10x DNase I reaction buffer were combined in a microfuge tube free from 
ribonuclease, the volume was adjusted to 5µL with DEPC-treated H2O, and samples 
were incubated at room temperature for 15 minutes to digest contaminating DNA in 
RNA samples. The reaction was inactivated by addition of 0.5µL 25mM EDTA 
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pH8.0 and incubation at 65°C for 10 minutes. 1µg oligo (dT)12-18 primer and 1µL 
10mM dNTP mix were added to samples, and the volume adjusted to 10µL with 
DEPC-treated H2O. Samples were incubated at 70°C for 10 minutes then placed on 
ice. 2µL 10x reverse transcriptase buffer, 20U RNasein ribonuclease inhibitor and 
200U MMLV reverse transcriptase were added to samples and the volume adjusted to 
20µL with DEPC-treated H2O. Tubes were incubated at room temperature for 10 
minutes, followed by incubation at 37°C for 50 minutes. The reaction was inactivated 
by heating at 94°C for 10 minutes. Synthesised cDNA was then used for quantitative 
real-time PCR (QRT-PCR). 
 
Quantitative Real-Time PCR 
Gene expression was analysed using QRT-PCR, the principle of which requires 
that cDNA is PCR amplified in a manner that produces a fluorescent signal 
proportional to the amount of target cDNA present. This may be done with either 
SYBR Green, which fluoresces when intercalated in DNA, or with a fluorescent probe 
that anneals to the target DNA and is degraded during the PCR reaction, which allows 
emission of the fluorescent dye. The fluorescent signal is detected in each sample 
following each cycle of the PCR reaction. The data is analysed by the setting of a 
threshold within the linear phase of the reaction, termed Ct value, and determining the 
number of cycles required for the fluorescent signal to reach that threshold for each 
PCR reaction amplifying target cDNA. The levels of cDNAs of interest are then 
calculated relative to that of a housekeeping gene, and fold differences are determined 
across samples. 
QRT-PCR reactions were performed in duplicate using Power SYBR Green 
Master Mix or SYBR Green Master Mix according to manufacturer’s instructions. 
Primers specific to the mouse ribosomal gene L19 were designed previously by others 
in laboratory and were used routinely, and primers specific to mouse NR3 were 
identical to those used elsewhere (Nicassio et al., 2005). Sequences of primers used 
for QRT-PCR are listed in appendix A. For QRT reactions 1µL of cDNA was added 
to 12.5µL master mix solution in each well of an optical 96-well plate. 2pmol of 
mouse NR3 primers or 7.5pmol of mouse L19 primers were added to reactions and 
volumes adjusted to 25µL with DEPC-treated H2O. Reactions were then mixed by 
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inversion and centrifuged at 522xg for 1 minute to collect the reactions at the bottom 
of the plate. Thermocycling was performed on an ABI PRISM 7700 Sequence 
Detection System (Applied Biosystems) with 40 cycles of 50oC for 2 minutes, 95oC 
for 10 minutes, 95oC for 15 seconds, 60oC for 1 minute, for a total of 40 cycles. 
NR3 levels in cDNA samples were determined by normalising to L19 
expression. This is performed by taking the mean Ct value for duplicate QRT-PCR 
reactions and calculating the ∆Ct value for NR3 in a cDNA sample by subtracting the 
mean Ct for L19 from the mean Ct of NR3. The levels of NR3 in cDNA samples were 
then compared by selecting a cDNA sample to relate other samples to and calculating 
the ∆∆Ct value by subtracting the ∆Ct of the selected sample to relate to from the ∆Ct 
values of other samples. ∆∆Ct values for samples were then converted to fold 
differences using the expression 2-∆∆Ct, which assumes the efficiency of each PCR 
cycle produces a 2-fold increase in amplicon levels. Fold differences were then 
multiplied by a factor of 100 to express the data as percentage mRNA expression 
levels. 
 
2.2.2 Cell Culture Methods 
Maintenance of Cell Stocks and Storage of Cells 
HEK-293, NIH/3T3 and COS-1 cells were maintained in standard medium 
consisting of DMEM supplemented with 10% (v/v) FBS, 100U/mL penicillin, 
100ng/mL streptomycin and L-glutamine at 37ºC and 10% CO2. Cells were grown as 
a monolayer on tissue culture grade plastics. To maintain cell stocks NIH/3T3 cells 
were typically split 1:10 twice each week, and HEK-293 and COS-1 cells were split 
1:20 twice per week. Cells were stored in DMEM containing 10% (v/v) DMSO under 
liquid nitrogen. 
 
Transfection Techniques 
DNA Transfection 
For transfection using Fugene 6 transfection reagent (Roche) cells were seeded 
into either a 96-well plate, a 10cm2 dish, an 8-well chamber slide or a T150 cell 
culture flask at ~30% confluence. For transfection using Lipofectamine 2000 
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transfection reagent (Invitrogen) cells were seeded into either a 96-well plate at ~50% 
confluence. Cells were seeded in phenol red free DMEM supplemented with 5% 
dextran-coated-charcoal stripped FBS. The following day cells were transfected 
according to manufacturer’s guidelines at 50-80% confluence using Fugene 6, or at 
~90% confluence using Lipofectamine 2000. The appropriate amounts of transfection 
reagent and Optimem were combined in accordance with the instructions of the 
transfection reagent manufacturer for each cell culture format, and incubated for 5 
minutes. DNA mixes were prepared with the manufacturer’s recommended amount of 
DNA for each cell culture format and empty pcDNA3.1 or pSG5 was used to keep 
transfection amounts constant within each assay and to perform mock transfections. 
The transfection reagent/Optimem solution was then added the DNA, mixed, and 
incubated for 20 minutes at room temperature to allow the DNA to complex with the 
transfection reagent. Complexes were added to the cells and incubated at 37°C. After 
18-24hrs cells were subjected to appropriate treatments and harvested 24hrs later. 
 
siRNA Transfection 
NIH/3T3 cells were seeded in phenol red free media containing 5% (v/v) 
dextran charcoal stripped FBS into gelatine coated 12-well plates at a density of 6x104 
per well or 6-well plates at a density of 1.2x105 per well, and cells transfected 4 hours 
later with Lipofectamine 2000 transfection reagent in accordance with manufacturers 
instructions. Briefly, 40pmol siRNA was diluted with Optimem to a final volume of 
100µL. 2µL Lipofectamine 2000 was added to 98µL Optimem and incubated at room 
temperature for 5 minutes. The Lipofectamine 2000 and siRNA mixes were then 
combined and incubated at room temperature for 20 minutes. 200µL cell culture 
media was then replaced with the transfection mix, the cells incubated at 37°C 
overnight, and the transfection procedure repeated the following morning. 
 
Generation of Cell Lines Stably Expressing NR3-V5 
Cells were transfected with DNA plasmids coding for NR3-V5 or empty vector 
possessing a neomycin resistance gene and cultured for 48 hours. Cells were then 
maintained in standard medium containing 300mg/mL G418 to select for transfectants, 
and as a positive control untransfected cells were maintained under the same 
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conditions. Cells were cultured in these conditions and cell numbers observed to 
diminish until all cells in the untransfected cultures had undergone cell death. 
Transfectants were maintained in 300mg/mL for a further 48 hours and then cultured 
in standard medium containing 150mg/mL G418. 
 
2.2.3 Protein Analysis 
Protein Expression in Bacteria 
DNA fragments were cloned into pGEX-6P2 in frame with GST to produce 
fusion proteins, and the resultant plasmids transformed into BL21 bacteria. A single 
colony was used to inoculate 5mL LB-broth with 100µg/mL ampicillin and incubated 
at 37°C overnight. Overnight cultures were then added to 45mL LB-broth and 
incubated at 37°C for 1 hour. Protein expression was induced by the addition of 25µL 
1M IPTG to give a final concentration of 500nM IPTG, and incubation at 24°C for 3 
hours. Cells were then collected by centrifugation at 4500xg and 4°C for 10 minutes 
and pellets lysed in 5mL NETN. Lysed cells were then sonicated twice for 10 seconds 
to break up the bacterial DNA. GST fusion proteins were purified by adding 125µL 
Glutathione Sepherose 4B beads previously washed with NETN and incubating with 
agitation for 2 hours at 4°C. For negative control samples containing GST alone, 
250µL lysate was adjusted to a volume of 5mL with NETN and used for purification 
to account for differences in protein expression levels. The beads were washed five 
times by centrifuging at 5720xg and resuspension in 5mL NETN, collected by 
centrifugation at 5720xg, and resuspended in an appropriate buffer for further 
processing. Typically, bacterially expressed proteins were used for GST pulldown 
assays, or a purification scaled up 3-fold was used for proteolytic cleavage. 
 
In Vitro Protein Synthesis 
In vitro protein synthesis was performed using the TNT Coupled Reticulocyte 
Lysate System or the TNT Quick Coupled Transcription/Translation System. These 
systems couple RNA transcription from a DNA template possessing a T3, T7 or SP6 
promoter with translation of the transcribed RNA in a single reaction that utilises 
rabbit reticulocyte lysate. Reactions were assembled on ice according to the 
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manufacturer’s guidelines and performed in a total reaction volume of 50µL using 
1µg of plasmid DNA and 20µCi L-[35S] methionine. Reactions were incubated at 
37°C for 90 minutes and the product used in GST pulldown experiments. 
 
GST Pulldown 
GST fusion protein bound beads were resuspended in 6mL NETN and 
radiolabelled in vitro synthesised proteins were diluted 1:5 by adding 200µL NETN 
containing 10% (v/v) glycerol. 600µL of beads and 50µL diluted radiolabelled protein 
were then combined and rotated overnight at 4°C. Beads were washed five times by 
centrifugation at 5720xg and resuspension in 1mL NETN. The beads were then 
collected by centrifugation at 5720xg and dried in a Savant DNA120 Speed Vac, 
before resuspension in 40µL Laemmli sample buffer. GST fusion protein loading 
controls were prepared by centrifuging 600µL of the GST fusion protein-bound beads 
by centrifuging at 5720xg, drying in a Speed Vac, and resuspension in 40µL Laemmli 
sample buffer. Loading Controls or samples and 10% inputs for the radiolabelled 
protein were loaded onto polyacrylamide gels and subjected to SDS-PAGE. Loading 
control gels were then subjected to Coomassie staining, and gels containing samples 
and 10% inputs were fixed in SDS-PAGE fixing buffer for 10 minutes and incubated 
in Amplify for 30 minutes. Gels were then dried on to filter paper using a Savant 
SGD2000 Slab Gel Dryer and sample gels exposed to a Molecular Dynamics Low 
Energy Phosphor Screen overnight, which was scanned used a Typhoon 8600 
Variable Mode Imager. 
 
Expression and Extraction of Proteins in Mammalian Cells 
NIH-3T3 or HEK-293 cells seeded were either transiently or stably transfected 
with plasmid DNA constructed to express the gene of interest in mammalian cells. 
Cells transiently or stably transfected with empty vector were used as negative 
controls. For TNFα treatments, cells were treated 18 hours post transfection with 
10ng/mL TNFα for 6 hours. For treatments with MG132, cells were treated with 
20µM MG132 at the appropriate timepoint prior to lysis. Whole cell extracts were 
taken by lysing cells directly in Laemmli sample buffer heated to 100°C, subjected to 
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a freeze thaw cycle, and heated at 100°C for 5 minutes to denature the proteins. 
Denatured whole cell extracts were then centrifuged at 17530xg for 5 minutes before 
loading into a polyacrylamide gel for SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). Protein extracts were taken by lysing cells with HEPES lysis buffer and 
rotating at 4°C for 20 minutes. Lysates were then subjected to a freeze-thaw cycle and 
were centrifuged at 17530xg and 4°C for 20 minutes to clear the lysates. The 
concentration of protein in cleared lysates was then measured by either BCA Protein 
Assay or Bio-Rad Protein Assay. 
 
Pulse Chase Experiments 
HEK-293 cells stably expressing NR3-V5 were seeded into gelatine-coated 24-
well plates at ~60% confluence and allowed to acclimatise overnight. Cells were then 
pre-treated with 20µM MG132 or DMSO for 3 hours, treated with 20ng/mL 
cycloheximide and cells harvested at the appropriate time point using Laemmli 
sample buffer. Samples were then subjected to Western blot. 
 
Measurement of Protein Concentration 
Protein concentration was determined by using BCA Protein Assay kit or Bio-
Rad Protein Assay. Reactions were performed in accordance with the manufacturer’s 
guidelines. 
 
BCA Protein Assay 
The BCA Protein Assay procedure is based on the ability of peptide bonds to 
reduce Cu2+ from cupric sulphate to Cu1+, which then chelates with two molecules of 
bicinchoninic acid forming a purple solution that absorbs light at 592nm. Protein 
extracts were diluted as necessary in HEPES lysis buffer, typically 1:10 or 1:100, and 
25µL added to one well a 96-well plate. Protein standards ranging from 25µg/mL to 
2mg/mL were prepared from BSA, and 25µL of each standard added to the 96-well 
plate. BCA working reagent was prepared by mixing 50 parts BCA Reagent A with 1 
part BCA Reagent B and 200µL was added to each standard and sample. The reaction 
was incubated for 30 minutes at 37°C and absorbance was measured at 592nm. 
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Bio-Rad Protein Assay 
The Bio-Rad Protein Assay is based on the Bradford assay, in which acidic 
solutions of Coomassie Brilliant Blue G-250 absorb light at 595nm when bound to 
protein. The concentrated reagent was diluted 1:5 to generate a working solution. 
Protein standards were prepared from BSA ranging from 20mg/mL to 625mg/mL, and 
samples were prepared by diluting appropriately, typically 1:10. 10µL of standard or 
sample was added to 500µL of diluted reagent, vortex mixed, incubated at room 
temperature for 5 minutes and absorbance at 595nm was measured. 
 
Immunoprecipitation from Protein Extracts 
Pre-clearing and Denaturing Samples 
Immunoprecipitations were performed on protein extracts possessing the same 
amount of total protein as determined by BCA protein assay or Bio-Rad Protein 
Assay under native or denatured conditions. Lysates were precleared with 25µL 
protein-A agarose for 1-16 hours rotating at 4°C, and centrifuged at 5720xg and 4°C 
for 1 minute. Samples requiring immunoprecipitation under native conditions were 
then used in the immunoprecipitation procedure outlines below. For samples requiring 
denaturing prior to immunoprecipitation, SDS and DTT were added to give final 
concentrations of 1% (w/v) SDS and 5mM DTT, and samples were heated at 100°C 
for 10 minutes. 9 sample volumes of HEPES lysis buffer was then added to dilute the 
SDS and DTT such that their effect on the efficiency of the immunoprecipitation 
would be minimised.  
 
Immunprecipitation Procedure 
Denatured or native samples were incubated with 0.5µg anti-V5 antibody and 
25µL protein-A agarose for 16 hours rotating at 4°C. Samples were then centrifuged 
at 5720xg and 4°C for 1 minute. Beads were washed four times with 1mL HEPES 
lysis buffer by resuspension and centrifugation. The beads were then either 
resuspended in 1mL 10mM Tris pH8.0 and used for proteolytic cleavage experiments 
or resuspended in 100µL Laemmli sample buffer and subjected to SDS-PAGE 
followed by silver staining or Western blotting. 
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Limited Proteolysis 
Mammalian expressed immunoprecipitated or bacterially expressed GST 
purified protein bound to the appropriate beads for purification was washed three 
times by centrifugation at 5720xg and resuspension with 1mL 10mM Tris pH8.0, and 
immunoprecipitated protein beads resuspended in 500µL 10mM Tris pH8.0 and GST 
purified protein beads resuspended in 100µL 10mM Tris pH8.0. V8 protease was then 
added to the samples to give final concentrations of 0, 0.2, 0.6 and 2.0µg/mL for 
immunoprecipitated protein, or 0, 0.2 and 2.0µg/mL for GST purified protein, and the 
samples rotated at room temperature for 90 minutes before stopping the reaction with 
1mM AEBSF. Beads were then collected by centrifugation at 5720xg for 2 minutes 
and the supernatant retained from GST purified samples, and the beads retained from 
immunoprecipitated samples. Supernatants were then mixed 1:1 with 2x Laemmli 
sample buffer and beads were resuspended in 100µL Laemmli sample buffer. 
Samples were then subjected to SDS-PAGE and further analysis by Coomassie 
staining or by Western blot. 
 
Nuclear Extract Method 
10cm plates were seeded with HEK-293 cells and transfected with 1µg test 
construct. At 36-48hrs post transfection cells were washed with chilled PBS and 
harvested by scraping with a cell lifter in 200µL nuclear extract buffer A. Cells were 
transferred to a 1.5mL centrifuge tube and incubated on ice for 20 minutes. 15µL 20% 
(v/v) NP-40 diluted in nuclear extract buffer A was added and the cells vortexed for 
10 seconds. The lysates were centrifuged at 17530xg for 30 seconds at 4ºC, the 
cytosolic supernatant removed and snap frozen on dry ice. 100µL Nuclear extract 
buffer B was added to the cell pellet, and pipetted up and down. The pellet was then 
incubated with the solution in a rotator at 4°C for 15 minutes to resuspend nuclear 
proteins. The lysates were then centrifuged at 17530xg at 4°C for 5 minutes, the 
nuclear supernatant removed and snap frozen on dry ice. Lysate fractions were stored 
at -80°C. 
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TCA Precipitation 
Protein samples were concentrated by precipitation with TCA and resuspension 
in Laemmli sample buffer. 0.1 sample volumes of TCA was added to the sample and 
incubated on ice for 45 minutes. Samples were centrifuged at 17530xg for 20 minutes 
and the pellets washed with 0.5mL chilled acetone. Samples were centrifuged at 
17530xg for 5 minutes and the residual acetone removed. The pellet was air-dried and 
resuspended in an appropriate amount of Laemmli sample buffer. TCA precipitated 
proteins were then used for SDS-PAGE. 
 
SDS-PAGE 
Polyacrylamide gels consisted of NuPage 4-12% (w/v) polyacrylamide gels, 
10% (w/v) polyacrylamide gels, or 12% (w/v) polyacrylamide gels. 10% and 12% 
resolving gels were poured by combining the components listed in the section 2.1.12, 
pipetting the gel solution between glass plates, and overlaying with H2O to ensure the 
gel is level. 5% stacking gels were then poured over set resolving gels and a comb 
inserted. Protein samples were whole cell extracts, protein extracts mixed 1:1 with 
Laemmli sample buffer, or protein extracts that had been subjected to TCA 
precipitation and resuspended in Laemmli sample buffer. Samples were heated at 
100°C for 5 minutes prior to loading onto gels. Typically 50µg of protein was loaded 
into one well of a polyacrylamide gel, alongside either Full-Range Rainbow 
Molecular Weight Marker or Novex Sharp Pre-Stained Protein Standards, and 
subjected to electrophoresis at 150V until the marker had sufficiently separated. 
 
Coomassie and Silver Staining 
Coomassie and silver staining procedures were performed on polyacrylamide 
gels in accordance with the stain manufacturer’s guidelines. 
 
Coomassie Staining 
Following SDS-PAGE gels were rinsed three times for 5 minutes with an excess 
of distilled H2O, fixed for 15 minutes in SDS-PAGE fixing buffer, and rinsed again 
with distilled H2O. Gels were incubated with EZBlue Gel Staining Reagent for 1 hour 
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or overnight, and washed with distilled H2O until background staining was reduced. 
Gels were then dried on to filter paper using a Savant SGD2000 Slab Gel Dryer. 
 
Silver Staining 
SDS-PAGE gels were fixed in silver fixing buffer for 1 hour or overnight, 
followed by washing in 30% (v/v) ethanol for 10 minutes. Gels were then washed 
with distilled H2O for 10 minutes, and incubated with Sensitiser solution for 10 
minutes, followed by a further wash with distilled H2O for 10 minutes and incubation 
with Silver solution for 10 minutes. Gels were then washed for 90 seconds with 
distilled H2O and developed in Developer solution until the appropriate staining 
intensity was achieved. Gels were either dried on to filter paper using a Savant 
SGD2000 Slab Gel Dryer, or stained protein bands cut out and subjected to mass 
spectrometry. Mass spectrometry was carried out by Dinah Rahman, Proteomics 
Facility, MRC Clinical Sciences Centre, Hammersmith Hospital. 
 
Western Blotting 
Following SDS-PAGE, proteins were transferred to Hybond PVD-F membrane 
by electroblotting using the Mini-Trans Blot system (Bio-Rad). The membrane was 
activated by briefly placing in methanol, and then rinsing in transfer buffer. It was 
then placed directly onto the gel, ensuring no air bubbles were present, and the gel 
and membrane placed between two pieces of 3mm filter paper and two sponge pads. 
This was assembled in transfer buffer and held together in a transfer cassette. 
Electroblotting was performed at either 50V at 4ºC overnight or 120V at 4°C for 1 
hour. Membranes were dried and reactivated by brief immersion in methanol and 
rinsing in TBS-T, and additional protein binding sites on the membrane were blocked 
with milk solution for 1 hour at room temperature or overnight at 4°C. Primary 
antibodies were diluted in milk solution, typically 1:1000, and supplemented with 
sodium azide before incubation with the membrane at either room temperature for 1 
hour or at 4°C overnight. Membranes were washed three times for 5 minutes with 
TBS-T, before incubation with the appropriate HRP-conjugated secondary antibody 
diluted 1:5000 in milk solution for 1 hour at room temperature. Membranes were 
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again washed three times for 5 minutes in TBS-T, and bound secondary antibody was 
then detected by incubation with ECL, ECL plus, or West Pico reagents. 
 
Immunostaining 
COS-1 cells were seeded into 8-well chamber slides and transfected with 10ng 
test construct. Transfection amounts were adjusted to 55ng using empty vector. 
Negative controls consisted of cells transfected with empty vector only. 36-48hrs post 
transfection cells were fixed in chilled methanol for 15 minutes, washed with sterile 
filtered PBS and permeabilised for 5 minutes with permeabilising buffer. Cells were 
washed as before, blocked with sterile filtered blocking buffer 1 for 30 minutes, and 
incubated for 30 minutes with blocking buffer 2 using normal serum from the species 
the secondary antibody was produced in. Cells were then washed in blocking buffer 
and incubated with primary antibody diluted 1:200 in blocking buffer overnight at 4ºC. 
Cells were then washed with blocking buffer and incubated with FITC-conjugated 
secondary antibody for 1 hour at 25ºC. Cells were washed with blocking buffer, 
mounted, and DAPI stained using Vectashield Mounting Medium with DAPI or 
ProLong Gold. Cells were then subjected to fluorescence microscopy and images 
taken at 250ms exposure. 
 
2.2.4 Yeast Two-Hybrid Screen 
Yeast two-hybrid screening was performed using the CytoTrap system, which is 
based on the Son-of-Sevenless (SOS) Recruitment System (SRS) (Aronheim et al., 
1997). Screening for protein-protein interactions was performed in accordance with 
the manufacturer’s instructions. 
 
CytoTrap Library Construction  
All enzymes and buffers were provided by Stratagene. The method used to 
construct of the cDNA library for screening protein-protein interactions provides an 
enrichment of full length cDNA. The cDNA fragments are size fractionated and 
directionally cloned into the yeast expression vector pMyr. 
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First-Strand cDNA Synthesis 
5µg mRNA purified from RNA samples extracted from embryonic/placental 
and brain tissue and first strand cDNA synthesis was performed by combining the 
mRNA with the supplied first-strand buffer, 2.8µg oligo-dT primer containing a XhoI 
restriction site, 40U RNase Block Ribonuclease Inhibitor and 600nM dNTPs 
containing 300nM methyl-dCTP to provide hemimethylated cDNA in an RNase-free 
microfuge tube and the volume adjusted to 48.5µL with DEPC-treated H2O. The 
primer was annealed to the template by incubating at room temperature for 10 
minutes, and 1.5µL of the supplied 75U Stratascript reverse transcriptase enzyme 
added and the reactions incubated at 42°C for 1 hour. 
 
Second-Strand cDNA Synthesis 
Second strand synthesis was performed by adding 10x second-strand buffer, 
300nM dNTPs containing 780nM dCTP, 300nM [α-32P] dATP, 3U RNase H, and 
99U DNA polymerase I, and the volume adjusted to 200µL with DEPC-treated H2O. 
Reactions were incubated at 16°C for 2.5 hours and the resultant double-stranded 
cDNA fragments were blunted by adding 5U Pfu polymerase and 255nM dNTPs. The 
blunted cDNA was purified by phenol-chloroform extraction. 
 
Ligation of EcoRI Adaptors, Phosphorylation of cDNA and Digestion with XhoI 
The purified cDNA pellet was resuspended and combined with 3.2µg EcoRI 
adapters, ligase buffer, 0.9mM rATP and 4U T4 DNA Ligase in final reaction volume 
of 11µL. Ligation reactions were incubated at 8°C overnight and the ligase inactivated 
by incubation at 70°C for 30 minutes. cDNA fragments were phosphorylated by 
addition of 10U T4 PNK, 1µL 10mM rATP, and 1µL 10x ligase buffer, and adjusting 
the reaction volume to 21µL. Reactions were incubated at 37°C for 30 minutes before 
heat inactivation at 70°C for 30 minutes. 28µL XhoI buffer supplement and 120U of 
XhoI were added in a final reaction of 52µL, and the reactions incubated at 37°C for 
1.5 hours. The cDNA digested with hemimethylated DNA sensitive XhoI was then 
purified by ethanol precipitation and the resulting cDNA pellet resuspended in 14µL
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STE and 3.5µL column loading dye was added. The processed hemimethylated cDNA 
fragments now possess EcoRI and XhoI sticky ends for directional cloning into the 
pMyr vector backbone (figure 2.1). 
 
Size Fractionation of cDNA Fragments 
The gel filtration column was prepared by packing Sepharose CL-2B gel filtration 
medium into a 1mL disposable pipette as indicated by Stratagene’s guidelines. The 
column was washed with 20mL of STE, and the cDNA loaded onto the column. 12 
100µL fractions were collected possessing 2 peaks of radioactivity, the first of which 
represents the cDNA containing fractions, and the second contains unincorporated 
radiolabelled nucleotides. The cDNA was then purified from the appropriate fractions 
by phenol-chloroform extraction, resuspended in 3.5µL DEPC-treated H2O, and 
assessed for nucleotide concentration by spotting onto an agarose plate containing 
ethidium bromide. 
 
Ligation of cDNA Fragments into pMyr Vector 
Fractions containing cDNA were ligated into the supplied pMyr vector pre-
digested with EcoRI and XhoI by combining 60ng cDNA insert, ligase buffer, 1mM 
rATP, 100ng of pMyr and 2U T4 DNA ligase in a final reaction volume of 5µL. 
Reactions were incubated at 12°C overnight and pilot transformations into XL10-
Gold Kan cells performed to examine transformation efficiency of each ligated 
fraction. 
 
Determining Transformation Efficiency 
To ensure that there is no over representation of a specific range of cDNA sizes, 
the transformation efficiency of each ligation reaction is determined. Transformations 
were made up to 1mL with SOC medium and 1µL and 10µL were plated onto LB-
chloramphenicol plates, and the number of colonies assessed. The number of colonies 
on the 1µL and 10µL plates were then multiplied by 1000 and 100 respectively to 
determine the number of colony forming units (CFU)/µL for each transformation.
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TTTTTTTTTTTTTTTTTGAGCT 
AAAAAAAAAAAAAAAAAC 
G 
AATTC 
Methylated First Strand cDNA 
Radiolabelled Second Strand cDNA 
Figure 2.1 Schematic of cDNA Fragments Generated for CytoTrap Library Construction 
cDNA fragments synthesised to possess EcoRI and XhoI sticky ends for directional cloning into the pMyr XR vector. XhoI is methylation 
sensitive and will not cut within the cDNA fragments. 
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Transformations were repeated but scaled-up 5-fold and the amount of cDNA insert 
normalised based on the number of CFU determined in each transformation. 
 
Preparing the cDNA Library 
Transformation reactions were pooled and 1µL and 10µL plated to determine 
the CFU/µL as before. The rest of the transformants were then plated on 15cm LB-
chloramphenicol plates, plating 20,000-30,000 CFU per plate, and incubated 
overnight at 37°C. The resulting colonies were then scraped in 6mL LB-broth, the 
plates washed 2mL LB-broth to recover the residual bacteria, and bacteria pooled. 
Half the bacteria were used to prepare library DNA by Maxiprep and the average size 
of insert was determined by PCR. 0.2 volumes of 80% (v/v) glycerol was added to the 
remaining bacteria, which were then stored at -80°C. Prepared library DNA was then 
used for transformation into cdc25H yeast cells to screen for protein-protein 
interactions. 
 
CytoTrap Yeast Two-Hybrid Screening 
Generation of Competent Yeast Cells 
Competent cdc25H yeast cells were prepared by streaking cdc25H cells onto a 
YPAD agar plate and incubating at room temperature for 4 days. A single colony was 
selected and dispersed into 1mL YPAD broth, which was then added to 50mL YPAD 
broth and incubated at 22°C and 220rpm for 14-19 hours until the OD600 measured 
greater then 1. The 50mL cultures were then added to 250mL YPAD broth, and 
incubated at 22°C and 220rpm for 3 hours. The OD600 was measured to ensure it was 
greater than 0.7. Yeast cells were then pelleted by centrifugation at 4500xg for 10 
minutes, and cells were washed with 50mL distilled H2O resuspension and 
centrifugation before resuspension in 50mL LiSORB. Cells were then incubated for 
30 minutes at room temperature, collected by centrifugation at 4500xg for 10 minutes, 
and resuspended in 300µL LiSORB. 400µL 20mg/mL sssDNA was denatured by 
heating to 100°C for 10 minutes, allowed to cool to room temperature and added to 
600µL LiSORB. 400µL of the sssDNA/LiSORB mix, 5.4mL PEG/LiOAc and 530µL 
DMSO was added to the cells, which were then used immediately for transformation. 
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Co-transformation of Competent Yeast Cells 
Competent yeast cells were co-transformed by adding 20µg library DNA 
derived from brain, 20µg embryonic/placental library DNA, 40µg of either pSOS-
NR3 or pSOS-NR3 LBD, and 200µL 1.4M β-mercaptoethanol to 10mL of competent 
yeast cells, aliquoting into 20 microfuge tubes and incubating at room temperature for 
30 minutes with occasional mixing. Control tranformations were set up by combining 
2µg pSOS DNA, 2µg pMyr DNA, 500µL competent yeast cells and 10µL 1.4M β-
mercaptoethanol. The transformations were heat-shocked at 42°C for 20 minutes, 
incubated on ice for 3 minutes, and collected by centrifugation at 3220xg for 10 
minutes. The pellets were washed by resuspension in 500µL 1M sorbitol and 
centrifuged at 3220xg for 10 minutes and resuspended in 250µL 1M sorbitol. Each 
transformation was then spread onto a 15cm SD glucose agar plate using sterile 3mm 
non-acid washed glass beads. Plates were incubated at room temperature for 48 hours, 
before replica plating onto 15cm SD galactose agar plates to induce library protein 
expression and incubated at the selective temperature of 37°C to identify interactor 
candidates. 
 
Primary Test for Interaction 
After 6 days and 10 days, colonies growing on SD galactose agar plates at 37°C 
were transferred with a sterile loop to SD glucose agar plates to prevent library 
protein expression, and incubated at room temperature for 48 hours. As a primary test 
for an interaction between interactor candidates and the bait protein, colonies were 
patched back onto SD galactose agar plates and onto 2 sets of SD glucose plates by 
picking colonies and suspending in sterile distilled water. 0.5µL was then spotted onto 
the plates. SD galactose agar plates were incubated at 37°C. As a negative control one 
set of SD glucose agar plates was also incubated at 37°C to ensure that colony growth 
was dependent on library protein expression. The second set of SD glucose agar plates 
was incubated at room temperature. 
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Secondary Test for Interaction and Isolation of Putative Interacting Constructs 
As a secondary test for an interaction between candidates and bait protein, 
patching was performed as in the primary test onto one set of SD galactose agar plates 
and one set of SD glucose agar plates, using the SD glucose agar plate from the 
primary test grown at room temperature as a source. After 48 hours, patches growing 
on SD galactose agar plates, but not SD glucose agar plates at 37°C, were picked and 
used to inoculate 5mL SD glucose broth. The cultures were incubated at room 
temperature and 220rpm for 3 days, and the cells pelleted by centrifugation at 4500xg. 
The pellets were resuspended in yeast lysis buffer and transferred to a fresh microfuge 
tube. 50µL 0.5mm acid-washed glass beads and 300µL phenol-chloroform were 
added and the cells vortexed for 1 minute. The samples were centrifuged at 17530xg 
for 2 minutes and the upper aqueous phase transferred to a fresh microfuge tube. The 
DNA was then isolated by ethanol precipitation, resuspended in 40µL H2O, and 
transformed by electroporation into DH5α bacteria. The DNA was then isolated by 
miniprep. 
 
Verification of Interaction 
2µg of the isolated putative interacting constructs were cotransformed with 2µg 
pSOS-NR3 or pSOS-NR3 LBD into 500µL of freshly prepared competent cdc25H 
cells, and spread onto SD glucose agar plates using glass beads as before, and 
incubated at room temperature for 6 days. Colonies were then patched as before onto 
SD galactose agar plates and SD glucose agar plates and incubated at 37°C. After 4 
days patched colonies were assessed for growth on SD galactose agar plates and lack 
of growth on the SD glucose agar plates. Colonies were then selected and prey 
plasmid DNA prepared by Zymoprep. 
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2.2.5 Functional Assays 
Reporter Gene Assays 
TNFα Assays 
For TNFα assays NIH-3T3 or HEK-293 cells were seeded into a 96-well plate 
and transfected either using Lipofectamine 2000 with 200ng of DNA consisting of 
30ng pGL3-NFκB firefly luciferase reporter, 5ng pRL-EF1α renilla luciferase 
reporter and varying amounts of test construct (NIH-3T3), or using Fugene 6 with 
55ng of DNA consisting of 15ng pGL3-NFκB luciferase reporter, 10ng pRL-TK 
renilla luciferase reporter and varying amounts of test construct (HEK-293). 125ng 
p65 was used as a positive control in NIH-3T3 transfections, and 30ng p65 was used 
as a positive control in HEK-293 transfections. For transfections with TNFR1, an 
IMAGE clone coding for the full length mouse TNFR1 (IMAGE 30061894, MGC 
60564, accession BC052675) was obtained (MRC Geneservice, Cambridge) and 10ng 
cotransfected into HEK-293 cells with Fugene 6. Cells were treated with 10ng/mL 
TNFα or the appropriate amount of vehicle 18hrs later, and harvested 6hrs post-
treatment. Experiments were performed in replicates of at least two. 
 
Ligand Screening Optimisation 
For optimisation of ligand screening assays HEK-293 cells were seeded into a 
96-well plate and transfected with 55ng of DNA consisting of 15ng pGL3-GAL4 
firefly luciferase reporter, 10ng pRL-TK renilla luciferase reporter and varying 
amounts of test construct. Cells were treated with 10nM oestradiol or the appropriate 
amount of vehicle 36-48hrs later, and harvested 24hrs post-treatment. 
 
Ligand Screening 
For Ligand screening assays HEK-293 cells were seeded into T150 flasks and 
transfected with 27.5µg of DNA consisting of 7.5µg pGL3-GAL4 firefly luciferase 
reporter, 5µg pRL-TK renilla luciferase reporter, 10µg empty pSG5, and either 5µg 
pSG5-VP16-GAL4-NR3 construct for test and low signal control samples, or 5µg 
pSG5-VP16-GAL4-CTRL construct for high signal control samples. 24hrs post 
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transfection cells were split into 96-well plates and treated with the appropriate 
compound at a concentration of 10µM, and control cells left untreated. 24hrs post 
treatment cells were harvested. 
 
Cell Harvesting 
To harvest from 96-well plates, 50µL of the cell culture medium was removed 
from the cells, 50µL of 2x LucLite reagent added, and the cells incubated in the dark 
for 15 minutes. After ensuring cell lysis was complete, reactions were transferred to a 
white plate to measure luminescence on a Wallac Victor2 1420. 25µL Renilla buffer 
was then added to each reaction, allowed to equilibrate for 30 minutes at room 
temperature, and luminescence reading was repeated. Firefly luciferase values were 
normalised using renilla luciferase values to account for experimental variation. 
 
Cell Proliferation Assay 
For cell proliferation assays cell number was determined by MTS assay using 
CellTiter 96 AQueous MTS reagent in accordance with manufacturer’s guidelines. 
The system is based on the conversion of MTS tetrazolium salt to formazan by 
dehydrogenase enzymes in metabolically active cells, and is routinely used to 
determine cell number. NIH/3T3 cells transfected with siRNA or HEK-293 cells 
stably transfected with NR3-V5 or empty vector were seeded into 96-well plates at a 
density of 0.5x104 cells per well in a culture volume of 100µL. Time points were 
taken at 0, 24, 48 and 72 hours post seeding by addition of 20µL MTS reagent, and 
incubation at 37°C for 1 hour. Absorbance at 490nm was read on a Wallac Victor2 
1420. RNA extraction for siRNA controls were performed in cells harvested at the 72 
hour time point. 
 
2.2.6 In Silico Techniques 
Sequence alignments were performed using the Align X program, which forms 
part of the Vector NTI software suite. The software package calculates the percentage 
identity and similarity between protein, DNA or RNA sequences. 3D molecule 
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images were generated using the 3D Molecule Viewer, which also forms part of the 
Vector NTI software suite. 
Predictions of protein disorder as an indication of structured regions were 
generated using the Regional Order Neural Network (RONN) prediction website. 
Predictions of transcription factor binding sites were generated with the Consite 
website with genomic sequences taken from the Ensembl and UCSC websites. Blast 
and Blat searches were performed using the NCBI and UCSC websites respectively. 
 
2.2.7 Statistics  
Probability values for one-tailed two-sampled t-tests were performed using the 
Excel software, which forms part of the Office software suite. T-tests were performed 
between measurements taken on samples from different cell transfections harvested at 
the same time point. Z-prime statistical tests were performed using the calculation 
below, where the terms high and low refer to the values for high and low controls for 
the assay. 
 
Z’ = 1 – (3 x SDhigh + 3 x SDlow) 
             (xhigh – xlow) 
 Chapter 3  Results 
101 
 
 
 
Chapter 3  
 
 
Characterisation of the Putative 
Nuclear Receptor-like Ligand Binding 
Domain of NR3 
 
 
 Chapter 3  Results 
102 
 3.1 Introduction 
The putative LBD region of NR3 is predicted by the Genome Threader 
algorithm to reside between amino acids 477 and 722 within the NR3 protein. To 
determine whether this region may be regarded as a bona fide LBD, two different 
approaches were employed. 
Firstly, the question of whether the putative LBD region of NR3 possesses a 
similar structure to that of bona fide NRs was addressed. A comprehensive method for 
determining protein structure is to employ X-ray crystallography. However, prior to 
such work preliminary structural experiments can be performed to determine the 
candidate protein regions for crystallography, and to ensure that the protein region of 
interest possesses a structured fold. In the absence of any data regarding the structure 
of NR3, limited proteolysis was carried out to determine the protein regions 
possessing a structured fold, which renders them resistant to proteolytic cleavage 
(Hubbard, 1998). 
Secondly, the question of whether the NR3 LBD binds a ligand was addressed 
by screening for a synthetic ligand that may bind and modulate the activity of NR3 in 
a luciferase reporter gene assay. Inpharmatica provided a library of ligands that had 
been synthesised for screening against the PPAR nuclear receptors, and as such 
represented a library of small hydrophobic molecules generated to screen against NR 
LBDs. This library was used to screen for compounds that could activate NR3 in the 
reporter gene assay system. 
 
3.2 Structural Analysis of NR3 
The folded 3-dimensional structure of NRs has been shown in many 
crystallographic studies to be well conserved across the superfamily. Such structured 
domains are known to be resistant to proteolytic digestion as the folding of the peptide 
renders the substrate residues inaccessible to the protease (Hubbard, 1998). As the 
putative LBD of NR3 is predicted to possess the same folded structure as the LBD of 
the NR superfamily, and due to the lack of reports discussing the 3-dimensional 
structure of NR3, limited proteolysis was performed to determine whether the region 
in which the LBD is predicted to reside is resistant to proteolytic degradation. 
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The protein sequence of NR3 was firstly assessed in silico for the presence of 
regions thought to be disordered using the RONN prediction methods (Yang et al., 
2005) (figure 3.1). If a region is disordered it is unlikely to fold into a structured 
domain, and as such would be susceptible to digestion with proteases. NR3 is 
predicted to be structured overall, with regions of disorder between amino acids 1-34, 
81-87, 226-231, 260-285, 343-371, 434-445 and 713-717. Therefore these predictions 
support the idea that the putative LBD region between amino acids 477-722 is a 
structured domain that should be resistant to proteolysis. Sequence analysis shows 
there are numerous substrate sites for V8 within NR3, however it would be expected 
that those in the disordered regions of NR3 would be cleaved more readily. As such, a 
schematic mapping cleavage sites that would be preferentially digested during limited 
proteolysis due to protein disordering can be produced (figure 3.1). These data show 
that if V8 digests NR3 preferentially at the regions predicted to be disordered the 
LBD region should reside in a peptide fragment 41.0kDa in size. 
 
3.2.1 Limited Proteolysis of Bacterially Expressed NR3 
To determine whether there are structured, proteolytic resistant domains 
present within NR3 limited proteolysis was carried out on bacterially expressed 
protein. Glutathione S-transferase (GST) tagged NR3 and, as a control, GST only 
were expressed in BL21 cells and purified by binding to glutathione conjugated 
sepharose 4B beads. Purified bound GST proteins were then digested with V8 
protease and the size of the peptide fragments present in the supernatant solution 
following the reaction were analysed by SDS-PAGE and Coomassie staining (figure 
3.2). A band corresponding to the size of GST (25.7kDa) was present in undigested 
GST control sample and GST control sample digested with 2.0µg/mL V8 protease 
(figure 3.2, lanes 1 and 3). However surprisingly the band is absent from the GST 
control sample digested with 0.2µg/mL V8 protease (figure 3.2, lane 2), however a 
band was observed on other occasions (data not shown). A further band is also present 
at ~45kDa in both undigested GST and GST-NR3 (figure 3.2, asterisk in lanes 1 and 
4), which is likely to be a non-specific protein co-purifying from the bacterial lysate 
as its migration suggests it is too large to be GST. As this band is absent from 
digested samples, it is appears to be readily digested by V8 protease (figure 3.2, lanes 
2, 3, 5 and 6). 
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Figure 3.1 Prediction of Protein Disorder and Protease Site Mapping for NR3 
The mouse NR3 protein sequence was used to predict the regions of disorder 
within the protein using the RONN server (http://www.strubi.ox.ac.uk/RONN). 
Peaks above 0.5 on the plot show regions predicted to be disordered. A schematic 
of the NR3 protein is overlaid highlighting where V8 protease substrate sites are 
present within regions of disorder (vertical black lines). The expected sizes of 
fragments following digestion are also shown. 
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Figure 3.2 Limited Proteolysis of GST-NR3 
Immobilised GST proteins were digested with the indicated concentrations of V8 
protease following expression in BL21 cells and purification by binding to 
glutathione conjugated sepherose 4B beads. The digested fragments present in the 
supernatant of GST (lanes 1-3) and GST-NR3 (lanes 4-6) samples were subjected 
to SDS-PAGE and Coomassie staining to analyse the size of fragments resistant to 
proteolysis. GST sample from lane 2 was not present in the experiment shown and 
was observed when the experiment was performed on other occasions. Asterisks 
denote non-specific bands from bacterial protein contamination. 
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Several bands can be observed in both undigested and digested GST-NR3 
samples (figure 3.2, lanes 4, 5, and 6). In the undigested GST-NR3 sample distinct 
bands can clearly be seen at ~120kDa, which is likely to correspond to the full length 
GST-NR3 protein (118.3kDa), ~90kDa, which is likely to correspond to the full 
length NR3 with the GST tag cleaved (92.3kDa), ~75kDa, ~60kDa, the non-specific 
band at ~45kDa, ~40kDa and a band corresponding to the size of GST at ~25kDa 
(figure 3.2, lane 4). Following digestion with 0.2µg/mL V8 protease a decrease in the 
levels of the ~120kDa and ~90kDa bands, and no change in levels of the bands at 
~75kDa and ~60kDa can be observed (figure 3.2, lane 4). In addition, an increase in 
the levels of the band at ~40kDa, a stabilisation of a band at ~55kDa and a band that 
appears to migrate at a size above that of GST at ~25kDa, giving the appearance of a 
smeared band (figure 3.2, lane 5). Following proteolysis with 2.0µg/mL V8 protease 
most bands present within the sample are digested with the exception of the bands at 
~75kDa and ~60kDa, and the smeared band present between 25-30kDa (figure 3.2, 
lane 6). As there is no change in the levels of the ~75kDa and ~60kDa bands 
following digestion these are unlikely to represent NR3 fragments, and as such may 
be proteolytic resistant bacterial that are either contaminants or proteins that interact 
with NR3. 
In silico analysis of the cleavage sites showed that if digestion occurred 
preferentially at substrate sites with regions predicted to be disordered, the LBD 
would reside in a 41.0kDa fragment (figure 3.1), which may correspond to the peptide 
fragment of ~40kDa observed following digestion. Furthermore, the predicted size of 
the putative LBD is 28.5kDa, thus it is possible that the smeared band observed 
between 25-30kDa in digested GST-NR3 samples (figure 3.2, lanes 5 and 6) may 
correspond to a fragment resulting from digestion at sites in close proximity to the 
predicted LBD boundaries. These data show there are a number of NR3 specific 
peptide fragments that are resistant to digestion with V8 protease, which suggests 
there are structured regions with NR3, including a region which may correspond to 
the size of the putative NR3 LBD. 
 
3.2.2 Limited Proteolysis of NR3 Expressed in Mammalian Cells 
The data generated from limited proteolysis in bacterially expressed protein provides 
evidence that there are structured domains resistant to proteolysis within NR3. 
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However, it is unclear as to where the boundaries of these domains reside and if the 
putative LBD region is one such domain. To map the regions of protease resistance 
V5 tagged NR3 was stably expressed in mammalian cells by transfection of 
pcDNA3.1-NR3-V5-6H, or empty vector as a negative control, into HEK-293 cells 
and selecting for transfected cells with G418. A protein extract was then taken and 
tagged NR3 purified by immunoprecipitation against the V5 tag. Immobilised tagged 
NR3 was then digested with V8 protease, and the fragments that remained bound to 
the protein-A agarose beads subjected to western blot against the V5 tag (figure 3.3). 
Comparison of mock samples to NR3-V5 samples show that the heavy and light 
chains of the antibody used for immunoprecipitation migrate at ~55kDa and ~23kDa 
respectively, and are resistant to digestion with V8 protease (figure 3.3, asterisk in all 
lanes). In addition a band at ~95kDa can also be observed, which is likely to be cross-
well contamination from NR3 samples (figure 3.3, lane 4). Distinct bands specific to 
NR3 samples over mock samples can clearly be observed at ~95kDa, ~70kDa, and 
~45kDa in undigested samples (figure 3.3, lane 5). Following digestion with 
increasing concentrations of V8 protease bands are also present at ~40kDa, ~18kDa 
and ~16kDa (figure 3.3, lanes 6-8). 
As the V5 tag is present at the C-terminus of NR3, it can be used to map the 
protease resistant regions of NR3. If NR3 is digested either side of the putative LBD 
boundaries, fragments of 42.6kDa and 14.1kDa should be observed (figure 3.3). 
These are similar in size to the fragments observed at ~40kDa, ~18kDa and ~16kDa, 
which may mark the boundaries of a structured region in NR3 that corresponds to the 
putative LBD. The N-terminal boundary of the 41.0kDa fragment that is predicted to 
possess the putative LBD region following digestion with V8 protease as indicated 
from the NR3 disorder prediction (figure 3.1), would be expected to give a fragment 
of 55.6kDa in this limited proteolysis assay. This fragment is not observed here, 
which may be due to it being masked by the heavy chain of the antibody used for 
immunoprecipitation. 
Taken together, the data from the limited proteolysis of NR3 expressed in 
bacterial and mammalian cells, and the in silico predictions of NR3 disorder, suggest 
the region that is predicted to possess a fold similar to that of a bona fide NR LBD is a 
structured and protease resistant domain. Therefore these data provide support for the  
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Figure 3.3 Limited Proteolysis of NR3-V5 
Protein extracts from V5-tagged NR3 and mock stably transfected cells were 
subjected to Immunprecipitation, and immobilised samples were digested with the 
indicated concentrations of V8 protease. The digested fragments remaining on the 
beads in mock (lanes 1-4) and NR3-V5 (lanes 5-8) samples were then subjected to 
western blot, probing for V5 to determine their size. Asterisks denote bands 
produced from the antibody used in the immunoprecipitation step. Cartoon depicts 
the predicted sizes of V5 containing fragments following V8 digestion either side 
of the LBD and in the regions of disorder closest to the LBD boundaries (vertical 
lines).  
95.8kDa LBD 
V5 
6H 
55.6kDa LBD 
42.1kDa LBD 
14.8kDa 
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idea that the NR3 LBD region is a candidate for crystallography to determine its 
structure, which would provide strong evidence either supporting or against the idea 
that NR3 possess a NR-like LBD. 
 
3.3 Screening for NR3 Ligands 
The preliminary structural work presented above suggests there is an ordered 
protease resistant region spanning the amino acids predicted to be an NR-like LBD 
within NR3. It is possible therefore that this region does possess a fold similar to that 
of an NR LBD and as such may bind ligand. To try to identify a ligand an assay was 
optimised and used to screen a library of synthetic compounds at Inpharmatica. 
 
3.3.1 Construction of Expression Vectors for Ligand Screening 
To screen the compound library of Inpharmatica, a heterologous reporter gene 
assay system was used that utilised fusion proteins possessing a GAL4 DBD fused to 
VP16 activation domain. The VP16 activation domain provides constitutive 
transcriptional activation of the reporter gene (Sadowski et al., 1988), allowing the 
screening of compounds to identify both agonists and inverse agonists and not relying 
on the supposition that the putative NR3 LBD is able to recruit coactivators. Three 
fusion proteins were used named VP16-GAL4-NR3, VP16-GAL4-ER and VP16-
GAL4-CTRL. These were generated by PCR amplifying DNA fragments coding for 
the GAL4 DBD, the mouse ERα LBD and a multiple cloning site, and ligating in 
frame with VP16 in a pSG5 vector backbone (figure 3.4A). The putative NR3 LBD 
was also amplified by PCR and ligated in frame with VP16-GAL4 in both the correct 
and incorrect orientations replacing the ERα LBD (figure 3.4B). Ligating DNA 
coding for the NR3 LBD region in the incorrect orientation to that coding for VP16-
GAL4 produces the VP16-GAL4-CTRL fusion protein, which codes for 11 amino 
acids, LGVFLAVLHSL, downstream of the GAL4 DBD as a stop codon is present in 
the position corresponding to the 12th amino acid (figure 3.4B). VP16-GAL4-ER 
serves as a positive control for the system able to be activated or repressed by ligand, 
and VP16-GAL4-CTRL serves as a negative control as it represents basal activation 
of the system by VP16. 
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Figure 3.4 Schematics of VP16-GAL4 Fusion Proteins used for Screening 
A) A fragment generated by PCR from pSG5-GAL4-ER containing the GAL4 
DBD fused to the mouse ERα LBD was cloned into pSG5-VP16 to create pSG5-
VP16-GAL4-ER. B) pSG5-VP16-GAL4-NR3 and pSG5-VP16-GAL4-CTRL were 
produced by subcloning the appropriate LBDs into pSG5-VP16-GAL4-ER 
digested with the appropriate enzymes. Underlined text denotes the enzymes used 
for subcloning. 
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3.3.2 Transcriptional Activity of VP16-GAL4 Fusion Proteins 
Transfection of VP16-GAL4-ER and VP16-GAL4-CTRL into HEK-293 cells 
produced a 9.5-fold and 6-fold increase in transcriptional activity of the reporter gene 
over mock transfected cells in the absence of ligand (figure 3.5), a response that was 
dependent on the amount of construct transfected (data not shown). The level of 
transcriptional activation remained unchanged upon treating cells expressing VP16-
GAL4-CTRL with 10nM 17β-oestradiol, however as expected such treatment 
enhanced the activity of VP16-GAL4-ER a further 29-fold (figure 3.5). 
Surprisingly, cells transfected with VP16-GAL4-NR3 did not produce a 
constitutive level of transcriptional activation, and as expected remained unresponsive 
to 10nM 17β-oestradiol administration (figure 3.5). A level of activity similar to that 
seen with untreated VP16-GAL4-ER and VP16-GAL4-CTRL expressing cells would 
have been expected, yet the level of activity was similar to that of mock transfected 
cells. Thus it is clear the putative LBD of NR3 suppresses transcription when fused to 
a GAL4 DBD and VP16 activation domain, and expressed in a heterologous reporter 
gene assay system. In order to activate the system, the fusion proteins must be 
translocated to the nucleus. It is possible that the NR3 LBD prevents the nuclear 
localisation of the fusion protein, or that VP16-GAL4-NR3 is not expressed to high 
levels when transfected into cells. 
 
3.3.3 Subcellular Localisation of VP16-GAL4 Fusion Proteins 
To determine the localisation of the fusion proteins, HEK-293 cells were 
transfected with the appropriate VP16-GAL4 construct, treated with 17β-oestradiol, 
subjected to immunostaining with anti-GAL4 DBD antibody and co-stained with 
DAPI. However, no staining could be observed with the anti-GAL4 DBD antibody 
(data not shown), which may be due to the fusion proteins being expressed at a level 
below the detection limit of the antibody. To address this, the assay was repeated in 
COS-1 cells (figure 3.6). COS-1 cells have been immortalised with SV40 virus and 
express large T antigen. Due to the presence of the SV40 origin of replication in the 
pSG5 vector backbone, large T antigen expressing cells will replicate the plasmid 
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Figure 3.5 Luciferase Response to Expression of VP16-GAL4 Fusion Proteins 
in a Heterologous Reporter Gene Assay System 
HEK293 cells were cotransfected with pGL3-GAL4 reporter, pRL-TK internal 
control reporter, and the appropriate VP16-GAL4 construct and incubated in the 
absence (open bars) or presence (closed bars) of 10nM 17β-oestradiol. Responses 
are fold induction of unstimulated mock transfected cells. Error bars represent 
standard deviation between duplicate samples. 
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Figure 3.6 Immunostaining of VP16-GAL4 Fusion Proteins 
COS-1 cells were transfected with the appropriate VP16-GAL4 fusion protein, treated 
for 24 hours with 10nM 17β-oestradiol, and subjected to immunostaining (first and 
third panels). Nuclei were counterstained with DAPI (second and fourth panels). 
Arrows denote nuclei of stained cells. 
Untreated 10nM 17β-oestradiol 
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(Gluzman, 1981), inducing higher expression of the gene of interest. Mock transfected 
cells showed no staining, as did cells transfected with VP16-GAL4-CTRL (data not 
shown). Cells transfected with pSG5-VP16-GAL4-ER possess a diffuse staining 
throughout the whole cell, whereas cells transfected with VP16-GAL4-NR3 show the 
staining is mainly excluded from the nucleus (figure 3.6). The staining patterns for 
both fusion proteins were unaltered following treatment with 10nM 17β-oestradiol, a 
result that is concordant with previous studies investigating the cytosolic and nuclear 
distribution of ERα (Picard et al., 1990). 
To confirm these results, expression and localisation was examined by 
determining the distribution of the fusion proteins in cytosolic and nuclear fractions 
from a nuclear extract. HEK-293 cells were transfected with the appropriate construct 
and a nuclear extract generated. Nuclear and cytosolic fractions were then subjected 
to western blot with anti-GAL4 DBD antibody. Anti-RNA polymerase II and anti-
GAPDH antibodies were also used to assess cross fraction contamination (figure 3.7). 
The anti-GAL4 DBD antibody gave a specific band at the correct sizes for VP16-
GAL4-ER (58.4kDa) and VP16-GAL4-NR3 (54.5kDa). A non-specific band was also 
seen in the nuclear fractions, as indicated by its presence in samples derived from 
mock transfected cells (figure 3.7, asterisk). VP16-GAL4-CTRL could not be 
detected (27.1kDa), which is concordant with immunostaining experiments. 
Examination of VP16-GAL4-NR3 protein levels show that the construct is expressed, 
however it is enriched in the cytosolic fraction over the nuclear fraction. Contrastingly 
VP16-GAL4-ER appears to be evenly distributed between the cytosolic and nuclear 
fractions, which was as expected (Picard et al., 1990). Examination of the controls 
shows there is low level contamination between the fractions (figure 3.7). These data 
highlight that NR3 appears to be largely absent from the nucleus and as such are in 
accordance with the data generated by immunostaining of transfected cells. This 
absence of high protein levels within the nucleus could account for the lack of activity 
observed in reporter assays. 
 
3.3.4 Screening Ligands for NR3 
The difference in transcriptional activation of the GAL4 reporter gene observed 
between cells expressing the control fusion proteins, and the cells expressing VP16-
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Figure 3.7 Subcellular Localisation of VP16-GAL4 Fusion Proteins 
HEK-293 cells were transfected with the appropriate VP16-GAL4 fusion protein or 
empty vector (mock) and subjected to nuclear extract. The distribution between the 
cytosolic (C) and nuclear (N) fractions of each fusion protein was determined by 
western blotting. PolII and GAPDH were also blotted for as controls for cross 
contamination. Arrows denote bands corresponding to fusion proteins, or for VP16-
GAL4-CTRL, the expected size of the protein. Asterisks denote non-specific bands in 
the nuclear fraction. 
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GAL4-NR3 provided the opportunity to use the system to screen for potential ligands. 
This is based on the assumption that a ligand binding to the putative NR3 LBD could 
induce a conformational change that prevents the retention of the fusion protein 
within the cytosol, allowing translocation to the nucleus and transcription of the 
reporter gene. Inpharmatica possess a compound library that was screened using the 
developed system to determine whether a synthetic compound could induce an 
alteration in NR3 LBD associated transcription. 
In total 2320 compounds were screened individually at a concentration of 10µM 
over 29 assay plates. Test wells contained cells transfected with VP16-GAL4-NR3 
that were then treated with test compound, and control wells consisted of either low 
signal controls provided by cells transfected with VP16-GAL4-NR3 and left untreated, 
or high signal controls that were cells transfected with VP16-GAL4-CTRL, and again 
left untreated. Each assay plate consisted of 8 low signal control wells, 8 high signal 
control wells and 80 test wells. Assay plates were analysed with z-prime statistic, 
which is a standard method of assessing the quality of high throughput screening data 
(Zhang et al., 1999). It compares the mean values of the low signal controls to the 
mean value of the high signal controls taking into account the variation of each. A 
high ratio and low variation between the sets of controls produces a high z-prime 
statistic. A perfect assay returns a z-prime statistic of 1, and a poor assay produces a 
z-prime statistic of below 0.5. Of the 29 plates screened 24 plates returned a z-prime 
statistic of greater than 0.5. 
Of the 2320 compounds screened, 89 compounds produced hits. That is they 
gave a greater value than a threshold value of 3 standard deviations above the mean of 
the low signal controls (data not shown). Of the 89 hits generated, the 15 greatest hits, 
which all produced responses more than 6 standard deviations above the mean of the 
low controls, were taken forward for further screening. 12 of these compounds were 
assayed on plates scoring a z-prime statistic of above 0.5 in the primary screen, and 3 
compounds were assayed on a plate scoring 0.39. However, these compounds were 
still further investigated due to their responses being over 6 standard deviations above 
the mean of the low signal controls. 
For a secondary screen, compounds were screened at increasing concentrations 
in either mock transfected cells or cells transfected with VP16-GAL4-NR3 (figure 
3.8). Compounds 1C1, 1G1, 2H2, 2H8, 1A4, 2B9, 1H1, 2D9, 2C2, 1F2 and 1C2 
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Figure 3.8 Luciferase Response in a Secondary Screen for Hit Compounds 
Cells were cotransfected with pGL3-GAL4 firefly luciferase reporter, pRL-TK renilla 
luciferase reporter internal control, and either empty pSG5 vector (open bars) or 
pSG5-VP16-GAL4-NR3 (closed bars), and subsequently treated with increasing 
concentrations of compound. Each experiment was performed three times, except for 
compound 1C1 which was performed twice. Error bars show the standard deviation 
between the experiments.  
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produced a dose dependent increase in reporter gene response in both mock and 
VP16-GAL4-NR3 transfected cells. Compound 2C8 produced a biphasic response in 
both mock transfected cells and cells expressing VP16-GAL4-NR3. The reduced 
response when cells were treated with 30mM 2C8 is possibly due to cell death, as the 
firefly and renilla luciferase values are greatly reduced (data not shown). Compounds 
2F2, 2C4 and 2B8 had little effect on the luciferase response observed in both mock 
and VP16-GAL4-NR3 transfected cells, producing a flat response in both. As the 
responses observed for all compounds were not significantly increased in VP16-
GAL4-NR3 transfected cells over mock transfected cells, it may only be concluded 
that any increase seen in a dose dependent manner is independent of VP16-GAL4-
NR3 expression and thus an artefact of the assay system. 
 
3.4 Summary and Conclusions 
Two approaches were taken to investigate whether the region of the NR3 protein 
was indeed a LBD. Firstly, preliminary structural work was performed to begin to 
determine whether the putative NR3 LBD possesses a fold similar to that of bona fide 
NRs. In silico predictions suggest that NR3 is an overall structured protein with little 
disorder, which would indicate NR3 may possess domains that a resistant to 
proteolytic digestion. By performing limited proteolysis on the NR3 protein expressed 
in both bacterial and mammalian system it was shown that there are clearly a number 
of domains that were resistant to proteolysis, and mapping studies showed that the 
LBD region may be one such domain. Therefore, the LBD region of NR3 represents a 
good candidate for further structural work by X-ray crystallography. 
In addition, a screen was performed to identify a synthetic ligand that may 
activate NR3 in a luciferase reporter gene system. It was shown that the NR3 LBD 
suppresses activity of a fusion protein in such a system, which may be explained by 
the exclusion of the VP16-GAL4-NR3 fusion protein from the nucleus. This system 
was used to screen a compound library provided by Inpharmatica based on the 
principle that a ligand binding to the NR3 LBD may induce a conformational change 
such that the inhibitory effect of the LBD is abrogated and the fusion protein may 
translocate to the nucleus to drive transcription of the reporter gene. Following the 
screening of 2320 compounds no ligand specific to NR3 activated the reporter system, 
and as yet a ligand remains to be found. 
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4.1 Introduction 
NR3 is reported to function within the signalling pathways stimulated by 
TNFR1 (Soond et al., 2003; Soond et al., 2006). To address the function of NR3, 
experiments investigating the involvement of NR3 in TNF signalling were repeated 
here. In addition, an unbiased approach was taken to further characterise the 
biological function of NR3 by screening for interacting proteins. Identification of 
interacting proteins may place NR3 in another characterised signalling pathway, and 
as such the functional significance of the protein interactions was investigated. 
 
4.2 Effect of Overexpression of NR3 on TNF Signalling 
NR3 has been described as a scaffold protein that interacts with TNFR1 and 
members of the TNFR1 signalosome independent of receptor activation. Upon 
stimulation with TNFα, overexpression of NR3 results in a potentiation of NF-κB 
signalling in reporter gene assays (Soond et al., 2003). The authors showed that 
responses elicited by NR3 were dose dependent in transiently transfected cells. In 
preliminary experiments performed here, HEK-293 cells were transiently transfected 
with an increasing amount of NR3 expression vector and treated with TNFα in NF-
κB reporter gene assays. No evidence of a dose dependent increase in NF-κB 
activation could be demonstrated in the absence or presence of TNFα (figure 4.1A). 
The reporter gene assay was then repeated in NIH/3T3 cells, as this cell type was used 
for such assays by others (Soond et al., 2003). These results were concordant with the 
data obtained in HEK-293 cells, although the overall magnitude of response produced 
was much lower (figure 4.1B). In addition, the interaction between NR3 and TNFR1 
was investigated by immunoprecipitation of from HEK-293 cells stably expressing 
V5-tagged NR3. However, TNFR1 could not be detected in immunoprecipitates 
(figure 4.1C). In view of the failure of the preliminary data presented here to 
recapitulate those reported by Soond et al (2003), an approach was employed that 
presumes no prior function for NR3 by screening for binding partners. Yeast two-
hybrid and immunoprecipitation based assays were used to identify NR3-interacting 
proteins. 
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Figure 4.1 Effect of NR3 Expression on NF-κB  
A and B) HEK-293 cells (A) and NIH/3T3 cells (B) were co-transfected with NF-
κB firefly luciferase reporter, renilla luciferase reporter as an internal control and 
increasing amounts of NR3 expression construct using Fugene 6 (HEK-293) or 
Lipfectamine 2000 (NIH/3T3), and incubated in the absence (open bars) and 
presence (closed bars) of 10ng/mL TNFα. As a positive control NIH/3T3 cells 
were co-transfected with 125ng p65 in place of NR3. Responses represent fold 
induction over unstimulated mock transfected cells (0ng). Error bars show the 
standard deviation between four replicates. 
 
C) NR3 tagged with V5 was immunoprecipitated from HEK-293 cells stably 
transfected with NR3-V5 or empty vector as a negative control, and probed in a 
western blot for V5 (upper blot) and TNFR1 (lower blot). Arrowheads denote band 
specific to TNFR1. 
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4.3 Screening for Binding Partners by Yeast Two-Hybrid 
The CytoTrap yeast two-hybrid system is based on the SRS system (Aronheim 
et al., 1997). This system fuses the bait protein to human SOS and the prey protein to 
a myristylation signal that targets the protein to the yeast cell membrane. The host 
strain is the temperature sensitive mutant S. cerevisiae strain cdc25H. This strain 
possesses a point mutation at amino acid 1328 of cdc25 protein, which inhibits growth 
at 37°C due to a deficiency in the Ras signalling pathway (Petitjean et al., 1990). An 
interaction between the bait and prey proteins results in recruitment of the bait SOS 
fusion protein to the yeast cell membrane where SOS can activate the Ras pathway 
and stimulate growth at the non-permissive temperature of 37°C (figure 4.2). 
Screening for binding partners can be performed by expressing both a prey protein 
from a cDNA library and a bait protein in cdc25H cells. Selection for protein-protein 
interactions is performed by incubating transformed yeast cells at 37°C and screening 
for growth of colonies. 
 
4.3.1 Construction of the cDNA Library 
When performing a yeast two-hybrid screen for protein-protein interactions it is 
important to use a cDNA library that incorporates a large number of genes that encode 
full length or long length cDNAs in order to express prey fusion proteins capable of 
interacting with the bait protein. It is also important the use a cDNA library in which 
there is as little over-representation or under-representation of genes as possible to 
allow genes that are not as highly expressed as others to be included in the screen. 
To generate prey cDNA libraries that represented a large number of genes 
double stranded 32P-labelled cDNA was synthesised from mRNA extracted from 
tissue derived from a number of murine embryos and placentas combined together to 
generate one library, and also from murine brain to generate a second library. The 
cDNA was size fractionated in to 12 fractions to prevent an enrichment of very small 
fragments in the library, and thus ensuring full length and long length cDNAs were 
used for library construction. A peak of radioactivity corresponding to the 32P-labelled 
cDNA was present in fractions 3-7 for the brain sample and 4-8 for the
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Cell Membrane 
Prey Ras hSos Bait 
GTP GDP 
Growth at 
37°C 
Myristylation 
Signal 
Figure 4.2 Principle of Screening for Protein Interactions in the SRS system 
Prey proteins are tethered to the cell membrane via a myristylation signal to which they are fused. Interacting bait 
proteins may rescue phenotype of the temperature cdc25H yeast strain through their fusion to human SOS (hSOS), 
which activates the Ras pathway, permitting growth at the selective temperature of 37°C. 
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embryonic/placental sample. Unincorporated 32P-dATP used for cDNA synthesis was 
present in fractions 11-12 for both samples, suggesting these fractions possessed little 
cDNA or very small fragments of cDNA. 
Pilot reactions to ligate the cDNA into the pMyr XR vector were performed for 
each fraction and transformed into bacteria to determine the transformation efficiency. 
Brain fractions 3-10 and embryonic/placental fractions 4-10 were used to ensure no 
cDNA was excluded. The number of CFU per fraction was calculated, which 
estimates the number of clones in each fraction and as such provides a guide as to the 
number of cDNA fragments ligated into the pMyr XR vector in each fraction (table 
4.1). These data allow the downstream library generation and amplification to be 
normalised, preventing the overrepresentation of genes in fractions with higher CFU 
within the library. As a negative control for the reactions a ligation was performed 
without a cDNA insert, which showed the background to the ligation reactions was 
1x102 CFU. Fractions 3-7 in brain samples and 5-8 in embryonic/placental samples 
possessed between 1.5x103-1x104 CFU (table 4.1, columns 1 and 2), and were used 
for downstream processing. Fraction 10 for the brain samples was not used because 
although it possessed 1.3x103 CFU it is likely to contain very small fragments. 
Selected fractions were processed further by scaling-up ligations and 
transformations normalising the amount of DNA used for ligation based on the 
observed CFU for each fraction. The number of CFU resulting from each scaled-up 
reaction was then determined to assess the success of the normalisation process. This 
showed that brain fractions were reasonably consistent and were between 1x104 and 
1.6x104 CFU (table 4.1, column 3). The embryonic/placental samples showed more 
variation, fractions 5-8 were between 7.5x103 and 1.2x104 and the ligation from 
fraction 4 possessed a CFU of only 5x102, however as all the cDNA was used in the 
ligation reaction it is likely that this is representative of the fraction not being enriched 
with cDNA (table 4.1, column 4). 
The scaled-up transformations were then pooled and plated to allow transformed 
bacterial colonies to grow. The number of CFU in the pooled bacteria was again 
determined to assess the number of clones each library is generated from, which 
indicates the number of cDNA fragments present in each library. Pooling and plating 
transformation reactions also acts as an amplification step as the colonies are then 
harvested and the library DNA prepared. The brain library possessed 8.4x104 CFU
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Table 4.1 CFU of Transformation Reactions for Constructing cDNA Libraries 
Size fractionated cDNA inserts were generated from mRNA derived from brain or a 
combination of embryonic and placental tissue, ligated into the pMyr XR vector, and 
transformed into bacteria. Small scale pilot reactions were performed to estimate the 
number of colony forming units (CFU) in each fraction (columns 1 and 2), and 
reactions were normalised and scaled-up to prevent over representation of genes in 
fractions with a higher CFU value. The CFU of normalised larger-scale reactions 
were again estimated to assess the level of variation in CFU among the fractions 
(columns 3 and 4). 
Fraction Brain Embryonic/Placental Brain Embryonic/Placental
3 6.2x103 N/A 1.6x104 N/A
4 5x103 2x102 1.4x104 5x102
5 4x103 3.2x103 1x104 8x103
6 1x104 8.2x103 1.1x104 1x104
7 6.2x103 4.6x103 1.6x104 1.2x104
8 7x102 1.5x103 N/A 7.5x103
9 6x102 7x102 N/A N/A
10 1.3x103 6x102 N/A N/A
CFU for Pilot Reactions CFU for Normalised Reactions
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and the embryonic/placental 3.5x104 CFU, indicating the libraries possess 8.4x104 
and 3.5x104 cDNA fragments as inserts respectively. However, the fragments were 
cloned into the pMyr XR vector directionally as outlined in chapter 2.2.4. Therefore 
there is a 1 in 3 probability of an insert being in the correct reading frame with the 
myrisytlation signal. This indicates that there are 2.8x104 and 1.2x104 functional prey 
clones within the brain and embryonic/placental libraries respectively. 
To examine the average insert size of each library colony PCR reactions were 
performed (figure 4.3). Both libraries possessed an average insert size of ~1kb, which 
ranged from 200bp to 4kb for the brain library, and 200bp to 2.5kb for the 
embryonic/placental library. cDNA libraries generated from mouse brain or 
embryonic tissue that are compatible for protein-protein interaction screening using 
the CytoTrap yeast two-hybrid method were not available from Stratagene at the time 
of library construction, however such products are now available and may be 
compared to the libraries generated here. Stratagene’s brain library possesses an 
average insert of 1.9kb and a CFU of 5.9x106, and the embryonic library possesses an 
average insert of 1.1kb and a CFU of 3.95x106. These data indicate that the libraries 
generated here possess around 100-fold less cDNA inserts than the Stratagene 
libraries, however the average insert length is comparable between to those present in 
the libraries offered by Stratagene. 
 
4.3.2 The NR3 LBD Interacts with 14-3-3η in a Yeast Two-Hybrid Assay 
To identify proteins that potentially interact with NR3, SOS-NR3 and SOS-NR3 
LBD were used as bait proteins in the yeast two-hybrid system to screen against the 
constructed libraries. Yeast cells were transformed in a 2:1:1 ratio of SOS fusion 
protein DNA, brain library DNA and embryonic/placental library DNA and cultured 
as outlined in chapter 2.2.4. Cells transformed with SOS-NR3 provided 124 colonies 
and SOS-NR3 LBD provided 82 colonies that grew in non-permissive conditions, 
which were patched on to plates for primary and secondary tests of interaction as 
outlined in chapter 2.2.4. 11 full length NR3 colonies and 31 NR3 LBD colonies 
passed these tests. cDNA library plasmid DNA from the positive candidates was then 
isolated and transformed into chemically competent DH5α bacteria to enable
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Figure 4.3 Average Insert of cDNA Libraries used for Two-Hybrid Screening 
Transformed bacterial colonies generated from normalised large-scale cDNA ligation 
reactions were subject to colony PCR to determine the average and range of insert size 
in both embryonic/placental and brain libraries. The average insert can be estimated at 
around 1kb for both libraries, and the range of insert sizes appears to be between 0.2-
2.5kb and 0.2-4.0kb for the embryonic/placental and brain libraries respectively. 
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miniprep DNA to be generated. Miniprep DNA was then sequenced to identify the 
cDNA library insert, the results of which are outlined in table 4.2. 
In the screen against SOS-NR3, surprisingly only 3 of the 11 candidates 
possessed a cDNA insert in frame with the myristylation signal within the pMyr XR 
vector and are fragments that correspond to coding regions of the mRNAs from which 
they are derived. These candidates were then co-transformed into yeast cells in a 1:1 
ratio with SOS-NR3 to verify the interaction within the two-hybrid system. No 
growth was observed at non-permissive temperatures, suggesting there was no 
interaction between the candidates and SOS-NR3 (table 4.2). Stratagene state that the 
phenotype of the cdc25H yeast cells may revert and allow growth at 37°C. It is 
possible that the positive results for the 11 identified colonies observed in the screen 
against SOS-NR3 were due to such a reversion. However, in the time intervening 
between the screen of full length NR3 and the screen of the NR3 LBD, it became 
apparent that due to the nature of the co-transformation procedure more than one prey 
plasmid may be taken up by yeast cells. When screening the NR3 LBD for interacting 
proteins, plasmids prepared from yeast cells were subject to PCR to identify those 
colonies with more than one prey plasmid. Most colonies appeared to possess a single 
construct, however some colonies possess up to four (figure 4.4). It is therefore 
plausible that in the 11 colonies selected from the full length NR3 screen there were 
more than one prey plasmid, and thus it may have been another unidentified plasmid 
that stimulated growth. These data allow the conclusion to be drawn that the 11 prey 
proteins identified did not interact with NR3, however it is not clear whether the 
reason for growth of colonies at the non-permissive temperature is due to a 
phenotypic reversion or due to the presence of a non-identified prey plasmid. 
For the NR3 LBD screen, prey plasmids isolated from candidates were 
sequenced, identifying inserts from candidates possessing a single plasmid or multiple 
plasmids. Of the 31 clones tested 29 were identified as containing a SOS prey plasmid. 
These were regarded as false positives as direct recruitment of SOS to the cell 
membrane would bypass the two-hybrid system and activate the Ras pathway, 
allowing growth at the non-permissive temperature. Two clones were not regarded as 
false positives and possessed inserts of Flt 3 interacting zinc finger protein 1 
(BC106113) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, η polypeptide (BC061497), the latter of which is identical to 14-3-3η, in
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Table 4.2 The Putative LBD of NR3 Interacts with 14-3-3η in a Yeast Two-
Hybrid Screen 
Full length NR3 (upper rows) and the LBD of NR3 (lower rows) were fused to 
human SOS and used for screening against the constructed cDNA libraries in the 
CytoTrap yeast two-hybrid system to search for interacting proteins. The library 
plasmid DNA was recovered and sequenced for each potential positive result to 
determine the identity of the candidate (column 1), the reading frame of the insert, 
and whether it corresponded to the coding region of the cDNA (column 3, 
Y=Correct Reading Frame, N=Incorrect Reading Frame, 3’UTR=insert corresponds 
to the 3’ untranslated region of the cDNA). Candidates in frame with the 
myristylation signal and representing the coding region of the cDNA were re-
screened in the system to assess the validity of the interaction (column 4, Y=Positive 
interaction, N=Negative interaction). No candidate was shown to robustly interact 
with full length NR3. Tyrosine 3-monooxygenase/Tryptophan 5-monooxygenase 
Activation Protein, which is also known as 14-3-3η, was found to interact with the 
NR3 LBD in this system.  
Identity of Candidate Accession Reading Frame Interaction
1 Follistatin-like 1 NM_007085 N
2 Alpha Tubulin 2 NM_011654 Y N
3 Hypothetical Domain of Unknown Function DUF143 Containing Protein AK010366 N
4 Secreted Phosphoprotein 1 NM_009263 Y N
5 Scavenger Receptor Class B, Member 1 (Scarb1) NM_016741 3'UTR
6 Niemann Pick Type C2 (Npc2) NM_023409 N
7 Similar to Ribosomal Protein S2 XM_001477049 N
8 Cyclin D1 NM_007631 3'UTR
9 Similar to Rpl136 Protein XM_001480807 N
10 NADH Dehydrogenase (Ubiquinone) 1 alpha Subcomplex NM_010886 N
11 Cytotoxic T Lymphocyte-associated Protein 2 alpha NM_007796 Y N
14 Flt3 Interacting Zinc Finger Protein 1 BC106113 Y N
20 Tyrosine 3-monooxygenase/Tryptophan 5-monooxygenase Activating Protein BC061497 Y Y
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Figure 4.4 PCR of Prey Plasmid Inserts from Zymoprep DNA 
Prey plasmid DNA was prepared from yeast colony candidates from the yeast two-
hybrid screen against the NR3 LBD and the plasmid inserts were amplified by 
PCR to identify the number of prey plasmids within each candidate. Arrow 
denotes 1kb. 
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frame with the myristylation signal (table 4.2). Upon co-transformation of the positive 
candidates into cdc25H yeast cells and testing for interaction at the non-permissive 
temperature of 37°C, 14-3-3η provided a positive result and thus appears to interact 
with NR3 in the CytoTrap yeast two-hybrid system, however an interaction between 
NR3 and Flt 3 interacting zinc finger protein 1 could not be confirmed (table 4.2). 
 
4.3.3 Verification of the Interaction between NR3 and 14-3-3η 
An interaction between proteins in a yeast two-hybrid system suggests the 
proteins are likely to directly interact. To verify this between NR3 and 14-3-3η, a 
GST pulldown assay was used to examine whether NR3 or the NR3 LBD and 14-3-
3η may directly interact in vitro. GST-NR3, GST-NR3 LBD or GST alone as a 
negative control were used in conjunction with in vitro synthesised radiolabelled 14-
3-3η in a GST pulldown assay as outlined in chapter 2.2.3.  14-3-3η did not co-purify 
with GST, GST-NR3 or GST-NR3 LBD in the pulldown (figure 4.5A, upper panel), 
suggesting NR3 and 14-3-3η do not interact directly. It is possible that the lack of 
interaction could be due to a low level of GST fusion protein in the assay. As a 
control, purified GST proteins were subjected to SDS-PAGE and Coomassie staining 
to assess the levels of expression and purification (figure 4.5A, lower panel), which 
shows relatively even loading and that the proteins are expressed to a level detectable 
by Coomassie staining, thus it is unlikely that the lack of interaction is due to low 
levels of GST fusion protein. 
It is possible that an interaction in a yeast two-hybrid screen is indirect, as the 
interaction may be mediated by proteins expressed endogenously in the host cell. To 
further examine the potential interaction between NR3 and 14-3-3η in vivo protein 
extracts from HEK-293 cells stably expressing NR3 tagged with V5 were used in 
immunoprecipitation experiments, followed by western blotting to examine whether 
14-3-3 proteins co-precipitated with NR3. HEK-293 cells stably transfected with 
empty vector were used as a negative control. Immunoprecipitation with anti-V5 
antibody clearly purified NR3-V5 (figure 4.5B, upper panel), however there is no 
evidence that members of the 14-3-3 family of proteins co-precipitate with NR3-V5, 
as probing the blot with an anti-14-3-3 antibody that detects all family members 
provides no signal in immunoprecipitated samples (figure 4.5B, lower panel). This 
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Figure 4.5 NR3 Does Not Interact 
with 14-3-3η in GST Pulldown 
and Immunoprecipitation Assays 
 
A) GST, GST-NR3 and GST-NR3 
LBD were incubated with 
radiolabelled 14-3-3η, interacting 
complexes purified, and subject to 
SDS-PAGE. 14-3-3η did not co-
purify with the GST fusion proteins 
to a detectable level (upper panel). 
GST fusion protein loading was 
assessed by Coomassie staining 
(lower panel). Arrow heads denote 
bands that correspond to the 
expected sizes of GST fusion 
proteins. 
 
B) Immunoprecipitations against 
V5 were performed in HEK-293 
cells stably transfected with empty 
vector (mock) or NR3-V5. 
Precipitates were subject to western 
blotting with anti-V5 antibody and 
an antibody that recognises all 
members of the 14-3-3 protein 
family. Co-purification of 14-3-3 
proteins with NR3-V5 was not 
detected. 
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suggests an interaction between NR3 and 14-3-3η in vivo, direct or indirect, may not 
be detectable. Coupled with the data provided by the GST pulldown experiments, 
these data suggest that NR3 does not interact with 14-3-3η in vitro or in vivo, which 
in turn indicates the interaction observed in the yeast two-hybrid screen may be an 
artefact of the system. 
 
4.4 Screening for Binding Partners for NR3 by Immunoprecipitation 
Screening for NR3-interacting proteins was also approached by utilising V5 
tagged NR3 in immunoprecipitation experiments. Co-precipitating proteins can be 
isolated from samples and identified by mass spectrometry.  
 
4.4.1 NR3 Interacts with DDB1 
NIH/3T3 cells were transfected with empty vector as a negative control, or 
DNA coding for NR3-V5, NR3477-797-V5 or NR31-722-V5. 42 hours later the cells were 
treated with 10ng/mL TNFα for 6 hours as NR3 has been implicated in TNF 
signalling (Soond et al., 2003; Soond et al., 2006), and stimulation of these pathways 
may effect the recruitment of proteins to NR3. Protein extracts were then generated 
and immunoprecipitations performed using an antibody recognising the V5 tag. 
Precipitates were subject to SDS-PAGE and silver staining. Numerous bands were 
present in the silver-stained gel, however the majority of these correspond to proteins 
that co-purified non-specifically in the precipitation as they are present in mock 
samples transfected with empty vector (figure 4.6A, lanes 1 and 5). In addition, the 
pattern of the bands observed was unaffected by treatment with TNFα (figure 4.6A, 
lanes 1-4 compared to lanes 5-8). Specific bands corresponding to the expected sizes 
of the different tagged NR3 constructs expressed in the cells were present at ~95kDa, 
~40kDa and ~80kDa for NR3-V5, NR3477-797-V5 and NR31-722-V5 respectively 
(figure 4.6A, lanes 2-4 and 6-8). In addition, a band was observed at ~130kDa in 
NR3-V5 and NR31-722-V5 precipitates that appeared to co-purify at stoichiometric 
levels. This band was absent from mock and NR3477-797-V5 precipitates (figure 4.6A, 
all lanes). These data therefore suggest the ~130kDa protein interacts in 
stoichiometric amounts with the N-terminus of NR3, and is not effected by treatment 
with TNFα. 
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Figure 4.6 NR3 Interacts with DDB1 
A) NIH/3T3 cells were transfected with empty vector or V5 tagged NR3 constructs 
and treated with TNFα for 6 hours. Fusion proteins were immunoprecipitated using 
the V5 tag and subject to SDS-PAGE and silver staining. Arrowheads denote 
immunoprecipitated NR3 constructs and asterisks denote bands corresponding to 
antibody heavy chains (~50kDa) and light chains (~25kDa). Red elipses denote a co-
precipitated protein that was identified as DDB1 by mass spectrometry. 
 
B) Immunoprecipitation with anti-V5 antibody was performed using protein extracts 
from HEK-293 cells stably expressing NR3-V5 or stably transfected with empty 
vector (mock). Precipitates were then subject the western blot with anti-V5 and anti-
DDB1 antibodies. 
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The silver-stained protein bands at ~130kDa were excised from the gel and 
subject to quadruple time-of-flight mass spectrometry. Numerous peptide fragments 
were identified, however only one fragment was regarded as a significant hit. This 
peptide fragment had the sequence VTLGTQPTVLR, which corresponds to a 127kDa 
protein named damage-specific DNA-binding protein (DDB) 1, as identified by 
protein BLAST searches. DDB1 is a protein that possesses multiple domains and acts 
as a substrate recognition subunit of an E3 ubiquitin ligase complex that is reported to 
be involved in regulation of the cell cycle and nucleotide excision repair (NER) of 
DNA damaged by UV light (Bondar et al., 2006; Hayes et al., 1998; Li et al., 2006a). 
These data therefore implicate NR3 in one or both of those processes. 
To confirm that DDB1 co-precipitates with NR3, immunoprecipitation 
experiments were also performed in HEK-293 cells stably transfected with NR3-V5 
or empty vector as a negative control. Following immunoprecipitation, western 
blotting was performed. Control blots with anti-V5 show the presence of NR3-V5 in 
precipitated samples (figure 4.6B, upper panel). Probing with anti-DDB1 antibody 
detects a band at ~130kDa in NR3-V5 precipitates, which is absent from mock 
precipitates (figure 4.6B). Coupled with the data generated by the silver-staining 
experiments, this supports the notion that NR3 interacts with DDB1 as NR3-V5 and 
DDB1 co-purify in immunoprecipitates from both HEK-293 cells and NIH/3T3 cells. 
 
4.5 Mapping the Interaction between NR3 and DDB1 
DDB1 is a member of an E3 ubiquitin ligase complex, and is responsible for the 
recruitment of substrates and substrate adaptors to the complex. The interaction 
between NR3 and DDB1 leads to the hypothesis that NR3 may be either a substrate 
for ubiquitination, an adaptor molecule involved in the recruitment of substrates, or a 
regulator of the process. Such functions may not necessarily be mutually exclusive 
and therefore NR3 may fulfil more than one of these roles. Characterisation of the 
interaction between DDB1 and NR3 will provide a better understanding of the nature 
of the interaction and may indicate the likely consequence of such an interaction. 
X-ray crystallographic studies of DDB1 when sequestered by  the V protein of 
the simian virus 5 showed that DDB1 possesses four domains, there are 3 β-propeller 
domains named A-C (BPA, BPB, BPC), and an α-helical C-terminal domain (CTD) 
(figure 4.7) (Angers et al., 2006; Li et al., 2006b). The BPA and BPC domains form a
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Figure 4.7 Crystal Structure of DDB1 and Interacting Proteins 
A) Crystal structure of DDB1 showing the three β-propeller domains (BPA, BPB 
and BPC) and α-helical C-terminal domain (CTD) (protein data bank ID: 2B5M; 
Li et al, 2006). 
 
B) Crystal structure of DDB1 in the reverse orientation to A). 
 
C) Crystal structure of the archetypical DDB1 complex bound to the V protein of 
the SV-5 virus (cyan) (protein data bank ID 2HYE; Angers et al, 2006). DDB1 
(blue) binds substrates in the cleft between its BPA and BPC domains. The CTD 
domain resides underneath this cleft. The BPB domain interacts with CUL4 
(green), which acts as the enzymatic core of the ligase with ROC1 (yellow). 
 
Image was generated using 3D Molecule Viewer which forms part of the Vector 
NTI software suite. 
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clam-shell like structure that provides a cleft into which substrates or adaptor 
molecules dock Furthermore, such studies have solved the structure of the 
archetypical DDB1 containing complex, which also comprises cullin (CUL) 4 and 
RING of cullin (ROC1) (figure 4.7C) (Angers et al., 2006). CUL4 and ROC1 form 
the catalytic core of the complex, and are responsible for the recruitment of the E2 
ubiquitin ligase. The N-terminus of the CUL4 interacts with the BPB region of DDB1 
(Angers et al., 2006), and therefore mapping the NR3 interaction to a domain of 
DDB1 may provide information as to the role NR3 plays when complexed with 
DDB1. To address this, GST pulldown assays were employed to screen deletion 
mutants of both NR3 and DDB1, and also to determine whether NR3 and DDB1 can 
interact directly. 
 
4.5.1 BPC of DDB1 is Required for Interaction with NR3 
The crystallisation of DDB1 has shown it possesses a complex structure (Angers 
et al., 2006). Although BPA, BPB and CTD are continuous polypeptide chains 
forming their respective 3-dimensionally structured domains, BPC is not continuous 
as the first blade of the β-propeller and the rest of BPC are interspersed by the BPA 
and BPB domains (figure 4.8). The structural characteristics of DDB1 were taken into 
account or the mapping studies, and mutant constructs were generated that delete 
portions of the protein according to the position of the individual domains. The 
radiolabelled mutant proteins were then tested for interaction with GST or GST-NR3 
as outlined in chapter 2.2.3. 
Full length DDB1 interacts with GST-NR3, producing a band of at least equal 
intensity to that of the input control. This supports the idea that NR3 and DDB1 
interact, and indicates the interaction is direct in nature (figure 4.8, DDB1). Deletion 
of the CTD allows DDB1 to retain the interaction with GST-NR3 although the level 
of signal detected is reduced compared to that of full-length DDB1, suggesting the 
interaction is not as high affinity (figure 4.8, DDB11-1043). However, deletion of the 
CTD and the C-terminal portion of BPC (figure 4.8A, DDB11-706), or deletion of the 
N-terminal portion of BPC resulted in an ablation of the interaction (figure 4.8, 
DDB117-1140), indicating BPC is required for NR3 binding. Deletion of the BPB 
domain retained the interaction with GST-NR3, which suggests BPB is not required
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Figure 4.8 NR3 Interacts with the BPC region of DDB1 
Mutant DDB1 constructs were generated according to the domain structure of DDB1, and the indicated radiolabelled proteins were subject 
to GST pulldown assays with GST and GST-NR3. Full length DDB1 (DDB11-1140) interacts directly with GST-NR3. The interaction is 
retained following deletion of CTD (DDB11-1043) and BPB (DDB∆BPB), and abolished following deletion of the N-terminal (DDB117-1140) and 
C-terminal (DDB11-704) portions of BPC. 
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for DDB1 binding NR3 (figure 4.8, DDB1∆BPB). These data indicate that NR3 binds to 
the BPC domain of DDB1, which is the region implicated in substrate recognition. 
Therefore it is possible that NR3 binds to DDB1 as a substrate or adaptor protein. 
 
4.5.2 The N-terminus of NR3 interacts with DDB1 
Immunoprecipitation experiments have implicated the N-terminus of NR3 as 
being required for the interaction with DDB1 (figure 4.6A). To further investigate the 
region of NR3 that binds to DDB1, deletion mutants of NR3 were fused to GST and 
used in conjunction with radiolabelled DDB1 in a GST pulldown assay. The positive 
control of GST-NR3 showed that DDB1 co-purified in the assay, which was not 
affected by C-terminal deletion (figure 4.9A, NR3 and NR31-722). However, deletion 
of the first 120 amino acids of NR3 resulted in loss of interaction with DDB1 (figure 
4.9A, NR3120-722). Furthermore, it was observed that amino acids 1-120 of NR3 fused 
to GST were sufficient to interact with DDB1 (figure 4.9A, NR31-120). No binding was 
observed with GST-NR3 LBD, which served as a negative control (figure 4.9A, NR3 
LBD). Coomassie staining of purified GST-fusion proteins shows all the fragments 
were expressed at the expected sizes (figure 4.9B). Interestingly bands could be 
observed in a number of samples at ~75kDa and ~60kDa, as observed in the limited 
proteolysis experiments outlined in section 3.2.1. The polypeptides were present in 
GST-NR3, GST-NR31-722, GST-NR3120-722 and GST-NR3 LBD samples, supporting 
the idea that they correspond to bacterial proteins that co-puryify with GST-NR3 and 
indicates that putative LBD of NR3 may be important for their co-puryfication. fusion 
proteins possessing the putative LBD region, This supports the idea that these 
polypeptides coThese data indicate the N-terminus of NR3 is responsible for the 
interaction with DDB1 and the site of interaction resides between amino acids 1 and 
120. The bioinformatic predictions for NR3 suggest the N-terminus possesses an 
armadillo repeat-like structure, which is a motif known to be involved in mediating 
protein-protein interactions (Herold et al., 1998; Kaufmann et al., 2000; Song et al., 
2003), and as such the results presented here support the notion that the N-terminus of 
NR3 possesses a structure that allows interaction with other proteins. 
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Figure 4.9 DDB1 Interacts with the N-terminus of NR3 
Radiolabelled full length DDB1 was incubated with GST-fused NR3 deletion mutants in a GST pulldown assay. 
 
A) Deletion of the NR3 C-terminus retains the interaction between GST-NR3 and DDB1 (NR31-722). Deletion of the N-terminus of NR3 
abolishes binding (NR3120-722). The N-terminal 120 amino acids of NR3 are sufficient to bind to DDB1 (NR31-120). GST-NR3 LBD serves as 
a negative control. 
 
B) Coomassie stained gel of GST-fused NR3 deletion mutants. Arrowheads denote the band corresponding to the correct fusion protein. 
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4.6 NR3 is Ubiquitinated and Degraded by the Proteasome 
DDB1 is the substrate recognition subunit of an E3 ubiquitin ligase complex 
involving CUL4 and ROC1. NR3 binds to the region that is important for substrate 
and adaptor docking (Angers et al., 2006), which are biological roles that are not 
necessarily mutually exclusive (Sugasawa et al., 2005). It may be hypothesised that 
NR3 is ubiquitinated, and as polyubiquitination is likely to lead to protein degradation 
at the proteasome (reviewed in Varshavsky, 2005), it is possible this is important for 
regulating NR3 levels. 
To determine whether NR3 levels are regulated by the proteasome, it is 
necessary to block its action, which may be done by administering MG132. The 
chemical has previously been used at concentrations of 10-50µM for between 0.5 and 
6 hours (Guo and Wang, 2007; Wassler et al., 2008). To optimise the MG132 
treatment for experiments examining the ubiquitination status of NR3, a time course 
treatment with 20µM MG132 was performed. The protein levels of the DDB1 target 
chromatin licensing and DNA replication factor (CDT) 1 were determined as an 
indicator of proteasomal blockade. Levels and NR3-V5 were also examined in 
response to MG132 administration. DDB1 and GAPDH served as negative controls 
for the optimisation as proteasomal blockade was unlikely to affect their protein levels. 
Treatment with MG132 produced an accumulation of CDT1 after 1-2 hours, which 
peaked at ~4 hours (Figure 4.10A). However, no accumulation of protein was 
observed for DDB1, NR3-V5, or the loading control GAPDH. These data show that 
proteasomal blockade was achieved effectively between 2-4 hours, and as such 
following MG132 pre-treatments were performed for 3 hours at a concentration of 
20µM.  
To investigate the ubiquitination status of NR3, a V5 tagged version of the 
protein was immunoprecipitated under native and denatured conditions from stable 
NR3-V5 expressing HEK-293 cells following treatment with MG132, as outlined in 
chapter 2.2.3. Immunoprecipitations were also performed in cells stably transfected 
with empty vector as a negative control. Samples were then probed for NR3-V5 and 
ubiquitin in a western blot to determine whether ubiquitinated material co-precipitated 
with NR3. For both native and denatured immunoprecipitations, probing for V5 
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Figure 4.10 NR3 is Ubiquitinated and Degraded by the Proteasome 
A) HEK-293 cells stably expressing V5-tagged NR3 were subject to treatment 
with 20µM MG132 for increasing lengths of time. Western blots were performed 
with antibodies to recognise the indicated proteins. 
 
B and C) HEK-293 cells stably transfected with NR3-V5 or empty vector (mock) 
were left untreated or treated with 20µM MG132 for 3 hours and 
immunoprecipitations with anti-V5 antibody under B) native and C) denatured 
conditions were performed. Immunoprecipitates were probed for V5 or ubiquitin 
(Ub) in a western blot. Arrowheads denote where NR3-V5 is expected to migrate. 
Asterisks denote bands corresponding to immunoprecipitation antibody heavy and 
light chains. 
 
D) Pulse chase experiments with HEK-293 cells stably expressing NR3-V5. Cells 
were left untreated or pre-treated with 20µM MG132 for 3 hours, and treated with 
20ng/mL cyclohexamide (Chx) for the length of time indicated. Levels of NR3-V5 
were assessed by western blot against the V5 tag. GAPDH was blotted for as a 
loading control. 
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detects numerous bands of differing molecular masses in NR3-V5 samples, and no 
bands in mock samples, indicating the bands are specific to NR3-V5 (figure 4.10B, 
lanes 1-4; figure 4.10C, lanes 1-4). The bands at lower molecular masses are likely to 
correspond to degraded fragments of NR3-V5, and the smear observed above the 
expected migratory size for NR3-V5 is likely to be modified NR3-V5. The lower 
molecular mass bands are enriched following administration of MG132 (figure 4.10B 
compare lane 3 to 4), suggesting some of the bands are partially proteasomally 
degraded NR3-V5. The upper molecular mass smear is also slightly enriched in native 
samples and enriched in denatured samples upon treatment with MG132 (figure 4.10B 
and C, compare lanes 3 and 4), which may indicate a portion of the smear corresponds 
to polyubiquitination. 
Probing the samples with an anti-ubiquitin antibody shows that ubiquitin does 
indeed co-precipitate with the samples immunoprecipitated under native conditions 
(figure 4.10B, lanes 5-8), indicating NR3 is associated with ubiquitinated material. 
This was recapitulated in immunoprecipitations performed following denaturation of 
samples (figure 4.10C, lanes 5-8). Denaturing samples prior to immunoprecipitation 
disrupts the protein structure and breaks protein-protein interactions, ensuring no 
associated proteins are co-precipitated. However, covalent modifications are retained. 
Therefore these data show that NR3 is ubiquitinated, and due to the smear pattern in 
the western blot, this is likely to be polyubiquitination, supporting the results observed 
when western blotting for V5 (figure 4.10B and C, lanes 1-4). 
Ubiquitinated material can also be observed in mock native immunoprecipitated 
samples treated with MG132, but not those left untreated (figure 4.10B, lane 5 and 6), 
indicating that some of the precipitated material in MG132 treated samples is non-
specific. However, the co-precipitated ubiquitinated material in native NR3-V5 
samples treated with MG132 is highly enriched implying most of the material present 
is specific to NR3-V5 (figure 4.10B, lanes 6 and 8). Some ubiquitinated material is 
present in native precipitates from NR3-V5 cells cultured in the absence of MG132, 
which contrasts the samples from mock cells cultured under the same conditions 
(figure 4.10B, lanes 5 and 7). This suggests NR3 is associated with ubiquitinated 
material in the absence of proteasomal blockade, although the quantity of material is 
lower than precipitates from NR3-V5 cells treated with MG132 (figure 4.10B, lanes 7 
and 8). No ubiquitinated material is present in denatured mock samples, or denatured 
 Chapter 4  Results 
143 
NR3-V5 samples derived from cells cultured in the absence of MG132 (figure 4.10C, 
lanes 5-7). 
Comparing the relative quantities of ubiquitinated material precipitated under 
native and denatured conditions shows that a greater amount of material is present in 
precipitates derived from native samples (compare figure 4.10A, lanes 5-8 and figure 
4.10C, lanes 5-8). Although a portion of the ubiquitinated material in native 
precipitates is non-specific, it is possible that NR3 is also associated with other 
ubiquitinated proteins. Taking the results from the immunoprecipitations performed 
on native and denatured protein samples together, these data show that NR3 is 
associated with ubiquitinated material and is polyubiquitinated itself. 
Polyubiquitination generally leads to degradation at the proteasome (Varshavsky, 
2005), which coupled with the data presented here showing NR3 polyubiquitination is 
detectable following treatment with the proteasome blocking agent MG132, strongly 
suggests the ubiquitin-proteasome may be important in regulating the protein levels of 
NR3. To address this idea, pulse chase experiments were performed in HEK-293 cells 
stably expressing NR3-V5. Cells were pre-treated for 3 hours with 20µM MG132 or 
left untreated, and treated with cyclohexamide to block protein translation. Cells were 
harvested at different time points and protein samples subject to western blot to 
determine the half life of NR3-V5. Following cyclohexamide administration, NR3-V5 
degrades rapidly with a half life of ~1 hour and is stabilised by pre-treatment with 
MG132 prior to cyclohexamide administration (figure 4.10D). This indicates that 
NR3 is degraded at the proteasome, and that the polyubiquitination observed in 
previous experiments is likely to be responsible for this. Interestingly administration 
of MG132 provided an accumulation of NR3-V5 protein (figure 4.10D), which 
contrasts the results observed for the MG132 timecourse experiments (figure 4.10A). 
However, the reasons for this are unclear as the level of cell confluence does not 
appear to affect NR3-V5 accumulation (data not shown), and the conditions between 
experiments were kept constant. 
Drawing together the data from this set of experiments with the data from the 
interaction and mapping studies it can be concluded that the NR3 binds to the 
substrate docking region of DDB1 and is polyubiquitinated, which results in 
degradation at the proteasome. 
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4.7 Effect of NR3 Expression on Cell Proliferation 
A potential role for NR3 in the regulation of cell cycle progression has been 
identified previously by screening for novel genes upregulated in cancer, suggesting it 
may play a role in cell cycle regulation (Nicassio et al., 2005). However, the authors 
did not characterise the effect of NR3 expression on cell proliferation. DDB1 is 
known to participate in cell cycle regulation by polyubiquitinating important 
regulatory proteins and marking them for destruction at the proteasome (Banks et al., 
2006; Bondar et al., 2006; Cang et al., 2006; Higa et al., 2006). NR3 is a potential 
substrate for DDB1, and thus lends support to Nicassio and colleagues’ initial 
hypothesis that NR3 may be implicated in regulation of the cell cycle. 
To test the effect of NR3 expression on cell proliferation, ectopic expression of 
NR3 was examined by determining the proliferative rate of HEK-293 cells stably 
expressing murine NR3 in comparison to HEK-293 stably transfected with empty 
vector. Transient transfection is inappropriate for such experiments as only a 
proportion of cells will be transfected, which may mask any effects produced by 
overexpression. Although genomic integration results in lower levels of expression in 
stable cell lines, 100% of the cells used in the assay ectopically express NR3, 
avoiding the problems associated with non-transfected cells in transient transfection 
assays. Cell number was monitored over a period of 72 hours by MTS assay. After 72 
hours there was a statistically significant increased rate of proliferation in the cells 
ectopically expressing NR3, although this was not apparent after 24 and 48 hours 
(figure 4.11A). This suggests that the HEK-293 cells ectopically expressing murine 
NR3 possess a proliferative advantage over cells stably transfected with empty vector.  
To further examine whether NR3 plays a role in cell proliferation, NR3 was 
knocked down using siRNA in NIH/3T3 cells. Although the cells have undergone 
transformation during the generation of the cell line (Todaro and Green, 1963), they 
are a murine fibroblasts that have not been virally immortalised or derived from a 
tumour. As such, they are a cell type that possess a relatively unperturbed cell cycle 
and represent a more physiologically relevant model of cell cycle regulation. 
Knockdown was performed by transfecting cells with either a pool of siRNA targeting 
NR3 or a non-specific siRNA as a negative control, and cell number over a 72 hour 
period was measured by MTS assay. Transfection of siRNA targeting NR3 achieved
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Figure 4.11 Effect of NR3 Expression on Cell Proliferation 
Cell number was determined over a time course by MTS assay at the given time 
point to examine the effect of NR3 levels on cell proliferation. Data points 
represent the mean of 4 independent experiments performed in at least duplicate 
and error bars represent standard error between experiments. Statistical 
significance (denoted by asterisk) was tested by the Mann-Whitney U test between 
control and test samples at the given time point. 
  
A) HEK-293 cells were stably transfected with NR3-V5 (closed circles) or empty 
vector (open circles) and proliferation examined over 72 hours. 
  
B) NIH/3T3 cells were transfected with a non-targeting control siRNA (siControl, 
open circles) or siRNA targeting NR3 (siNR3, closed circles) and proliferation 
examined over 72 hours. Inset shows representative NR3 mRNA levels in cells 
harvested at the 72 hour time point. 
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~95% knockdown at the mRNA level over non-targeting siRNA (figure 4.11B, inset), 
however no significant difference in cell proliferation was observed after 72 hours 
between non-targeting siRNA and siRNA targeting NR3 as the gradients pertaining to 
the growth curves for each transfection are similar (figure 4.11B). This data appears 
to indicate that NR3 is not required for cell proliferation in NIH/3T3 cells. However, 
it is also possible that 95% knockdown of NR3 at the mRNA level is not sufficient to 
abrogate the physiological function of NR3. 
From these experiments it can be concluded that HEK-293 cells expressing 
murine NR3 proliferate at an increased rate than cells transfected with empty vector, 
which may be due to the increased NR3 levels within the cells. However, it appears 
NR3 is not to be required for cell proliferation, as reduction of the NR3 transcript by 
~95% had no effect on the rate of cell proliferation. 
 
4.8 Summary and Conclusions 
Screening for proteins that interact with NR3 was approached in two ways. 
Immunoprecipitation experiments with V5-tagged NR3 proteins were performed and 
precipitating proteins were detected by SDS-PAGE followed by silver staining. This 
technique provided a detectable interaction with DDB1, which was confirmed in a 
different cell system by immunoprecipitation of V5-tagged NR3 and co-precipitation 
of endogenous DDB1. GST pulldown experiments showed the interaction was direct 
and mapping studies showed the BPC domain of DDB1 was required for interaction, 
which is involved in ubiquitination substrate recognition. The interaction was also 
mapped to the N-terminus of NR3, which is predicted to possess an armadillo repeat-
like structure, a motif important in protein-protein interactions (Herold et al., 1998; 
Kaufmann et al., 2000; Song et al., 2003). Therefore, it may be concluded that the N-
terminus of NR3 binds to the region of DDB1 that is involved in the recognition of 
substrates for ubiquitination. In addition, a yeast two-hybrid based approach was also 
employed. This system implicated 14-3-3η as a protein that interacts with the LBD of 
NR3. However these results could not be confirmed using other assays, indicating the 
interaction may not be physically relevant.  
DDB1 is part of an E3 ubiquitin ligase complex also including CUL4 and ROC1. 
The role of DDB1 is to directly recruit substrates for ubiquitination or adaptor 
molecules that in turn recruit substrates (Angers et al., 2006). The interaction between 
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NR3 and DDB1 gives rise to the idea that NR3 may be ubiquitinated, which often 
leads to degradation at the proteasome (Varshavsky, 2005). Immunoprecipitation 
experiments show that NR3 ubiquitination can be detected upon proteasome blockade. 
Furthermore, pulse chase experiments show NR3 protein levels are stabilised in the 
presence of MG132. From these data it can be concluded that NR3 is 
polyubiquitinated and as a result is degraded at the proteasome. 
DDB1 is known to possess a role in the ubiquitination of cell cycle regulators 
(Banks et al., 2006; Bondar et al., 2006; Cang et al., 2006; Higa et al., 2006). In 
addition, NR3 has been implicated as possessing a potential role in cell cycle 
regulation (Nicassio et al., 2005). As such the effect of NR3 expression levels on cell 
proliferation was addressed. HEK-293 cells that stably expressed mouse NR3 possess 
a significant proliferative advantage over cells stably transfected with empty vector. 
However, when depleted of NR3, NIH/3T3 cells show no difference in cell 
proliferation over control cells. These data suggest that NR3 expression may have a 
positive effect on the cell cycle, however further experiments must be performed to 
confirm this. It may also be concluded that NR3 expression is not required for cell 
proliferation in NIH/3T3 cells. 
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5.1 Introduction 
Due to the interaction between NR3 and DDB1 previous experiments have suggested 
NR3 may play a role in regulating the functional pathways in which DDB1 is 
involved. To assess the biological function of NR3 in vivo a conditional knockout 
mouse model is currently being generated in conjunction with the services offered by 
Genoway, Lyon. The initial cloning steps and targeting vector construction were 
undertaken within the laboratory here and the completed targeting vector was then 
passed to Genoway, who were responsible for the generation of heterozygous floxed 
mice. 
 
5.2 Gene Structure of NR3 and Strategy for Deletion 
Blat searches with the NR3 cDNA sequence (accession BC033274) on the 
UCSC genome bioinformatics server (http://genome.ucsc.edu/) reveals the NR3 gene 
consists of 19 exons spanning a 58kb region within the qH1 region of chromosome 2 
(figure 5.1). The start ATG of the gene is present in exon 1, and the termination codon 
is present within exon 19. The NR3 gene is flanked downstream by myosin heavy 
chain 7B cardiac muscle β gene in the reverse orientation and upstream by the α-
mannosidase gene in the same orientation, separated by 0.3kb and 9.3kb of genomic 
DNA respectively. The targeting strategy selected involves flanking exon 1 with loxP 
sites allowing a tissue specific deletion of the start ATG codon within exon 1 upon 
crossing floxed mice with mice expressing Cre recombinase in the tissue of interest. 
With such a strategy it is important to avoid disrupting important regulatory elements, 
thus allowing endogenous expression of the targeted gene in the absence of Cre 
recombinase. 
To identify appropriate sites for loxP insertion, the mouse genomic DNA 
sequences either side of exon 1 of the NR3 gene were analysed in conjunction with 
the equivalent human sequences using Consite (http://mordor.cgb.ki.se/cgi-bin/ 
CONSITE/consite) to identify conserved potential transcription factor binding sites. 
This revealed there are three conserved clusters of transcription factor binding 
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Figure 5.1 Gene Structure of NR3 
Schematic of the gene structure of NR3. The NR3 gene resides on region qH1 of chromosome 2 in mice, and is flanked either side by the 
myosin heavy chain 7B cardiac muscle β and α-mannosidase genes. The NR3 gene consists of 19 exons, with the translational start site in exon 
1 and the termination codon in exon 19. 
Chr 2qH1: 155,091,224-155,149,244 
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sites upstream of the NR3 core promoter (figure 5.2A). Cluster 1 resides furthest from 
the transcriptional start site between -5783bp and -4093bp and contains the greatest 
number of conserved transcription factor binding sites. Cluster 2 is the smallest 
cluster and is situated between -2167bp and -2152bp. Cluster 3 is the shortest distance 
from the transcriptional start site, residing between -712bp and -18bp. In addition to 
regulatory elements that are present within the promoter, it is possible elements may 
reside in intron 1, including binding sites for transcription factors (Fedorova and 
Fedorov, 2003). Intron 1 spans 19kb in the mouse and 14kb in the human, therefore a 
similar transcription factor binding site analysis was performed on the 10kb region of 
intron 1 immediately downstream of exon 1 (figure 5.2B). The conserved 
transcription factor binding sites could again be grouped into 3 clusters. Intronic 
cluster 1 is the smallest cluster and closest in proximity to exon 1, situated between 
16bp and 603bp downstream of exon 1. Cluster 2 is the largest group and resides 
between 1319bp and 3260bp downstream of exon 1. Cluster 3 is the furthest group 
from exon 1 being present between 4245bp and 5364bp downstream of exon 1. 
Based on this analysis, it was decided that the distal loxP site should be placed 
within the BstBI restriction enzyme recognition site positioned at 553 base pairs 
upstream of the translational start site, and the proximal loxP site be placed within 
intron 1, 1799 base pairs downstream of the translational start site within exon 1, 
representing a distance of 2.35kb between the two sites. Placing the loxP sites in these 
positions avoids the disruption of any of the potential transcription factor binding sites 
identified by in silico analysis of the promoter and intron 1. A schematic of the final 
targeting vector is shown in figure 5.3. The targeting vector possesses short and long 
homology arms that allow the loxP sites to be homologously recombined at the 
correct genomic locus. The long homology arm contains distal loxP site, and the 
proximal loxP site resides between the long and short homology arms. Insertion of the 
neomycin resistance cassette in conjunction with the proximal loxP site allows the 
initial selection of clones in which homologous recombination has successfully 
occurred within the short homology arm. The diphtheria toxin A gene located 
upstream of the long homology arm allows for selection against clones that have not 
successfully undergone homologous recombination within the long homology arm 
region (figure 5.3). However, it is possible that recombination may occur downstream 
of the distal loxP site. Thus clones are then screened for presence of the distal loxP
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Figure 5.2 Alignment of Conserved Transcription Factor Binding Sites 
The genomic DNA sequences surrounding exon 1 of the NR3 gene in the mouse 
and human genomes were aligned and analysed in silico using Consite (http:// 
mordor.cgb.ki.se/cgi-bin/CONSITE/consite) to identify conserved transcription 
factor binding sites. Analysis is of the 10kb region A) upstream of the translation 
start codon and B) downstream of exon 1. For each set of data three clusters of 
conserved transcription factor binding sites could be identified. The proposed sites 
for loxP insertion are denoted by the arrow in each figure. 
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Figure 5.3 Schematic of the Floxed NR3 Gene 
Schematic of the targeting vector being constructed. The long homology arm consists of a 5.9kb region of DNA that includes a BstBI 
restriction site 0.5kb upstream of exon 1, where the distal loxP site is inserted. The short homology arm consists of a 1.75kb region. The 
proximal loxP site and neomycin resistance cassette (Neo) are inserted into the EcoRI restriction site between the long and short homology 
arms. The neomycin resistance cassette is flanked by FRT sites, allowing excision with Flp recombinase. The diphtheria toxin A (DTA) 
gene represents a method of selecting for clones that have undergone homologous recombination within the long arm.  
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site by PCR and Southern blot to determine whether recombination has occurred at an 
appropriate upstream position or downstream of the distal loxP site. To minimise the 
disruption of any regulatory elements within intron 1 the neomycin selection cassette 
will be removed in floxed mice. To enable this, the neomycin cassette is flanked by 
FRT sites that will recombine in the presence of Flp recombinase (figure 5.3), thus 
deleting the neomycin selection cassette while retaining the inserted proximal loxP 
site. 
 
5.3 Targeting Vector Construction 
The cloning strategy employed to generate the homology arms and for targeting 
vector construction involves the isolation of a 1.75kb short homology arm 
downstream, and a 5.9kb long homology arm upstream of the proximal loxP site and 
neomycin cassette. It is within the long homology arm that the BstBI site proposed for 
distal loxP site insertion is present (figure 5.3). 
 
5.3.1 Generation of the Short Homology Arm 
Isolation of the short homology arm was performed in triplicate by PCR to 
generate a 3.5kb amplicon containing the region spanning the EcoRI and BstZ17I 
restriction sites from 129S genomic DNA, which was then TOPO cloned into the 
pCR4 vector. Clones containing the separate fragments were then sequenced to 
determine polymorphisms between the 129S and C57Bl sequences by alignment of 
the individual fragments and the C57Bl sequence, which showed the short homology 
arm region is 99.32% homologous between the two mice strains. PCR induced 
mutations could also be identified in this manner by searching for differences between 
sequences of the three separate clones. Clone 5 possessed a number of mutations and 
was discarded from further cloning steps. Clone 19 possessed five PCR induced 
mutations in total (figure 5.4). Three transversion mutations were present, two C-T 
mutations 1533bp and 1952bp downstream of the 5’ terminus of the PCR fragment, 
and a T-C mutation at 3350bp. A transition mutation in the form of A-T was present 
at 3032bp, and an insertion of cytosine base was observed at 2232bp. Clone 20 
possessed two transversion mutations, T-C at 678bp and A-G at 787bp. There were
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Figure 5.4 Correction of Mutations Generated by PCR During the Cloning of 
the Short Homology Arm 
Schematic representing the PCR fragment generated to isolate the short homology 
arm. Three independent fragments were produced and cloned, of which clones 19 
and 20 were used in subsequent cloning steps. Blue asterisks shows PCR induced 
mutations in clone 19, and red asterisks denote mutations within clone 20. The 
AatII-NsiI fragment from clone 19 was subcloned into clone 20 to produce a clone 
free from mutation within the short homology arm region. 
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also instances of a deletion and an insertion of a thymine base at 2629bp and 3258bp 
respectively (figure 5.4). Due to the positioning of an NsiI restriction site within the 
short homology arm region, subcloning of a fragment digested with AatII and NsiI 
from clone 19 and ligation into clone 20 digested with the same enzymes, resulted in a 
modified clone named RWH1-SAmod free from PCR induced mutations within the 
1.75kb short homology arm region (figure 5.4). The modified clone was therefore 
used for the further cloning steps outlined in section 5.3.3. The 2.9kb control short 
homology arm region present within RWH1-SAmod was used by Genoway to 
optimise PCR conditions to screen for homologous recombination within the short 
homology arm region as outlined in appendix B.  
 
5.3.2 Generation of the Long Homology Arm 
The long homology arm was isolated by digestion of a BAC clone from a 129S 
genetic background containing the NR3 genomic DNA. The BAC clone was purified 
and digested with XhoI and NsiI, which should produce 46 fragments ranging in size 
between 22bp and 12299bp. The fragments were ligated into empty pCR2.1 vector 
digested with XhoI and NsiI. A total of 46 colonies were screened by PCR for the 
presence of the required 6.7kb insert. Clones 16 and 33 produced the expected 
amplicon of 0.5kb as indicated by the positive controls of the purified BAC clone 
DNA and also a colony PCR performed using a small amount of BAC clone glycerol 
stock (figure 5.5A). As such, clones 16 and 33 were further analysed by restriction 
analysis for presence of the 6.7kb XhoI-NsiI fragment. Upon digestion of clones 16 
and 33 with XhoI and NsiI, several bands were observed for each clone (figure 5.5B), 
including a band at the expected size of 6.7kb. The 6.7kb fragment generated from the 
digestion of clone 33 was isolated and subcloned into empty pCR2.1 digested with 
XhoI and NsiI to generate vector RWH1-LAbac. This was then sequenced to 
determine polymorphisms between 129S and C57Bl mice, which showed the two 
strains were 98.62% homologous. RWH1-LAbac was then used for the subsequent 
subcloning steps outlined in section 5.3.3. 
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Figure 5.5 Cloning the Long Homology Arm for Targeting Vector Construction 
A) Agarose gel showing clones possessing an insert corresponding to the long 
homology arm region. PCRs were performed using colonies from transformed cells as 
a template and identified two positive clones (clones 16 and 33). As positive controls 
PCRs were performed using the purified BAC construct (BAC) and also a glycerol 
stock of the BAC construct (Glyc) as template. 
 
B) Agarose gel showing restriction patterns of clones 16 and 33 following digestion 
with XhoI and NsiI. Neither clone produced a single band upon digestion. However, 
both clones possess a band at 6.7kb, which corresponds to the size of required the long 
homology arm fragment. 
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5.3.3 Generation of the Final Targeting Vector 
RWH1-SAmod and RWH1-LAbac were used in a series of subcloning steps to 
generate the final vector designed to target the NR3 locus. Genoway provided three of 
the vectors they use routinely for this procedure. G139 possesses the neomycin 
selection cassette, pGA1 was used the backbone for the targeting vector, and G112 
possessed the diphtheria toxin A negative selection gene. Details of vector maps can 
be found in appendix B. 
 
Subcloning the Short Homology Arm into Neomycin Cassette Vector G139 
To subclone the short homology arm into the G139 vector, which possesses the 
neomycin selection cassette and proximal loxP site, the control short homology arm 
region spanning 2.9kb was inserted (figure 5.6A). The resultant vector can then be 
used for optimisation of the PCR screen to determine presence of homologous 
recombination in embryonic stem (ES) cells, and also used for subsequent cloning 
steps. RWH1-SAmod was digested with the restriction endonucleases EcoRI and 
BstZ17I and ligated into vector G139 digested with EcoRI and EcoICRI, and 
transformed into DH5α. Both BstZ17I and EcoICRI leave the digested DNA blunt 
and are therefore compatible for cloning applications. Miniprep DNA was isolated 
from a total of 8 bacterial colonies and diagnostic restriction digest analysis with SpeI 
of the resultant vector named RWH1-SA-C+ performed. SpeI cuts within the 
neomycin cassette and the short homology arm region and gave the expected 
fragments of 6.3kb and 1.3kb in clone 2 (figure 5.6B). RWH1-SA-C+ from clone 2 
was sequenced and an aliquot sent to Genoway for optimisation of the screening 
strategy. RWH1-SA-C+ was also used for downstream subcloning applications. 
 
Insertion of the Distal loxP Site into the Long Homology Arm 
In the strategy agreed with Genoway, the distal loxP site is inserted into the 
BstBI restriction site in the long homology arm (figure 5.3). The loxP site was 
inserted by linearising vector RWH1-LAbac with BstBI and dephosphorylating the 
resultant fragment. A pair of complementary oligonucleotides possessing
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RWH1-SA-C+ cut w/SpeI 
exp. 6.2kb, 1.3kb 
Figure 5.6 Subcloning the Short Homology Arm into Vector G139 
A) Schematic detailing the strategy for subcloning the short homology arm region 
into vector G139 downstream of the neomycin selection cassette (Neo) and proximal 
loxP site. Restriction enzyme sites depicted in red show the sites used for subcloning. 
Underlined restriction enzyme sites denote enzymes used for diagnostic digest. 
 
B) Agarose gel of the diagnostic digests of RWH1-SA-C+ with SpeI following 
ligation of the short homology arm region into vector G139. The lanes of positive 
samples possessing the correct diagnostic restriction pattern are identified above the 
gel. Expected fragment sizes are 6.2kb and 1.3kb. 
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EcoNI-loxP-BamHI-NsiI sites and with compatible ends to BstBI were 
phosphorylated, annealed and ligated into the linearised RWH1-LAbac vector to give 
RWH1-LA-loxP, as outlined in figure 5.7A. Miniprep DNA was purified from 24 
colonies and diagnostic digestion with BamHI carried out, which cuts in the inserted 
oligonucleotides and within the pCR2.1 vector backbone. Diagnostic digests 
generated the expected fragments of 7.1kb and 3.6kb in all but 4 of the selected 
colonies (figure 5.7B). Positive miniprep DNA samples were then sequenced to 
determine which possessed the loxP site inserted in the correct orientation. This 
confirmed clones 2, 3, 4, 5, 17, 20 and 21 were correct, and clone 2 was selected for 
downstream cloning steps involving RWH1-LA-loxP. 
 
Subcloning the Neomycin Cassette and Homology Arms into pGA1 
The backbone for the targeting vector is the Genoway plasmid pGA1. RWH1-
SA-C+ was used to subclone the neomycin resistance cassette, proximal loxP site and 
the short homology arm into pGA1, and RWH1-LA-loxP was used to subclone in the 
long homology arm with the distal loxP site inserted. An overview of these 
subcloning steps is given in figure 5.8. The selected cloning strategy involved the 
synthesis of complementary oligonucleotides spanning 890bp in length that possessed 
92bp from the 3’ end of the long homology arm connected via a 21bp linker to 733bp 
of the 3’ terminus of the short homology arm (figure 5.8). The sequence of the 
complementary oligonucleotides is detailed in appendix B. The oligonucleotides were 
synthesised, cloned into the pGA1 vector, and sequence verified by Top Gene 
Technologies, Quebec to generate RWH1-GA1-linker. The neomycin cassette, 
proximal loxP site and 5’ region of the short homology arm were then subcloned into 
this vector by digesting RWH1-SA-C+ with HpaI and Bsu36I and ligating into 
RWH1-GA1-linker digested with the same restriction endonucleases to produce 
RWH1-Neo/SA. The ligation reaction was transformed into DH5α and 8 colonies 
were selected for miniprep. Miniprep DNA was then analysed by diagnostic 
restriction digest with AvrII, which cuts within the neomycin cassette and short 
homology arm. All 8 colonies possessed the correct insert as reactions produced 
fragments of 5.3kb and 1.2kb, although digestion was incomplete (figure 5.9A). 
Miniprep DNA from colony 1 was selected and the sequence of RWH1-SA/Neo was 
verified by DNA sequencing. 
 Chapter 5  Results 
161 
 
 
 
 
 
 
11 12 
A) 
B) 
1 2 3 4 5 7 8 
6kb 
3.5kb 
6kb 
3.5kb 
10 
23 13 14 15 16 17 19 20 21 22 
RWH1-LA-loxP cut w/BamHI 
exp. 7.1kb, 3.6kb 
Figure 5.7 Subcloning the Distal loxP Site into the Long Homology Arm 
A) Schematic showing the strategy for subcloning the distal loxP site into the long 
homology arm region. Restriction enzyme sites depicted in red show the sites used 
for subcloning. Underlined restriction enzyme sites denote enzymes used for 
diagnostic digest. 
 
B) Agarose gel of the diagnostic digests of RWH1-LA-loxP with BamHI. The lanes 
of positive samples possessing the correct diagnostic restriction pattern are identified 
above the gel. Expected fragment sizes are 7.1kb and 3.6kb. 
BamHI 
Exon 1 
BstBI XhoI EcoRI 
loxP 
BamHI 
Long Arm (5.9kb) 
Exon 1 loxP 
BstBI 
XhoI EcoRI 
BamHI BamHI 
3.6kb 
Long Arm (5.9kb) 
BstBI BstBI 
RHW1-LAbac 
RHW1-LA-loxP 
 Chapter 5         Results 
162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Subcloning the Short and Long Homology Arms into pGA1 
Schematic detailing the strategy for subcloning the short homology arm, neomycin selection cassette (Neo) and proximal loxP site into the 
vector pGA1, followed by the long homology bearing the distal loxP site. Restriction enzyme sites depicted in red show the sites used for 
subcloning. Underlined restriction enzyme sites denote enzymes used for diagnostic digest. 
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Figure 5.9 Restriction Analysis of the Subcloned Short and Long Homology 
Arms in pGA1 
Agarose gels of the diagnostic digests of A) RWH1-Neo/SA and B) RWH1-
LSA/Neo. The lanes of positive samples possessing the correct diagnostic restriction 
pattern are identified above the gel. Expected fragment sizes are given below the 
gels. 
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A fragment possessing the 5’ terminus of the long homology arm with the distal 
loxP site inserted within the proposed BstBI restriction site was generated by 
digesting RWH1-LA-loxP with XhoI and AatII (figure 5.8). This was then ligated into 
RWH1-SA/Neo digested with the same enzymes to produce RWH1-LSA/Neo, and 
transformed into DH5α bacteria. Colonies were selected for miniprep and analysed by 
diagnostic digest with BamHI (figure 5.9B). Samples 2, 4, 7, 14 and 16 possessed the 
correct size fragments of 9.6kb and 2.7kb following digestion. The samples were 
sequenced and sample 4 was used for further subcloning applications. 
 
Subcloning the Diphtheria Toxin Selection Cassette the Targeting Vector 
To generate the final targeting vector, the negative selection cassette containing the 
diphtheria toxin A gene must be inserted upstream of the long homology arm. DNA 
coding for the diphtheria toxin A negative selection cassette was provided by 
Genoway in the G112 plasmid. This was digested with AscI and NotI which cut either 
side of the cassette (figure 5.10A), and also with Tth111I, which cuts the DNA within 
the vector backbone to aid the isolation of the selection cassette. The AscI and NotI 
digested selection cassette fragment was ligated into RWH1-LSA/Neo digested with 
the same restriction endonucleases to generate the final targeting vector named 
RWH1-HR. The ligation reaction was transformed into DH5α cells, and 12 colonies 
selected for miniprep isolation of plasmid DNA. Diagnostic restriction analysis of the 
purified miniprep samples with ApaI shows that samples 1-9 and sample 12 possessed 
the correct restriction pattern of fragments at 9.8kb and 5.9kb (figure 5.10B). The 
presence of the correct insert in samples 10 and 11 could not be confirmed due to a 
low yield following miniprep purification of plasmid DNA. Samples 6, 7 and 8 were 
DNA sequenced to ensure they were correct. An aliquot of the final targeting vector 
RWH1-HR from sample 8 was then passed to Genoway for the downstream processes 
involved in the generation mice floxed at the NR3 gene locus. A summary of this 
work is provided in appendix B. 
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Figure 5.10 Construction of the Final Targeting Vector 
A) Schematic showing the strategy for subcloning the diphtheria toxin A (DTA) 
selection cassette into RWH1-LSA/Neo to yield the final targeting vector RWH1-
HR. Restriction enzyme sites depicted in red show the sites used for subcloning. 
Underlined restriction enzyme sites denote enzymes used for diagnostic digest. 
 
B) Agarose gel of the diagnostic digest of the final targeting vector RWH1-HR with 
ApaI. Numbers above lanes represent miniprep samples. Expected fragment sizes are 
9.8kb and 5.9kb. 
10kb 
6kb 
1 2 3 4 5 6 7 8 9 10 11 12 
RWH1-HR cut w/ApaI 
exp. 9.8kb, 5.9kb 
B) 
A) 
DTA 
AscI NotI 
ApaI AscI XhoI 
HpaI 
Long Arm (5.9kb) 
Exon 1 loxP 
BstBI 
AatII NotI 
EcoRI 
BcgI 
Neo 
FRT FRT 
loxP 
EcoRI Bsu36I 
Short Homology Arm 
 
ApaI 
NotI 
XhoI 
HpaI 
Long Arm (5.9kb) 
Exon 1 loxP 
BstBI 
AatII 
EcoRI 
BcgI 
Neo 
FRT FRT 
loxP 
EcoRI Bsu36I 
Short Homology Arm 
 
ApaI 
DTA 
AscI 
ApaI 5.9kb 
G112 
RHW1-HR 
 Chapter 5  Results 
166 
5.4 Summary of the Generation of NR3 Knockout Mice 
This chapter describes the cloning and subcloning procedures undertaken to generate 
a vector designed to target the NR3 locus. Correct homologous recombination 
between the targeting vector and genomic DNA in ES cells results in exon 1 of the 
NR3 gene being flanked with loxP sites, which are placed in positions that are 
predicted to be of minimal disruption to NR3 expression prior to deletion of the exon. 
Gene deletion may be performed in either a global or a tissue specific manner in mice 
homozygous for the floxed gene by crossing them with mice expressing Cre 
recombinase in the appropriate tissues. Such breeding work is currently being 
undertaken by Genoway. 
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6.1 Structure of the Putative LBD Region of NR3 
Inpharmatica have used a threading algorithm to predict a number of proteins 
encoded by the human genome that may possess a structure similar to that of a ligand 
binding domain found in bona fide NRs. NR3 is one such protein that is predicted to 
fold into a ligand binding domain-like structure between amino acids 477 and 722. 
This region was shown to be resistant to limited proteolysis which indicates that it 
may form a structured domain. This is concordant with disorder predictions for NR3. 
However, the protease resitant region corresponding to the putative LBD was mapped 
using a C-terminal tag and mapping studies performed with an N-terminal tag may 
have also provided structural information to support this conclusion. Immobilised 
bacterially expressed GST-fusion proteins may have been useful for such studies by 
examining the size of fragments present on beads following digestion. 
Protease mapping experiments performed on bona fide nuclear receptors have 
shown that the size of the LBD following digestion of full length receptor is ~30kDa 
(Couette et al., 1996; Keidel et al., 1994; Modarress et al., 1997; van den Bemd et al., 
1996). The size of the protease resistant putative LBD region within NR3 is estimated 
to be ~27kDa, supporting the idea that this region of NR3 possesses a folded domain 
of a similar size to that of a NR LBD. The binding of ligand is thought to stabilise the 
structure of the LBD, which may account for the dearth of reported apo-LBD crystal 
structures relative to those in the holo-conformation. In keeping with this notion, 
others have found that the apo-LBD is more susceptible to digestion than the holo-
LBD (Couette et al., 1996; Keidel et al., 1994; Modarress et al., 1997; van den Bemd 
et al., 1996), however such experiments were performed using up to 100-fold higher 
concentrations of protease. At similar concentrations of protease to those used here, it 
is observed that the NR apo-LBDs are resistant to digestion. If the putative NR3 LBD 
does require a stimulus to induce a more structured conformation in a manner similar 
to that of nuclear receptors, the peptide fragments observed here following digestion 
may reflect either a less structured inactive conformation or a more structured 
activated conformation. 
The results from limited proteolysis presented here provide evidence that the 
putative LBD region of NR3 is a structured domain, and as such represents a 
candidate for further structural work. X-ray crystallography is a technique that allows 
the modelling the 3-dimensional structure of a protein or protein domain in vitro, 
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providing a good representation of the conformation a protein is likely to reside in 
under physiological conditions. Therefore crystallographic studies offer the 
opportunity of producing an unequivocal answer to the question of whether NR3 
possesses a NR LBD-like fold within its structure. 
 
6.2 Ligand Binding of NR3 
Within the superfamily of nuclear receptors, two thirds of receptors are 
regulated by a ligand (figure 1.1A). In addition, the oestrogen-related receptors are 
orphan receptors that are known to fold into an active conformation, but may bind 
synthetic molecules within the LBD (Chao et al., 2006; Greschik et al., 2004; Kallen 
et al., 2004). As the preliminary structural work reported here suggests the putative 
LBD of NR3 forms a protease resistant fold and the bioinformatic predictions of 
Inpharmatica suggest that fold is similar to that of a NR LBD, a ligand binding screen 
was performed. 2320 compounds were screened in a reporter gene based assay but no 
ligand was identified. One may speculate as to the reason for this. 
Firstly, the compound library used for ligand screening was provided by 
Inpharmatica and was focussed towards screening against the PPARs, which may bias 
the library towards structures that are more readily accommodated within the PPAR 
ligand binding pocket. The ligand binding pocket of the PPARs is large in comparison 
to the rest of the superfamily, possessing a cavity of around 1400Å3, which has been 
shown to be large enough to accommodate two fatty acids bound simultaneously (Itoh 
et al., 2008). It may be that the compounds present within the library are of 
appropriate structures to bind to a large cavity but may not bind effectively to smaller 
cavities. As it is impossible to estimate the size of a putative ligand binding pocket 
within NR3, it is conceivable that the compound library may not have been 
appropriate to identify a ligand for NR3. However, it has been determined that ligand 
binding within the LBD of nuclear receptors with large binding pockets such as PXR 
may be mediated by a number of different amino acids, which may account for their 
promiscuous binding properties (Watkins et al., 2001). In addition a recent report has 
shown that residues within the large binding pocket of PPARγ make different contacts 
with different fatty acid ligands (Itoh et al., 2008). As such, it is conceivable that a 
library focussed toward the screening of PPAR ligands may contain compounds with 
wide ranging structures. Furthermore, although details of the compound structures 
 Chapter 6  Discussion 
170 
within the library were not made available, Inpharamatica have indicated that the 
library possesses compounds that are structurally similar and dissimilar to known 
PPAR ligands (Adrian Kinkaid, personal communication). This suggests that a variety 
of different chemical structures were available within the library for screening, and 
not just those that may bind preferentially to the PPAR receptor. In addition, as the 
library is designed to be used for screening against members of the nuclear receptor 
superfamily the compounds within the library are likely to be a selection of small 
hydrophobic molecules, which is a description that fits most synthetic ligands for NRs. 
This suggests the library available was more appropriate for ligand screening against a 
putative NR-like LBD than a more general library that possesses a much larger range 
of chemical structures. 
The limitations of the reporter gene assay used for the NR3 ligand screen are 
another consideration when interpreting the results. The screen was based on the idea 
that the VP16-GAL4-NR3 fusion protein used was enriched in the cytoplasm, and 
thus may not drive transcription of the reporter gene in the nucleus. It is possible that 
the putative NR3 LBD binds to transcriptional repressors to inhibit the activity of the 
fusion protein, however from the interactions studies performed here there is no 
evidence to suggest this. The ligand screen was performed based on the hypothesis 
that a ligand binding to the putative LBD of NR3 may induce a conformational 
change such that the fusion protein is translocated to the nucleus and the reporter gene 
transcribed. As the system employed a VP16 activation domain, which is known to be 
active in such assays (Sadowski et al., 1988), it does not rely on the supposition that 
the putative LBD of NR3 is able to recruit coactivators to stimulate transcription of 
the reporter gene. It is conceivable that one of the ligands screened may have bound to 
the putative NR3 LBD and, regardless of any conformational change that may have 
occurred, did not induce translocation of the fusion protein to the nucleus. Under such 
circumstances the ligand would not have been identified as a positive hit. However, in 
the absence of another screening assay such an idea cannot be confirmed. 
It must also be noted that the number of ligands screened against the putative 
NR3 LBD is up to 100-fold smaller than screens performed elsewhere (Willy et al., 
2004). Therefore, it may be suggested that one reason a ligand was not identified may 
be related to the scale of the screen performed. However, there are also examples of 
screens against nuclear receptors using much smaller numbers of compounds than that 
of Willy et al (2004) that have proved fruitful in their synthetic ligand identification 
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(Mao et al., 2008; Wu et al., 2005). In addition, there are also a number of orphan 
receptors yet to have either an endogenous or synthetic ligand to which they bind 
identified (figure 1.1A). It is also known that although some receptors are 
promiscuous in their ligand binding (Li et al., 2003), crystallography studies have 
shown that some receptors such as Nurr1, which possesses bulky amino acid residue 
side chains in the cavity that represents the ligand binding pocket, and DHR38, which 
possesses a small ligand binding pocket of 30Å3, are not thought to bind ligand at all 
(Baker et al., 2003; Wang et al., 2003). It is possible that should NR3 possess an NR-
like LBD, that it may be more closely related to that of a receptor that is incapable of 
binding a ligand. It is also postulated that the ancestral LBD of NRs is likely to be an 
orphan receptor and that ligand binding was a gain of function during evolution 
(Escriva et al., 1997). Furthermore, it is suggested that the LBD region of NRs 
emerged initially as a separate module, and that DNA rearrangements may have fused 
it to the DBD of a transcription factor (Barnett et al., 2000; Laudet et al., 1992). NR3 
does not conform to the domain organisation associated with nuclear receptors as 
outlined in chapter 1.3, and also lacks homology to an NR LBD at the amino acid 
level. It is therefore conceivable that NR3 may be more related to the putative 
ancestral LBD, and as such may be similar to an orphan receptor with regards its 
ability to bind a ligand.  
In the instance that the putative LBD of NR3 is similar in structure to the LBD 
of bona fide nuclear receptors yet does not bind ligand it is possible that post 
translational modifications are responsible for inducing an active conformation. The 
study of post translational modifications of NRs has shown that phosphorylation 
status of AF-1 may regulate transcriptional activity for some receptors, which in turn 
may be influenced by ligand binding (Chen et al., 2000; Wang et al., 2002b). It has 
been reported that phosphorylation may also regulate the subcellular localisation (Qiu 
et al., 2003). Studies on the LBDs of receptors have shown that this region may also 
be post translationally modified. Y537 within the human ERα LBD, and its murine 
equivalent Y541, is positioned very close to AF-2 and known to influence the activity 
of the receptor (Weis et al., 1996; White et al., 1997). Mutation to a small non-
aromatic residue resulted in constitutive activation of the receptor (Weis et al., 1996; 
White et al., 1997; Yudt et al., 1999). Recent work has also suggested the 
phosphorylation of the residue may be important for the interaction ERα and c-Src, 
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suggesting such modification may have a role in the non-genomic actions of the 
receptor (Barletta et al., 2004). Similarly phosphorylation and sumoylation have also 
been studied in the androgen receptor, glucocorticoid receptor and mineralocorticoid 
receptor LBDs, however the functional significance of these modification is also 
unclear (Lin et al., 2001; Tallec et al., 2003; Tian et al., 2002; Wen et al., 2000). 
Studies of LBD phosphorylation in RXR and RAR have shown that such 
modifications can regulate their activity (Rochette-Egly et al., 1995; Solomon et al., 
1999), and that phosphorylation of ser-260 in RXR inhibits recruitment of 
coactivators to the receptor, which may be due to a disruption of the AF-2 positioning 
following ligand binding (Macoritto et al., 2008). This contrasts the mechanism of 
regulation conferred by phosphorylation of ser-369 within the RAR LBD, which 
increases phosphorylation of ser-77 in the AF-1 region resulting in increased 
transcriptional activity (Gaillard et al., 2006). Should NR3 possess a fold that is 
structurally similar to that of the LBD region of a nuclear receptor, it is possible that it 
may be regulated by post translational modifications that may modulate the activity of 
the protein. 
 
6.3 Proteins that Interact with NR3 
6.3.1 Screening for Interactions Using a Two-Hybrid Assay 
In this study proteins with which NR3 interacts were screened for by using a 
yeast two-hybrid assay that is based on the SRS system, originally described by 
Aronheim et al (1997). The results of the screen indicated that putative NR3 LBD 
interacts with 14-3-3η, which is one of the 7 members of the 14-3-3 family of proteins. 
This family is involved in the regulation of numerous cellular processes, such as 
transcription, cell cycle progression, signal transduction, metabolism, stress responses, 
and apoptosis (reviewed in Tzivion et al., 2006). The family is known to interact with 
over 200 proteins, modulating their function by altering activity, localisation, 
recruitment to complexes, post translational modifications, and protein stability 
(Tzivion et al., 2006). However, the interaction observed between 14-3-3η and NR3 
in the yeast two-hybrid system could not be confirmed using other assay systems, 
suggesting the result is specific to the two-hybrid system and is therefore of 
questionable physiological significance. 
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Aronheim et al (1997) proposed the SRS system as an alternative to yeast two-
hybrid methods that are based on a transcriptional readout. It is suggested that the 
SRS system does not possess the limitations associated with transcription-based 
methods, including those that may arise from the screening of transcriptional 
regulators that may constitutively activate or repress the system and the screening of 
proteins that do not translocate to nucleus (Allen et al., 1995; Aronheim et al., 1997). 
Based on the results presented here regarding the localisation of a VP16-GAL4-NR3 
LBD fusion protein the SRS system is a more appropriate yeast two-hybrid assay to 
use over one based on a transcriptional readout, as there is the likelihood that the NR3 
bait protein may not translocate to the yeast nucleus and fail to allow the transcription 
of the reporter gene. 
Although the SRS system was developed as an alternative to conventional yeast 
two-hybrid assays (Aronheim et al., 1997), it is not without limitations itself. The 
assay utilises a yeast strain that carries a mutation within the cdc25 gene, which 
inhibits growth at the selective temperature of 37°C. The prey protein is tethered to 
the membrane via a myristylation signal and recruitment of the bait protein fused to 
SOS allows activation of the Ras signalling pathway, enabling growth at 37°C. 
However, as indicated by the results presented here, the presence of SOS within the 
cDNA library may bypass the necessity for an interaction between bait and prey 
proteins. Furthermore, the phenotype of the yeast strain used is susceptible to 
spontaneous reversion allowing growth at 37°C. Although there are such problems 
associated with the method, there are numerous reports outlining the use of the system 
to identify interacting proteins (Aronheim et al., 1997; Chang, 2002; Gil et al., 2002; 
Hendron et al., 2002; Su et al., 2002; Wang et al., 2002a).  
 
6.3.2 Screening for Interactions Using Immunoprecipitation 
Proteins that interact with NR3 were also screened for using 
immunoprecipitation. This showed that NR3 interacts with DDB1, which was 
confirmed by both GST pulldown and further immunoprecipitation experiments. The 
mapping studies presented here show that the N-terminus of NR3 interacts with the 
substrate docking region of DDB1 (Angers et al., 2006; Li et al., 2006b). The N-
terminus of NR3 is predicted to possess a structure similar to that of the armadillo 
repeat motif, which is involved in mediating protein-protein interactions and therefore 
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such a structure may be responsible for mediating the interaction with DDB1 (Herold 
et al., 1998; Kaufmann et al., 2000; Song et al., 2003). During the course of these 
studies, NR3 has been reported to interact with both DDB1 and its binding partner 
CUL4, although this did not represent the focus of the report (Angers et al., 2006). 
However, such work serves to confirm the interaction between NR3 and DDB1. 
DDB1 is a substrate recognition subunit of an E3 ubiquitin ligase complex also 
involving CUL4 and ROC1 (Angers et al., 2006). It is known that DDB1 can recruit 
ubiquitination substrates to the complex both directly and indirectly via adaptor 
proteins (Angers et al., 2006; He et al., 2006; Sansam et al., 2006; Sugasawa et al., 
2005). It may therefore be hypothesised that NR3 binds to DDB1 either as a substrate, 
an adaptor, or a regulatory molecule. To address this, the ubiquitination status of NR3 
was examined. NR3 was shown to be polyubiquitinated in the presence of the 
proteasome blocker MG132, indicating that the modification leads to degradation at 
the proteasome. These data were supported by pulse chase experiments showing that 
NR3 could be stabilised by blockade of the proteasome. Therefore NR3 may be a 
substrate for ubiquitination by an E3 ubiquitin ligase that contains DDB1. 
The use of tandem affinity purification performed separately on DDB1 and 
CUL4 has shown that a group of 16 proteins termed the DDB1-CUL4 associated 
factors (DCAFs) that interact with both DDB1 and CUL4 possess WD40 repeat 
motifs (Angers et al., 2006). These motifs are thought to mediate the interaction with 
DDB1 (He et al., 2006), and of the DCAFs identified some are known to be adaptors 
and substrates for DDB1 ligase complexes (Angers et al., 2006). Sequence analysis of 
NR3 shows that it is not predicted to possess a WD40 repeat motif, and therefore is 
unlikely to bind to DDB1 in the same manner as the DCAFs. However, the adaptor 
molecule de-etiolated 1 (DET1) was also identified as an interacting protein with both 
DDB1 and CUL4, yet does not possess a WD40 repeat motif (Angers et al., 2006). 
Therefore the role of NR3 as an adaptor molecule for DDB1 complexes may not be 
ruled out on the basis that it does not possess a WD40 repeat motif. It should also be 
noted that adaptor molecules recruited to DDB1 may also be substrates, as 
exemplified by DDB2 (Sugasawa et al., 2005). This protein mediates the recruitment 
of DDB1 substrate XPC to an E3 ubiquitin ligase complex consisting of DDB2-
DDB1-CUL4 in response to UV induced damage of DNA. Following 
polyubiquitination of XPC, DDB2 is polyubiquitinated itself to mark it for 
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degradation at the proteasome (Sugasawa et al., 2005). Thus it is plausible that NR3 
may be an adaptor and a substrate molecule for DDB1. 
Previous studies have reported that the activity of E3 ubiquitin ligase complexes 
that possess CUL4 may be modulated by binding regulatory proteins and complexes. 
The protein CAND1 binds to cullin family of proteins and prevents interaction with 
substrate recruitment subunits such as DDB1 (Goldenberg et al., 2004). This 
interaction is prevented by neddylation of the cullin protein, which is thought to 
sterically hinder the binding of CAND1 (Goldenberg et al., 2004). The COP9 
signalosome is responsible for deneddylation of cullins, and thus allow CAND1 
access to its binding site (Cope and Deshaies, 2003; Goldenberg et al., 2004). Studies 
examining the association of DDB1 and CAND1 with CUL4 suggest this mechanism 
of regulation appears to apply to the CUL4-DDB1 interaction (Hu et al., 2004). In 
addition, more recent studies have found that a complex containing DDB1 may also 
regulate the activity of CUL4 ligases. The DDD complex comprises of DDB1, a 
protein called DET1 and DDB1 associated (DDA1), and substrate adaptor molecule 
DET1. It regulates the activity of CUL4 E3 ligase complexes by allowing the 
recruitment of E2 ubiquitin ligases, but preventing the maintenance of the ubiquitin 
thioester bond that is necessary for the transfer of the ubiquitin molecule to the 
substrate (Pick et al., 2007). DDA1, the primary role of which seems to be regulatory, 
has been shown to bind to the BPA domain of DDB1 (Pick et al., 2007). As this 
region forms part of the substrate docking cleft of DDB1 (Angers et al., 2006), it is 
possible that NR3 may play a role similar to DDA1, and thus regulate the activity of 
the complex. 
 
6.4 Assessing the Function of NR3 
6.4.1 Potential Role of NR3 in Cell Cycle Regulation 
The interaction between NR3 and DDB1 implicates NR3 in the processes with 
which DDB1 is involved. E3 ubiquitin ligase complexes containing DDB1 control the 
levels of proteins known to be involved cell cycle progression and NER (Bondar et al., 
2006; Li et al., 2006a). It is also speculated by others that NR3 may be involved in the 
regulation of the cell cycle (Nicassio et al., 2005). To provide evidence for such a role, 
the effect of NR3 expression on cell proliferation was examined. The results 
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presented here indicate that a stable human cell line overexpressing mouse NR3 
possesses a proliferative advantage over control cells, although it is unclear as to 
whether the observed effect is specific to NR3 overexpression. It is possible that 
stable integration of the cDNAs coding for NR3 and the selective marker into the 
genome of the transfected cells may have disrupted regulatory mechanisms inducing 
an increased proliferative rate. However, this is unlikely as the cell line is a polyclonal 
line that is derived from a mixed population of transfected cells. Therefore genomic 
integration of the cDNAs will have occurred at different loci in the different cells that 
survived the selection process, indicating the response may be specific to NR3 
overexpression. To confirm this, further experiments are required, such as the use of 
an inducible overexpression system to determine whether the same effect is observed 
in the same cell line in the absence and presence of NR3 overexpresion. 
In addition to NR3 overexpression, the effect of NR3 depletion using siRNA 
was examined in NIH/3T3 cells. No effect was observed, indicating that NR3 is not 
required for proliferation in that cell type. However, knockdown was typically 
observed to be ~95% at the mRNA level. In the absence of an antibody that detects 
endogenous levels of NR3 in a western blot, it is impossible to determine the effect of 
such knockdown on protein levels and it cannot be assumed that it will be of a similar 
magnitude. Furthermore, it is plausible that ~95% depletion of NR3 is not sufficient 
to abrogate the function of NR3 to a detectable level. However, it must also be noted 
that NR3 was observed to be upregulated following viral transformation of cells and 
in some tumours (Nicassio et al., 2005), and NIH/3T3 cells do not represent such a 
cell type (Todaro and Green, 1963). Therefore it is possible that NR3 expression may 
be more important in the regulation of the cell cycle following viral infection or 
tumourogenesis. 
The regulation of cell cycle control proteins mediated by DDB1 appears to 
involve their polyubiquitination to mark them for degradation. Negative cell cycle 
regulator p27Kip1 has been described as a target for ubiquitination and degradation 
following association with a DDB1-CUL4 complex that utilises S-phase kinase 
associated protein 2 (Skp2) as an adaptor molecule (Bondar et al., 2006). This 
degradation is thought to occur in S-phase and allow the progression of the cell cycle. 
CDT1 is a DNA replication licensing factor, the activity of which must be controlled 
to prevent re-replication of DNA during S-phase. Such regulation may occur by 
inhibition of CDT1 by geminin (Tada et al., 2001; Wohlschlegel et al., 2000), or by 
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polyubiquitination and degradation of CDT1 (Arias and Walter, 2006; Nishitani et al., 
2006; Sansam et al., 2006). The proteolytic regulation of CDT1 is mediated by two 
distinct pathways, one involving DDB1-CUL4 complexes and one involving an 
analogous complex possessing another cullin family member comprised of CUL1 and 
Skp2 (Nishitani et al., 2006). DDB1-CUL4 induced polyubiquitination has been 
reported to require proliferating cell nuclear antigen (PCNA), which may act as a 
clamp to target the DDB1 complex to chromatin (Arias and Walter, 2006), and is 
thought to be mediated by adaptor protein CDT2 (Sansam et al., 2006). Furthermore, 
the study of a DDB1 complex containing CUL4, CDT2, PCNA and mouse double 
minute 2 (MDM2) has shown that it regulates the levels of tumour suppressor gene 
p53 in unstressed cells, and lack of such regulation leads to cell cycle arrest in G1-
phase (Banks et al., 2006). 
In addition to their role in cell cycle regulation in unstressed cells, DDB1-CUL4 
comlplexes also regulate the cell cycle in response to DNA damage. Following 
treatment with UV light to induce DNA damage, MDM2 is degraded by a DDB1-
CUL4-PCNA complex, which leads to stabilisation of p53 (Banks et al., 2006). 
Cellular stresses such as DNA damage lead to activation of p53, resulting in cell cycle 
arrest and activation of DNA repair pathways (reviewed in Jin and Levine, 2001). 
Similarly, DDB1 target CDT1 is also degraded in response to UV light-induced DNA 
damage, preventing the licensing of replication origins and protecting the cell from 
replicating damaged DNA (Higa et al., 2006; Hu et al., 2004; Sansam et al., 2006).  
In the results presented here, NR3 has been shown to be polyubiquitinated 
which marks it for degradation at the proteasome. Given the interaction observed with 
the substrate docking region of DDB1, it is possible that such ubiquitination is 
mediated by DDB1, and therefore one may speculate that NR3 may indeed be 
involved in the regulation of the cell cycle similar to other DDB1 substrates. 
 
6.4.2 Potential Role of NR3 in Nucleotide Excision Repair 
The DDB1-CUL4-ROC1 complex is also thought to be directly involved in the 
NER process to remove DNA lesions following UV light exposure (El-Mahdy et al., 
2006; Li et al., 2006a; Moser et al., 2005; Sugasawa et al., 2005). Following DNA 
damage the DDB1 complex bound to adaptor molecule DDB2 recognises and binds to 
the UV-induced lesions. NER protein XPC is recruited to lesions and binds to DDB2, 
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resulting in the polyubiquitination of XPC. Such modification allows XPC to more 
tightly associate with damaged DNA and enhance repair (Sugasawa et al., 2005). 
DDB2 is then polyubiquitinated by DDB1-CUL4-ROC1, marking it for degradation 
(El-Mahdy et al., 2006; Sugasawa et al., 2005). Furthermore, the DDB2-DDB1-
CUL4-ROC1 complex has been shown to remodel chromatin by the 
polyubiquitination of histones H2A, H3 and H4 following DNA damage with UV 
light, a response which is thought to enable the recruitment of repair complexes to 
sites of damage (Kapetanaki et al., 2006; Wang et al., 2006). It is conceivable that 
NR3 may play a role in the direct regulation of NER performed by DDB1. DDB2 is 
thought to bind directly to DDB1, as they co-purify from damaged DNA as a 
heterodimer (Keeney et al., 1994). As DDB2 is both a substrate and adaptor for 
DDB1-CUL4-ROC1 mediated ubiquitination, it would be predicted that the binding 
site within DDB1 for DDB2 would overlap that shown here to be important for 
interaction with NR3. Therefore it would also be predicted that any role NR3 
possessed in the direct regulation of NER would not involve it complexing with both 
DDB1 and DDB2 simultaneously. 
 
6.4.3 DDB1 Studies in the Whole Organism and Potential Other Roles for DDB1 
Complexes 
Studies involving the effects of loss of DDB1 in flies by gene disruption and 
depletion with siRNA have shown that DDB1 is involved in the development of the 
organism, and is required for cell proliferation genomic stability (Shimanouchi et al., 
2006; Takata et al., 2004). Global knockout of the DDB1 gene in mice unsurprisingly 
resulted in embryonic lethality at day E12.5 (Cang et al., 2006). Studies were 
therefore performed on conditional knockout mice which showed similar results to 
those observed in Drosophila. Deletion of DDB1 in the brain and lens, and in the 
epidermis of mice leads to p53 induced apoptosis of proliferating cells and genomic 
instability (Cang et al., 2006; Cang et al., 2007). These studies serve to underline the 
necessity for DDB1 in the regulation of the cell cycle and DNA repair. 
However, it is noteworthy that most of the DCAF proteins identified by Angers 
et al (2006) remain functionally uncharacterised. It is therefore possible that they may 
not be involved in regulation of the cell cycle and NER, implicating DDB1 in other 
biological processes. This leads to the speculation that NR3 may be involved in a 
 Chapter 6  Discussion 
179 
process unrelated to the regulation of the cell cycle and NER, and as such its 
interaction with DDB1 may represent a novel process in which DDB1 is involved.  
 
6.4.4 DDB1 Forms Part of a Ligand Regulated E3 Ubiquitin Ligase Complex 
The aryl hydrocarbon receptor (AhR) is a protein that is functionally analogous 
to NRs. The AhR is generally regarded as a xenobiotic receptor that heterodimerises 
with the aryl hydrocarbon nuclear translocator (ARNT) and transcribes target genes, 
such as the cytochrome P450 enzymes, in response to environmental toxins (reviewed 
in Barouki et al., 2007). However, a role for the AhR outside detoxification has also 
been implied (Barouki et al., 2007), which has led to the suggestion of eicosanoids 
and their metabolites as endogenous ligands (Chiaro et al., 2008; Schaldach et al., 
1999; Seidel et al., 2001). Recent work has shown that the AhR-ARNT heterodimer 
can form a complex with DDB1-CUL4-ROC1 and transducin-β-like 3 in a ligand 
dependent manner, thus forming a ligand regulated E3 ubiquitin ligase (Ohtake et al., 
2007). The assembled E3 ligase polyubiquitinates ERα to target it for degradation at 
the proteasome, a process that appears to be independent of ERα ligand and ser-118 
phosphorylation induced degradation (Ohtake et al., 2007). The existence of a ligand 
regulated E3 ubiquitin complex involving DDB1 is an intriguing prospect. If NR3 
does possess an LBD that may bind ligand, it is possible that when part of a complex 
with DDB1 it may function analogously to the AhR E3 ligase. However, it is worth 
noting that any such analogous function is likely to be mechanistically different as the 
interaction between the AhR-ARNT heterodimer and the E3 ligase is mediated by 
CUL4, and not DDB1 as in the case for NR3 (Ohtake et al, 2007). 
 
6.4.5 Elucidation of NR3 Function by the Generation of Null Mice 
To understand the biological role of NR3 in vivo mice that do not express NR3 
are being generated. This has involved the construction of a targeting vector that 
allows the employment of a strategy to insert loxP sites flanking exon 1 of the NR3 
gene, in which the translational start codon is located. The construction of the 
targeting vector was performed here by cloning the long and short homology arms, 
and inserting them with the appropriate loxP sites and selection cassettes into the 
vector backbone. This was then passed to Genoway to generate heterozygous floxed 
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mice as outlined in appendix B. Currently heterozygous floxed mice have been 
generated by Genoway, in which no severe defect or phenotype has been observed, 
indicating that the insertion of loxP sites at the chosen loci has not disrupted gene 
expression. These mice possess a neomycin selection cassette that has been excised in 
some but not all cells by the backcrossing of floxed mice with Flp expressing mice. 
Currently a breeding program to completely excise the neomycin selection is being 
undertaken. Following the generation of heterozygous floxed mice in which the 
neomycin selection cassette has been excised in all cells, homozygous floxed mice 
will be bred. Such animals will be crossed with mice globally expressing Cre 
recombinase to delete NR3 in the whole animal, and initial phenotypic analysis will 
be performed on homozygous NR3 knockout mice. 
One may only speculate as to what the phenotype of NR3 null mice may be. The 
data of others suggest NR3 possesses a role in TNF signalling (Soond et al., 2003; 
Soond et al., 2006), and therefore null mice may possess defects in such signalling 
pathways. Given the link with NR3 and the regulation of the cell cycle based on the 
data of Nicassio et al (2005) and the interaction with cell cycle regulator DDB1 
presented here, it is possible null animals may possess a defect in cell proliferation. 
This may provide a similar phenotype to that of DDB1, which were shown to possess 
developmental defects lethal to embryos (Cang et al., 2006). If NR3 were to be 
involved in DNA repair, it may be predicted that null mice may possess genomic 
instability as observed in DDB1 knockout mice (Cang et al., 2006; Cang et al., 2007), 
or be prone to tumours similar to mice lacking DDB2 (Itoh et al., 2004; Yoon et al., 
2005). It is also possible that mice lacking NR3 may not show an overt phenotype. 
This seems unlikely as one may predict the role of NR3 to be important. The 
conservation of the protein extends to the genome of the simple chordate Oikopleura 
dioica, which possesses one of the smallest genomes in chordates (Seo et al., 2001). 
NR3 also does not appear to be a member a family of homologous proteins as 
indicated by BLAST searches, and as such one might predict that NR3 deletion would 
not produce a phenotype that is masked by a redundancy effect from proteins 
possessing overlapping function. 
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6.5 Overall Conclusion 
NR3 is predicted by bioinformatic methods to possess a NR-like LBD structure. 
Although it is unlikely NR3 acts as a transcription factor due to the lack of a 
characterised DBD, it is possible that the LBD may modulate the activity of NR3. The 
aim of this project was to characterise the biological function of NR3 and to examine 
the role of the putative LBD region within that function. Others have suggested NR3 
may possess a role in TNF signalling and the regulation of the cell cycle (Nicassio et 
al., 2005; Soond et al., 2003; Soond et al., 2006). The work presented here has shown 
that NR3 associates with DDB1, a member of an E3 ubiquitin ligase complex 
involved in regulation of the cell cycle and NER, indicating NR3 may be involved in 
those processes. The generation of NR3 null animals may provide evidence to support 
this implication. 
Preliminary structural work performed on the putative LBD suggests the region 
is ordered and structured, lending support to the idea it may be structurally similar to 
the LBD of a bona fide nuclear receptor. It is hypothesised that the putative LBD 
region regulates the activity of NR3 in a functionally analogous manner to which the 
LBD of bona fide nuclear receptors regulates their activity. In the absence of a 
confirmed biological function for NR3 it is not possible to test this hypothesis. 
However, given the characterisation of a DDB1 E3 ubiquitin ligase complex 
involving the AhR that may be regulated by ligand (Ohtake et al., 2007), it is possible 
NR3 may possess an analogous role to the AhR within the DDB1 complex. 
 
 
 Appendix A 
182 
 
 
 
 
Appendix A 
 
 
List of Primers 
 
 Appendix A 
183 
Primer Name Primer Sequence (5' - 3')
BGH Rev D-TOPO TAGAAGGCACAGTCGAGG
M13 Fwd TOPO-TA GTAAAACGACGGCCAG
M13 Rev TOPO-TA CAGGAAACAGCTATGAC
SP6 Promoter ATTTAGGTGACACTATAG
T7 D-TOPO TAATACGACTCACTATAGGG
Primer Name Primer Sequence (5' - 3')
Cyto LBD F CGAATGGAGCACAGCAAGAAATACCCCGCGGCCGCTTGGTCA
Cyto New FL F TAATCATACGCGTGATGGCGGCAGCGCCCGCAG
Cyto New FL R2 TGACCAAGCGGCCGCTCACTCCTCAGTGAAGTCTCTG
Cyto New LBD R2 TGACCAAGCGGCCGCGGGGTATTTCTTGCTGTGC
pMyr Seq Fwd ACTACTAGCAGCTGTAATAC
pMyr Seq Rev CGTGAATGTAAGCGTGACAT
pSOS Seq Fwd CCAAGACCAGGTACCATG
pSOS Seq Rev GCCAGGGTTTTCCCAGT
Primer Name Primer Sequence (5' - 3')
dBPA Mut 1 Fwd GAAGCCTACTGCAGTTAACGGCTGTGTGACC
dBPA Mut 1 Rev GGTCACACAGCCGTTAACTGCAGTAGGCTTC
dBPA Mut 2 Fwd GCTCCTATGTAGTGGCCATGGAAACCTTTGTTAACTTAGGACCCATTGTGG
dBPA Mut 2 Rev CCACAATGGGTCCTAAGTTAACAAAGGTTTCCATGGCCACTACATAGGAGC
dBPC Mut 1 Fwd CGGAACGGCATTGGAATTCATGAGCATGCCAG
dBPC Mut 1 Rev CTGGCATGCTCATGAATTCCAATGCCGTTCCG
dBPC Mut 2 Fwd CACCATTGGCACCATCGATGGAATTCAGAAGCTCCATATTCGCAC
dBPC Mut 2 Rev GTGCGAATATGGAGCTTCTGAATTCCATCGATGGTGCCAATGGTG
DDB1 Del BPA Fwd CACCATGTCGTACAACTACGTCGTA
DDB1 Del BPA Fwd 2a CACCGGCTGTGTGACCGGACACTTTAC
DDB1 Del BPA Rev AAAGGTTTCCATGGCCACTA
DDB1 Del BPB Fwd CACCATGATCCATGAGCATGCCAGCA
DDB1 Del BPB Rev GATGGTGCCAATGGTGAGAG
DDB1 Del BPC Fwd 1 CACCATGGATATGTGTGTGGTGGACCT
DDB1 Del BPC Fwd 2 GTTGTTCGAATTCACGATGAGATCCAGAAGCTCCA
DDB1 Del BPC Rev 1 GTGAATTCCAATGCCGTTCCGGAT
DDB1 Del BPC Rev 2 GTTGTTCGAATTCATGGATCCGAGTTAGCTCCT
DDB1 Del BPC Rev 2b ATGGATCCGAGTTAGCTCCT
DDB1 Del BPC Rev 2c GTTGTTCGAATTCTATGGATCCGAGTTAGCTCCT
DDB1 Seq 1 ATGTCGTACAACTACGTCG
DDB1 Seq 1 Rev GTTACGACGTAGTTGTACG
DDB1 Seq 10 AACCTCCTGTTGGACATGC
DDB1 Seq 2 TAAGCAGAGTGGCGAAAGC
DDB1 Seq 2 Rev AATGCTTTCGCCACTCTGC
DDB1 Seq 3 AACAGGAGAATGTAGAAGCC
DDB1 Seq 4 ATGGTGTTGTATTTGTCGGG
DDB1 Seq 5 AGAGACAGAACTGATGGGC
DDB1 Seq 6 GACATCTCAGCTCGTATCC
DDB1 Seq 7 TCCTCTCAACTCAGATGGC
DDB1 Seq 8 TCTACAAAACGAGTATGCCC
DDB1 Seq 9 CTTGCCTACAAGCCTATGG
DDB1 Seq UTR 11 GTTTTCTTGGCATGGGAGG
DDB1 Seq UTR 12 GTTCCACTGTCTTGAGAG
Primer Name Primer Sequence (5' - 3')
GST Rev Del F1 TAATCATAGATCTTTTTTGACCGAGAGGGACAAA
GST Rev Del R1 TGACCAAGCGGCCGCGGTCTCAGTGAACTGCACC
GST Rev Del R2 TGACCAAGCGGCCGCAAATTTCCTGTCTTCAGTTACAAA
GST Rev Del R3 TGACCAAGCGGCCGCATCGAAATTGGATACTAAGGAAC
GST-NR3 FL Fwd TAATCATAGATCTATGGCGGCAGCGCCCGCAG
GST-NR3 LBD Fwd TAATCATAGATCTAACAACCAGGAGCTAAATGAGC
GST-NR3 N-term Del Fwd 1 TAATCATAGATCTACTCAAGAAGCTACATACCCA
GST-NR3 N-term Del Fwd 2 TAATCATAGATCTCAGCAGCAGCTTGCTAACTT
GST-NR3 N-term Del Fwd 3 TAATCATAGATCTCTAGGCACTTCGGAGGAG
GST-NR3 N-term Del Fwd 4 TAATCATAGATCTGGACTCAACAATTTGTTCGAC
GST-NR3 N-term Del Rev 1 GTTCCTTAGTATCCAATTTCGATGCGGCCGCTTGGTCA
GST-NR3 N-term Del Rev 2 CCCCACTGTGTTCCCTTCTGCGGCCGCTTGGTCA
GST-NR3 N-term Del Rev 3 GAGAACAAGTACTTGCTGCTCGCGGCCGCTTGGTCA
GST-NR3 N-term Del Rev 4 CTGATGAAGTTCAACGTCGATGCGGCCGCTTGGTCA
pGEX Poly Fwd GATCCGGTACCAGATCTCCAG 
pGEX Poly Rev AATTCTGGAGATCTGGTACCG 
List of Primers
Primers used for DDB1 Constructs
General Sequencing Primers
Primers used for GST Fusion Constructs
Primers used for CytoTrap Constructs
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Primer Name Primer Sequence (5' - 3')
KO F4 SA GGAAAAGACCGTAAGTCACAGG
KO Final DTA Fwd TCCAGAAGTAGTGAGGAGGC
KO Final DTA Rev CTCTTCTGGACTCTACCAGC
KO Final LA-Neo Fwd TACCACTGCCCTCTTAGTGC
KO Final LA-Neo Rev TGCCTGCTCTTTACTGAAGG
KO Final SA-Back Fwd GATCATCACAGGACCTAACC
KO Final SA-Back Rev CACTTTATGCTTCCGGCTCG
KO Final SA-Neo Fwd GATGTGGAATGTGTGCGAGG
KO Final SA-Neo Rev GTAGCGCACACCTTTGATCC
KO R4 SA TGAAGGCATCAATAAGTTACAGAG
KO R5 SA GGGGCTTCACTCAGAGGACT
KOS Gen SA 1r GTTTCAAATCACAGGTGACC
KOS Gen SA 2r TGGTCTACAGAGTAAGTTCC
KOS Gen SA 3r TAACAGATGCAACAGTAGCG
KOS Reg A 1 CTTTCAGGGCCGTTGTTTC
KOS Reg A 2 GCTTATTAAGTGTAATGATTGATGTCC
KOS Reg A 3 GAGGTGTATAGGGCACAACC
KOS Reg A 3r GGTTGTGCCCTATACACCTC
KOS Reg A 4r GCGAGTCACCTACCCTCATC
KOS Reg A 5r CTCCCATCAACACTGTTTGG
KOS Reg B 1 CGCTGAAGGAGGCAATTTAG
KOS Reg B 2r GGCTAAGAAGGTAAGCAATC
KOS Reg B 3r GCGCTCTAATCCAACATCTG
KOS SA Int 1 F AAATGACTAATGGGCAACTCC
KOS SA Int 2 R GACAGGGTTTCTCTGTGTAGC
KOS SA Int 3 F CTGGAACTTACTCTGTAGACC
KOS SA Int 4 R CCTTTAGTCCCAGCACTCG
KOS1 CATATCGTACATCTACATAGGG
KOS10 GGCAGCGATCTCAAATGCC
KOS10a CATGGCATCCTAATTTGGC
KOS10ar GCCAAATTAGGATGCCATG
KOS11 GTATGAGGAGTACAGCTGG
KOS11a GAATGGACTGAGGGCTAGG
KOS11ar CCTAGCCCTCAGTCCATTC
KOS11b CCACTAGGGGCGATGTAGAG
KOS12 CCGGGTAACATCCTGCTG
KOS12a GGTATTGATGGCGCGTCTAAGC
KOS12ar GCTTAGACGCGCCATCAATACC
KOS12b GTGTTAGTGTATTTCAGGTGC
KOS12br GCACCTGAAATACACTAACAC
KOS12c GGTGATCCCAGAACTTACTTTG
KOS12d GGTGATCCCAGAACTTACTTTG
KOS13 GTGTGAGATTTTTCTATACACC
KOS13a GAGAAATACTTGCTCTGTCC
KOS14 GACTACAGGTGCCTTCTACC
KOS14a CAGGGTTTTTCCTTGCTCTGC
KOS15 GCTGCTCATTGTGGTTACC
KOS16 CAGATTTATTAAGTGCACTGC
KOS17 GGTAGTAATGACATCTGTCC
KOS18 GATCATCACAGGACCTAACC
KOS19 GTTCCTCTTCCACCAGACC
KOS2 GGTGAAAGGAAAGAATAGACC
KOS20 GCTGCAGAGTCAGATCTGC
KOS3 CCCACAGGTTTCTGGAAACC
KOS3a GGTATGCTCATGTGATTGC
KOS4 GGAAAGGCATCTTGGTTAGC
KOS4a GGTCAGAGGTTAGCATTCAGG
KOS5 GGTACTGATCTGGGTACTGG
KOS5a GGAGAACTTGAGGCAGACTGG
KOS6 GTACTTCTAACAGCTCTGTGC
KOS6a CCTGTTTCTGATTCTTCTCC
KOS6b CAGATTACTCTGTGTAGCC
KOS7 GGAACTCACTCTGTAGACC
KOS7a GAACTCAGAGATCAGCCTGC
KOS7ar GCAGGCTGATCTCTGAGTTC
KOS7b CTAAACCCTCCCTCTTCTTGC
KOS8 CTGGAGTGTCTGAAGACAGC
KOS8a GCAGATTTCTGAGTTCGAGG
KOS9 GTCTACAGAGTGAGTTCTAGG
KOS9a CCTTTCACCAACATGGGTTC
KOS9ar GAACCCATGTTGGTGAAAGG
RWH1-E2 GCTCTGTCCTTGAAGCCAGAATACC
RWH1-F2 GAAGGGGGATAGCTTTTGAGTCAGG
RWH1-G1 GCTTCTACCCACTGACTCATCTCTCC
RWH1-G2 GAGGTGATAAGCAGAACAGCAGAGG
RWH1-H1 CGGTCCTTCTGTAGGATAACTTCGTATAATGTATGCTATACGAAGTTATGGATCCATGCATGG 
RWH1-H2 CGCCATGCATGGATCCATAACTTCGTATAGCATACATTATACGAAGTTATCCTACAGAAGGAC
Primers used for Knockout Constructs
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Primer Name Primer Sequence (5' - 3')
NR3 (D-Topo)-F CACCATGGCGGCAGCGCCCGCAG
NR3 (D-Topo)-R CTCCTCAGTGAAGTCTCTGTCTATG
NR3 ISf TAATACGACTCACTATAGGGTGTACAAACTGGAAGTGC
NR3 ISr AATTAACCCTCACTATAGGGTGTTGAGCAGCAAGTACT
NR3 LBD C 722 Rev GGGGTATTTCTTGCTGTGCTCC 
NR3 LBD N 477 Fwd CACCATGGCCAACAACCAGGAGCTAAATG 
NR3 Seq 1 CTCAAGAAGCTACATACCC
NR3 Seq 2 GACAAACACACGCTTCTTG
NR3 Seq 3 GCTGCAGGTCATGAAGAAG
NR3 Seq 4 CCTGCTTGCCTACATATCC
NR3 Seq 5 CATGGACATAGACAGAGAC
NR3 Seq 6 CAGGCAGAGAGGCTCCTGAG
NR3 Seq LBD Fwd CCAGAGTTTCAGTGACCACC
NR3 Seq LBD Rev CCTTATCCTTGTGCAGGTAG
Primer Name Primer Sequence (5' - 3')
3' NR3 BglII GAAGAGAGATCTTTAGGGGTATTTCTTGCTGTGCTCC
3' NR3 EcoRI GAAGAGGAATTCTTAGGGGTATTTCTTGCTGTGCTCC
3' pSG5 vector primer GAAGAGACTAGTGTCGACCAGACATGATAAGATAC
NR3 LBD GAL4 5' AGCTTCGAGAATTCAACAACCAGGAGCTAAATGAGC
VP16 GAL4 5' primer GTGCAGGCAATTGCTGAAGCTACTGTCTTCTATCGAAC
Primer Name Primer Sequence (5' - 3')
mTRPC4AP QRTPCR F GGAATGACGACAAACACACGC
mTRPC4AP QRTPCR R GCTGAGAAGAGCAGCTTGGTTG
QRT-PCR Primers
Primers used for NR3 Constructs
Primers used for VP16-GAL4 Constructs
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B.1 Summary of the Plasmids used in the Generation of the NR3 
Targeting Vectors 
Schematic diagrams of the plasmids used for generation of the final targeting 
vector as outlined in chapter 6 are shown in figures B.1-B.10. All schematics were 
generated by Genoway, Lyon. The sequence of the sense oligonucleotide synthesised 
by Top Gene Technologies is shown in figure B.11.  
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G139 
4699 bp
LacZ
ampicilin
LoxP
FRT
FRT
PGKpolyA+
PGK  pro moter
LacZ promoteur
F1(+)origin
ColE1 origin
n eomycin  gene
HpaI (4653)
NcoI (532)
SpeI (1369)
G112 (pDGDTA3)
6676 bp
ccdB
Kanamycin
DTA
ColE1 origin
SV40 polyA
§ globine polyA
§ ch icken  p romoter
Plac
CMV promoter
F1 origin
SpeI (308)
NcoI (669)
NcoI (2019)
NcoI (3454)
NcoI (4931)
Figure B.2 Schematic of the Vector G112 
G112 possesses the diphtheria toxin A negative selection cassette (DTA). 
Figure B.1 Schematic of the Vector G139 
G139 possesses the proximal loxP site and neomycin positive selection cassette 
consisting of the neomycin resistance gene flanked by FRT sites. 
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RWH1-LAbac 
10649 bp
ATG codon
pCR2.1
exon  1
LA
NcoI (1535)
SpeI (3845)
SpeI (7489)
RWH1-SAmod 
7496 bp
KanaR
AmpR
cloning site
ATG
STOP
ATG
STOP
Plac
pUC ori
SA
SAmax
NcoI (1426)
SpeI (3925)
SpeI (5207)
Figure B.4 Schematic of the Vector RWH1-LAbac 
RWH1-LAbac possesses the long homology arm (LA) in a pCR2.1 backbone. 
Figure B.3 Schematic of the Vector RWH1-SAmod 
RWH1-SAmod possesses the corrected short homology arm (SA) and the control 
homology arm (SAmax) regions.  
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RWH1-SA -C+ 
7556 bp
LacZ
ampicilin
LoxP
SAmax
FRT
FRT
PGKpolyA+
PGK  promoter
LacZ promoteur
F1(+)origin
ColE1 origin
neomycin  g ene
SA
HpaI (2895)
NcoI (3473)
SpeI (4310)
SpeI (5614)
RWH1-LA -LoxP 
10712 bp
LoxP
ATG codon
pCR2.1
exon  1
LA
NcoI (1535)
SpeI (3845)
SpeI (7552)
Figure B.6 Schematic of the Vector RWH1-LA-LoxP 
RWH1-LA-LoxP possesses the long homology arm (LA), the proximal loxP site in 
a pCR2.1 backbone. 
Figure B.5 Schematic of the Vector RWH1-SA-C+ 
RWH1-SA-C+ possesses the short homology arm (SA) and the control homology 
arm (SAmax) regions, the proximal loxP site, and the neomycin positive selection 
cassette. 
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RWH1-GA1-linker 
3746 bp
AmpR lac Z
linker
LA 3' part
SA 3'
T7
T3
f1 (+) origin
Col E1 origin
HpaI (790)
RWH1-Neo/SA  
6542 bp
AmpR
LoxP
lac Z
SA
LA 3' part
FRT
FRT
PGKpolyA+
PGK  promo ter
T7
T3
f1 (+) origin
Col E1 origin
neomycin  g ene
HpaI (3740)
NcoI (4318)
SpeI (5155)
SpeI (6459)
Figure B.8 Schematic of the Vector RWH1-Neo/SA 
RWH1-Neo/SA possesses the short homology arms (SA), the proximal loxP site, 
and the neomycin positive selection cassette. 
Figure B.7 Schematic of the Vector RWH1-GA1-linker 
RWH1-GA1-linker possesses a 3’ region of the long homology arm and a 3’ 
region of the short homology arm interspersed by a polylinker sequence. 
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RWH1-LSA -Neo 
12347 bp
AmpR
LoxP
lac Z
SA
FRT
FRTLoxP
ATG codon
PGKpolyA+
PGK  promo ter
T7
T3
f1 (+) origin
Col E1 origin
neomycin  g eneexon  1
LA
HpaI (104)
NcoI (682)
SpeI (1519)
SpeI (2823)
SpeI (10164)
RWH1-HR 
15785 bp
AmpR
LoxP
lac Z
SA
FRT
FRT
LoxP
ATG codon
DTA cassette
PGKpolyA+
PGK  promoter
T7
T3
f1 (+) origin
Col E1 origin
neomycin  gen e
exon  1
LA
HpaI (5930)
NcoI (6508)
NcoI (12723)
NcoI (14073)
NcoI (15508)
SpeI (3643)
SpeI (7345)
SpeI (8649)
SpeI (12362)
Figure B.10 Schematic of the Final Targeting Vector RWH1-HR 
The final targeting vector possessing the long (LA) and short homology arms 
(SA), the diphtheria toxin A (DTA) negative selection cassette, the distal and 
proximal loxP sites, and the neomycin positive selection cassette. 
Figure B.9 Schematic of the Vector RWH1-LSA-Neo 
RWH1-LSA-Neo possesses the long (LA) and short homology arms (SA), the 
distal and proximal loxP sites, and the neomycin positive selection cassette. 
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5’-GGCGCGCCAAGCGGCCGCTTCTCGAGTAGACGTCCTCCTACCACTGCCCTCT 
TAGTGCTGGGACTACAGGTGCCTTCTAACAAACCCAGAAATCTTCAATAGTTTGA
GCCATATGTTGAATTCGTGATATCCCGTTAACATCCTCAGGCCCCTCCCCAGCTA
CCCATCCTTCTGCTCTGTCTTGCTGTGAGCTTGACCAAAAGCCCTGAAGGTTTAT
CTGAGTCATACCATATGGTAGAATTTCCTTGGGAAAGACTGGATTTTGAGGTTAA
GATGGGCCTGAGTTGAATCCTAGTTCCAGCCTGTGTTAGCCAGTGCCCCTAGGCT
AAATCAGTCTCTTCAGATCCCCGTTTTATTATTTCTAAAGTGGTAGTAATGACAT
CTGTCCTGTAAGGTTGTTAGGCATGTCAGGTGAAACAGTAGGTCTAGAAAGGTTA
GCCAGTGTACCAAATACTGGCTATTTGATAAATAGTTACTCTTAGCTAATTAGTA
ATTAGACTGGACTTTTTGAGAGAGTGCCTTAATTTTCTTTGTATCTTCAGAGCGT
CAGACCATGCCAAGCACTTGATAGGAAGGATTTAGGAAACTATTTGAGTTGGAAT
ATTGTATCCTCAGTCTGTGTCTGTCATAGTCACTCTCCAGTAGTCCCAGCTTTAA
AGTGTTCTAGAGTCAGATCACCTGTGATTTGAAACCTGGCTCTGGTACATTCTTG
CTTTATTGTCTTTGGAAAAGTTATTTACTATCTGTTTCTTTATCTGTAAAATAGA
GATCATCACAGGACCTAACCTCTTAAGATTATGATGAAGAAAAATGAGTTTTTAT
AAGAAAACCTTGAAAATAGTAGCCGAAGTATAATGAGTGTGCAGAAAGGTCGTCG
CGATTTTAATTAA-3’ 
Figure B.11 Sequence of the Sense Oligonucleotide Synthesised by Top Gene 
Technologies 
Complementary oligonucleotides of the sequence above were synthesised and 
cloned into the Genoway vector pGA1 by Top Gene Technologies. Blue text 
denotes the 3’ region of the long homology arm and red text denotes the 3’ region 
of the short homology arm. 
 Appendix B 
194 
B.2 Summary of the Work Carried Out at Genoway 
Genoway are responsible for carrying out the work in the generation of NR3 
floxed mice following the completion of targeting vector construction. All work 
described in this section was performed by Genoway. 
 
B.2.1 Electroporation of ES Cells and Detection of Homologous Recombination 
To prepare the targeting vector for electroporation into ES cells, Genoway 
linearised it using NruI restriction endonuclease, which digests the vector downstream 
of the short homology arm. In four separate transfections, the linearised vector was 
electroporated into ES cells, where recombination may occur between genomic DNA 
and the targeting vector. ES cells that had undergone recombination were selected by 
treatment with 200µg/mL G418 48 hours post transfection. A total of 565 clones 
resistant to G418 were isolated and amplified in 96-well plates. Duplicates of the 
clones were made, using one copy to store at -80°C and the other to purify genomic 
DNA. Genomic DNA was then screened for homologous recombination to ensure the 
NR3 locus was correctly targeted. 
The initial screening strategy Genoway employed was one based on PCR. To 
screen for homologous recombination of the short homology arm, the PCR reaction 
was optimised using RWH1-SA-C+ as this possesses an extended 3’ region of the 
short homology arm (figure B.12A). The forward primer is designed to anneal within 
the neomycin selection cassette and the reverse primer downstream of the short 
homology arm, producing a 3kb amplicon. This screening method provides a 
convenient and accurate way of determining whether recombination downstream of 
the neomycin resistance cassette has occurred at the NR3 locus. Genoway used 
RWH1-SA-C+ diluted in 10ng of genomic DNA. Dilutions represented the either 0.1, 
1 or 10 copies of plasmid per copy of genome to determine the sensitivity of the PCR. 
The positive controls in the absence of genomic DNA give an increase in PCR 
product with increasing template. PCR products of the correct size are observed in the 
presence of genomic DNA, although with a lowered yield (figure B.12B). The 
negative control reactions of genomic DNA alone and no template do not provide a 
PCR product, indicating the primers are specific to the targeting vector. A dilution of
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3kb 
Neo 
FRT FRT 
loxP 
BcgI EcoRI 
Short Homology Arm (1.75kb) 
HpaI 
Destroyed 
BstZ17I/EcoICRI 
Control Short Homology Arm (2.9kb) 
RHW1-SA-C+ 
Homologous Recombination PCR Amplicon (3kb) 
Figure B.12 PCR Screening Strategy for 3’ Homologous Recombination 
A) Schematic depicting the position of primer hybridisation during the PCR 
reaction. The forward primer anneals to the neomycin cassette (Neo) and the 
reverse primer anneal downstream of the short homology arm. 
 
B) Agarose gel of PCR reaction optimisation performed by Genoway. RWH1-SA-
C+ was diluted to give the equivalent of 0.1, 1 or 10 copies of the vector per copy 
of the genome within 10ng of wild-type (WT) genomic DNA. This was then used 
as a template alone for PCR as a positive control, or mixed with 10ng WT genomic 
DNA to determine the sensitivity and specificity of the PCR reaction. Negative 
control reactions used 10ng WT genomic DNA alone or no template (H2O). 
A) 
B) 
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1 copy of RWH1-SA-C+ per copy of genome emulates the conditions that would be 
expected following homologous recombination. These results indicate the PCR 
system optimised by Genoway is sensitive and specific enough to detect homologous 
recombination of the short homology arm. Using this method Genoway identified a 
total of 40 clones that provide PCR products of the expected size (data not shown). 
Similarly a PCR based method was employed by Genoway to determine correct 
recombination at the 5’ end of the targeting vector, thus integrating the distal loxP site 
at the NR3 locus. However, both primers were designed by Genoway to hybridise to 
genomic sequences and as such the PCR fragments require DNA sequencing to 
determine the presence of the distal loxP site. As the loxP site integration occurs at 
one allele, the sequencing data displays a double signal at the appropriate locus. Using 
this method Genoway screened the 40 positive clones identified as having undergone 
homologous recombination within the short homology arm region, which indicated 14 
clones to have also undergone homologous recombination at within the 5’ region of 
long homology arm, thus allowing the integration of the distal loxP site within the 
NR3 locus (data not shown). 
A secondary screen was also employed by Genoway to confirm the 
recombination event in positive clones was homologous using the method of Southern 
blot. To detect homologous recombination within the 5’ region of the long homology 
arm, genomic DNA was digested with NsiI and subject to Southern blot using a probe 
designed to hybridise upstream of the long homology arm (figure B.13A). Non-
targeted alleles should possess a fragment of 10.9kb, whereas targeted alleles should 
produce a fragment 7.7kb in size. For detecting homologous recombination within the 
short homology arm, genomic DNA was digested with EcoRV and a probe used that 
hybridises within the short homology arm (figure B.13B). This should detect a 5.9kb 
fragment for targeted alleles and a 11.1kb fragment for non-targeted alleles. In both 
cases clones in which homologous recombination has occurred should produce bands 
for both targeted and non-targeted alleles, as only one allele is floxed. Figure B.13 
shows data representative of Genoway’s Southern blot screening method. Clone 9-1C 
was indicated by PCR to have undergone homologous recombination within the short 
homology arm and the 3’ region of the long homology arm, thus is negative in the 
Southern blot for distal loxP site integration (figure B.13A), but positive for 
recombination within the short homology arm (figure B.13B). Clone 10-1A was
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Neo 
FRT FRT 
loxP 
BcgI EcoRI 
Long Arm (5.9kb) Short Arm (1.75kb) 
Exon 1 loxP 
BstBI 
HpaI EcoRI 
EcoRV EcoRV EcoRV 
XhoI 
Detected Fragment (5.9kb) 
Probe 
Targeted NR3 Locus 
BcgI EcoRI 
Exon 1 
BstBI XhoI 
EcoRV 
EcoRI 
Detected Fragment (11.1kb) 
Endogenous NR3 Locus 
Probe 
EcoRV 
Neo 
FRT FRT 
loxP 
BcgI EcoRI 
Long Arm (5.9kb) Short Arm (1.75kb) 
Exon 1 loxP 
BstBI 
HpaI EcoRI 
NsiI NsiI NsiI 
BcgI EcoRI 
Exon 1 
BstBI XhoI 
NsiI 
EcoRI 
NsiI 
XhoI 
Detected Fragment (7.7kb) 
Detected Fragment (10.9kb) 
Probe 
Probe 
Targeted NR3 Locus 
Endogenous NR3 Locus 
Neo 
FRT FRT 
loxP 
BcgI EcoRI 
Exon 1 
BstBI 
NsiI 
HpaI EcoRI 
NsiI 
XhoI 
Detected Fragment (12.7kb) 
Probe 
Partially Targeted NR3 Locus 
A) 
B) 
Figure B.13 Southern Blot Screening for Homologous Recombination 
Southern blot analysis of homologous recombination occurring within A) the 5’ 
region of the long homology arm and B) the short homology arm. Schematics 
depict the position of probe hybridisation and expected fragment size based on 
recombination status. Restriction enzymes in red denote those used to digest DNA 
for Southern blot analysis. Gels are representative of the data generated by 
Genoway. 
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determined to be positive for both homologous recombination within the short 
homology arm and 5’ region of the long homology arm, which is confirmed by 
Southern blot (figure B.13A and B). In total 5 of the 14 clones suggested to be 
positive by PCR were confirmed to have undergone homologous recombination at the 
appropriate locus by Southern blot performed at Genoway. These clones are referred 
to by Genoway as 10-1A, 28-2H, 30-4F, 31-3B and 31-1C. 
 
B.2.2 Generation of Floxed Mice and Current Status of the Project 
The ES cells used by Genoway are removed from 3.5 day old embryos at the 
blastocyst stage, which allows their reintroduction by microinjection to blastocysts 
having following genetic manipulation. Clones 10-1A, 28-2H, 31-3B and 31-1C were 
injected into harvested blastocysts, which were then implanted into foster mothers. 
Pregnant foster mothers give birth to chimeric pups that possess cells derived from the 
injected floxed ES cells or from the ES cells pertaining to the blastocyst. The ES cells 
used by Genoway for transfection and subsequent blastocyst injection are derived 
from 129S strain of mouse, which possess an agouti coloured coat. The blastocysts 
are harvested from C57Bl mice, which have a black coloured coat. The dependency of 
the coat colour on the genetic background of the mice allows the estimation of the 
proportion of cells derived from the floxed ES cells as chimeric offspring possess a 
mixed coat colour. The work undertaken by Genoway to generate chimeras is 
summarised in table B.1. 
Following the generation of chimeric offspring, chimeras must be backcrossed 
with wild-type mice to enable germline transmission of the floxed allele. Genoway 
have carried out breeding programs for the male chimeric mice generated by ES cell 
microinjection and blastocyst re-implantation that are estimated to display a level of 
chimerism of ~80%. Such breeding has been performed with male mice derived from 
ES cell clones 10-1A, 28-2H, 31-3C and with female mice globally expressing Flp 
recombinase that will remove the neomycin selection cassette from the floxed allele. 
Breeding from mice derived from clones 10-1A and 31-3C did not yield germline 
transmission of the floxed allele. However, germline transmission was observed in 
chimeric mice derived from clone 28-2H, and a total of 11 agouti pups were generated 
by the breeding program. As the ES cells from which these animals were derived 
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Floxed Clone No. of Injected 
Blastocysts
No. of 
Reimplantations
No. of 
Pregnancies
Total No. of 
Pups Born
No. of Pups 
Still Born
Total Number Level of 
Chimerism
Total Number Level of 
Chimerism
10-1A 46 3 3 17 0 8 20% 5 20%
28-2H 71 5 3 3 0 1 80% 2 50%
31-3B 14 1 1 3 3 2 80% 0 0
31-3C 28 2 2 6 0 5 3x80%, 2x50% 1 80%
Foster Mothers Male Chimeras Female Chimeras
Table B.1 Summary of the Work Carried out by Genoway to Generate Chimeric Mice 
Transfected ES cells clones identified by Genoway using PCR and Southern blot techniques as having undergone homologous recombination 
were microinjected into blastocysts harvested from pregnant mice. Injected blastocysts were then implanted into foster mothers to generate 
chimeric offspring. The level of chimerism is an estimation of the percentage contribution of cell genotype from injected ES cells based on 
coat colour. 
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possess both a targeted allele and a non-targeted allele, 50% of the animals will be 
heterozygous mice floxed at the NR3 locus. Genoway performed PCR genotyping to 
determine which offspring were heterozygous for the floxed NR3 locus, and to ensure 
the neomycin selection cassette was excised in those mice. Although ~50% of the 
offspring were found to be heterozygous floxed mice, such screening using primers 
that are designed to amplify the selection cassette showed only partial excision was 
achieved (data not shown). This indicates that the excision event has occurred in some 
but not all cells within the heterozygous floxed mice. Therefore the mice offspring 
must be backcrossed with the Flp expressing line again to ensure excision of the 
neomycin selection cassette in all cells. This backcross is currently being undertaken 
by Genoway. 
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